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ABSTRACT 
 
Replication selective oncolytic viruses (OVs) are a rapidly expanding 
therapeutic platform for cancer treatment. OVs are characterized by genetic 
alterations that ablate critical viral protein functions essential for viral 
replication in normal cells, but non-essential in tumor cells, thus targeting viral 
replication to tumor cells.  
dl1520 was the first oncolytic virus described, and we have demonstrated that 
dl1520 is effective against anaplastic thyroid carcinoma (ATC) cells and tumor 
xenografts; its antineoplastic effects are enhanced by paclitaxel, doxorubicin, 
lovastatin and ionising radiation. We have also shown that the second 
generation oncolytic adenovirus dl922-947 possesses a greater antitumor effect 
than dl1520 against ATC cells, and that the anti-VEGF monoclonal antibody, 
Bevacizumab, increased the effects of dl922-947 by improving viral 
distribution within the tumor mass. Furthermore, we have also shown that 
AZD1152, a selective Aurora B kinase inhibitor, negatively affects the growth 
of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic 
virus dl922-947.  
So far, preclinical and clinical studies have clearly shown the antineoplastic 
potential of oncolytic viruses, at least for local treatment, but have also 
highlighted the need to find associations that could improve their activity. 
Association of viruses with specific combinations, not only able to directly kill 
tumor cells but also to increase viral oncolytic activity, would represent a 
powerful therapeutic tool for the treatment of human neoplasia, in particular for 
diseases lacking of effective treatment.  
The main treatment of ATC consists of irradiation plus chemotherapeutic 
drugs. In order to identify novel treatment able to enhance the effects of OVs, I 
have evaluated the effects of ionising radiation in combination with dl922-947, 
focusing my attention on which type of cell death was activated in the 
combined treatment. Moreover, I have studied the effects of dl922-947 on the 
DNA damage response pathway and I have also evaluated the effects of an 
ATM inhibitor on dl922-947’s activity.  
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1. BACKGROUND 
 
1.1 Oncolytic viruses as anticancer drugs 
 
The notion that viruses may be able to eradicate cancer has existed 
since the early 20th century (Sinkovics and Horvath 1993; Sinkovics and 
Horvath 2000; Southam and Moore 1952). Several viruses were tested both in 
experimental settings and in humans during the 1950s and 1960s. Among the 
first viruses to be used in a controlled fashion in clinical studies was a vaccine 
strain of rabies virus to treat 30 patients with melanomatosis, eight of whom 
showed tumor regression (Pack 1950). A few years later the oncolytic efficacy 
of adenovirus serotype type 4, (which at that time was referred to as RI 
(respiratory infectious) virus), was tested in humans (Southman et al. 1956), as 
well as the flavivirus West Nile virus (Southam and Moore 1952) and the 
paramyxoviruses mumps and Newcastle disease virus (NDV) (Asada 1974; 
Okuno et al. 1978). Many viruses were tested in animal models. For instance, 
bovine enterovirus showed efficient lysis of syngeneic tumors in 
immunocompetent mice (Taylor et al. 1971). These studies provided the first 
evidence of therapeutic potential in humans. However clinical studies were 
unimpressive and many viruses elicited side-effects which ultimately ended the 
trials. As a result, the initial interest in viruses as anti-cancer agents declined 
during the following decades, as deduced from the number of publications 
from that time, and studies were mainly conducted using experimental models. 
Later in the 1990s interest in viruses as a treatment for cancer was rekindled, 
and today virotherapy is asserting itself as a novel treatment option alongside 
surgery, chemo- and radio-therapy. Many genetic and physiological features 
specific for malignant cells relating to particular gain-of-function or loss-of-
function mutations explain why cancer cells are so generous hosts for viruses. 
Cancer cells have undergone a mini-evolution (point-mutations, larger 
chromosomal shifts and alterations), providing them with selective growth 
advantages over normal cells (Cahill et al. 1999). While cancer cells gain 
growth-enhancing attributes, they may simultaneously lose critical components 
of the intracellular defense mechanisms and thus become fertile ground for the 
replication of many viruses. Moreover, malignant cells may express higher 
levels of virus receptors compared to normal cells, which makes them more 
susceptible to infection (Vaha-Koskela et al. 2006). Cancer-selective oncolytic 
viruses replicate preferentially in cancer cells, thereby amplifying the initial 
input dose, and as a result destroy those cells at the end of replication cycles by 
lysis. The viral progeny are then released, enabling them to infect neighboring 
cells, which results in multiple self-perpetuating rounds of infection, 
replication, lysis and spread throughout the tumor, all while sparing normal 
cells, hence toxicity is limited. Of note, oncolytic viruses can kill apoptosis-
resistent tumor cells, and hence do not have cross-resistance with existing 
therapies. Despite the advances made in oncolytic viral therapies, the field 
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awaits a true revolutionary breakthrough success, as was initially envisioned 
with the development of the field. The limitations in success may be due to the 
intrinsic biological properties of the tumor targets. Notably, a subpopulation of 
cancer cells that are often resistant to conventional treatment regimens and are 
responsible for the initiation of tumors in xenograft models have recently been 
discovered and characterized. This treatment resistant subpopulation still lacks 
full definition but has been characterized as cancer-initiating cells or cancer 
stem (or stem-like) cells (CSC). As with other treatment modalities, previous 
oncolytic virus agents have targeted the general tumor cell population and have 
not specifically targeted the CSC subpopulation. From the viewpoint of disease 
phenotype, CSCs embody the refractory nature observed among many cancers; 
very competent initial tumor establishment (Li et al. 2007) and extremely 
aggressive metastatic nature (Hermann et al. 2007). Furthermore, recent 
discoveries indicate that CSCs embody chemo- and radioresistance (Shah et al. 
2007; Ishii et al. 2008), and have been correlated with advanced disease and 
resistance to current therapies (Hermann et al. 2007), and thus help explain the 
clinical treatment resistance of these cancers. As CSCs are critical for tumor 
initiation, progression, persistence, and the development of metastasis, the 
success or failure of cancer treatment approaches may be influenced greatly by 
the presence and treatment sensitivity of these cells. Oncolytic vectors 
conceptually provide the means to effectively target and eradicate CSCs, kill 
the general tumor cell population, and carry therapeutic transgenes to alter the 
tissue microenvironment to make it unfavorable for the EMT (epithelial-
mesenchymal transition) phenomena as well as tumor propagation. 
Specifically, Ad-based oncolytic vectors, or CRAds, have shown the ability to 
accomplish all of these goals and have provided favourable patient safety 
profiles in early clinical trials. CRAds offer a targeted therapy directed toward 
CSCs and can affect the general tumor cell population directly through shared 
targets or indirectly via synergistic effects with chemotherapy and radiation 
therapy, favoring a multiple modality approach to CSC targeting and 
eradication with overall cancer cure. Additionaly, viral replication within a 
tumor may help mobilize the immune system by inducing the release of 
cytokines and by liberating tumor antigens (Ries et al. 2000; Cody and Douglas 
2009), contributing to a more efficient anti-tumor immune response.  
Members from an increasing number of virus families are being considered for 
cancer gene therapy. In the following some further details will be given about 
some of these viruses.  
 
1.2 Herpes simplex virus 
 
Vectors based on herpes simplex virus (HSV)-1 are, together with the 
adenoviruses, further along in their development and testing for virotherapy. 
HSV-1 is an enveloped, double-stranded linear DNA virus whose genome 
spans 152 Kb encoding over 80 genes. Approximately half of the genes are 
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necessary for virus replication. The HSV-1 genome is composed of unique 
long (UL) and unique short (US) segments, which are both flanked by inverted 
repeats. Infection can be either lytic or latent. During lytic infection, HSV-1 
genes are expressed in a temporally regulated cascade consisting of three 
phases, designed α, β, and γ. HSV-1 offers a number of advantages over other 
viral vectors system. These advantages include: the potential for incorporating 
a large foreign DNA; neurotropism, rendering gene delivery to the CNS more 
effective; the sensitivity to antiherpetic agents like ganciclovir provides a 
safety mechanism by which viral replication could be abrogated; moreover, 
HSV-1 never integrates and persists as an episome even during latency so the 
risk of insertional mutagenesis is not an issue. There are two general strategies 
that are employed to target HSV-1 replication to cancer cells. The first involves 
deletion or inactivation of viral genes that are essential for viral replication in 
normal cells but dispensable in tumor cells, such as HSV-tk, ribonucleotide 
reductase, and γ134.5. The initial HSV-1 mutant studied for tumor-selective 
replication, dlsptk, contains a 360-bp deletion within HSV-tk, and it was used 
to treat malignant gliomas in rodents (Martuza 1992). Accordingly, dlsptk 
replicates well in cultured tumor cells and induces significant growth inhibition 
of human U87 gliomas growing in the brains of nude mice. However, this 
HSV-1 mutant has not been tested in clinical trials because it produces 
neurotoxicity at higher titers, and it is resistant to the antiviral agents acyclovir 
and ganciclovir by virtue of its disrupted HSV-tk gene. Investigators looked 
instead at developing HSV-1 mutants that maintain sensitivity to acyclovir and 
ganciclovir and that exhibit less neurovirulence by deletion of the γ134.5 gene. 
One such γ134.5-null mutant is G207 (MediGene, Inc.; San Diego, CA) which 
exhibits tumor-cell-specific replication and antitumor efficacy in both in vitro 
and in vivo models of malignant glioma (Mineta 1995) and a study of a phase I 
was conducted in patients with glioma (Shah 2003). However, there are 
challenges that arise when working with HSV-1 vectors. First, genetic 
manipulation of HSV-1 is difficult due to the large size of the viral DNA. A 
second potential obstacle when using HSV-1 recombinant vectors is the fact 
that most humans have pre-existing herpes immunity, which could potentially 
impair gene delivery. Potential neurotoxicity is a third problem inherent to 
HSV-1 vectors when delivered into the central nervous system.  
 
1.3 Polyomavirus  
 
Polyomaviruses are double-stranded DNA viruses with a relatively 
small circular genome (5.3 Kb). Recombinant polyomavirus vectors based on 
the SV40 virus have been around since the turn of the millennium, and 
although inherently non-lytic, Cordelier et al. (2007) recently demonstrated 
significant tumor-specificity in vitro and growth inhibition in a mouse model of 
pancreatic cancer using tumor-specific promoters to drive the expression of an 
inhibitory protein from such a vector. The main advantages of polyomavirus 
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vectors is their remarkable ability to escape immune recognition, they do not 
evoke a neutralizing antibody response, and durable transgene expression 
(Strayer et al. 2005). 
 
1.4 Poxvirus 
 
Poxviruses are large, enveloped, dsDNA viruses with a complex 
genome harboring multiple immune-modulating genes. The most commonly 
used poxvirus in cancer targeting is vaccinia virus (VV). As the wildtype strain 
WR causes local tissue destruction (necrosom), the derived vectors have been 
attenuated by removal of thymidine kinase or other genes (Guo et al. 2005; 
McCart et al. 2001). Many VV vectors efficiently kill tumors in preclinical 
settings. However, although replication-competent vectors have been able to 
enhance the survival of both immunodeficient and immunocompetent mice 
carrying different types of tumors, significant infection of other organs has also 
been observed, indicating that VV vectors still need to be optimized (Guo et al. 
2005). As an example, the novel replication-competent vector JX-594 based on 
strain Wyeth showed impressive oncolysis of tumors and metastases in 
syngeneic models in both rats and rabbits upon i.v. administration (Kim et al. 
2006). JX-594 is an oncolytic poxvirus engineered for replication, transgene 
expression and amplification in cancer cells harbouring activation of the 
epidermal growth factor receptor (EGFR)/Ras pathway, followed by cell lysis 
and anticancer immunity. In a recent clinical trial it has been demonstrated that 
JX-594 selectively infects, replicates and expresses transgene products in 
cancer tissue after intravenous infusion, in a dose-related fashion. Normal 
tissue were not affected clinically. This platform technology opened the 
possibility of multifunctional products that selectively express high 
concentration of several complementary therapeutic and imaging molecules in 
metastatic solid tumors in humans (Breitbach et al. 2011).  
 
1.5 Parvovirus 
 
Parvoviruses are non-enveloped single-stranded DNA viruses (5Kb 
genome). The family includes the helper-dependent viruses, including the 
adeno-associated viruses (AAV), which require molecular functions supplied 
in trans via co-infection with herpes- or adenoviruses, whereas the autonomous 
parvoviruses can replicate with the help of cellular factors. Of these, only the 
autonomous parvoviruses are oncolytic, although both display oncosuppressive 
effects. Parvoviruses can inhibit the transforming capacity of other oncogenic 
viruses (Mousset and Rommelaere 1982), and have been shown to suppress the 
proliferation of some cancer cell lines by inducing cell cycle arrest and 
terminal differentiation (Bantel-Schaal 1995). Anti-tumor efficacy by these 
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viruses may involve both oncolysis and tumor suppression/reversion (Cornelis 
et al. 2004).  
 
1.6 Reovirus  
  
Reoviruses are very common in the human respiratory and 
gastrointestinal tract. While attenuated in healthy tissue, reoviruses are 
inherently oncolytic and show high tumor-specificity upon remote 
administration. Marked inhibition of tumor growth and prolonged survival of 
immunocompetent mice was observed upon multiple i.v. injections in a model 
of lung-metastasizing mammary cancer (Hirasawa et al. 2003). In this study, 
the oncolytic efficacy was reduced in pre-immunized animals, indicating that 
pre-existing immunity poses an obstacle with this virus. The first indications 
that reovirus could be used to treat established or inhibit metastases came from 
xenografts models of human cancer in immunocompromised animals (Norman 
et al. 2002; Yang et al. 2003; Alain et al. 2002; Yang et al. 2004). Xenografts 
of a human breast cancer cell line were inoculated over both the left and right 
hind flanks and reovirus was injected into only one flank tumor (Norman et al. 
2002). Reovirus replication and regression was observed at both injected and 
non-injected contralateral sites. In another study, reovirus administered 
intracranially was able to eradicate breast cancer metastases in the CNS of 
nude mice and to prolong survival of immunocompetent rats with 
leptomeningeal breast cancer metastases when administered intrathecally 
(Yang et al. 2004).  
 
1.7 Paramyxovirus  
 
This vast group of viruses includes prototypic members such as measles 
virus, mumps virus and the Newcastle disease virus (NDV), all of which have 
been used in cancer targeting. The history of NDV as an anti-tumor agent in 
humans began in 1965 with a clinical trial led by Dr’s Cassel and Garrett who 
used the live attenuated 73-T strain to treat a patient with cervical carcinoma 
(Cassel and Garrett 1965). Subsequently, NDV has been used both as 
oncolysate and live virus in several clinical trials. As an example of the latter, 
in one study a purified poultry vaccine dubbed MTH-68/H based on live 
attenuated NDV was administered i.v. to a total of 14 patients with grade IV 
glioblastoma multiforme since 1996 (Csatary et al. 2004). Of these patients, 
five died of the cancer, two died of other causes and the remaining seven were 
alive at the time of the publishing of the paper in 2004. Four of these patients 
who had been alive for 5-9 years had received i.v. virus as their sole form of 
treatment. A phase I/II clinical trial using i.v. administration of another live 
attenuated neurotropic NDV strain, NDV-HUJ, to treat glioblastoma and three 
phase I trials using the live NDV vector PV701 to treat patients with multiple 
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types of cancers were recently completed (Freeman et al. 2006; Lorence et al. 
2003).  
 
1.8 Picornavirus  
 
Several members of these positive strand RNA viruses are being 
developed into tools for virotherapy. Poliovirus infects a wide variety of human 
cancer cell lines and primary explants (Ansardi et al. 2001). By attenuation of a 
neurovirulent poliovirus strain by replacement of the viral internal ribosome 
entry site (IRES) with the corresponding sequence from the closely related 
human rhinovirus type 2, Gromeier et al. (2000) were able to obtain a highly 
efficacious recombinant virus, PV1(PVS)-RIPO, which displayed significant 
tumor tropism and oncolytic potential in subcutaneous and i.c. human 
astrocytoma xenografts in nude mice. Whereas the subcutaneous tumors were 
efficiently eradicated upon a single i.v. administration, the brain tumor 
xenografts responded only to i.t. injection despite that the vector was 
neurotropic and replication-competent. In another study, this virus was able to 
cause complete tumor regression in a small number of athymic rats harbouring 
i.c. human glioma xenografts upon intrathecal administration. In addition to the 
recombinant vectors, a live attenuated strain of poliovirus 1 has shown promise 
as an oncolytic agent (Toyoda et al. 2004).  
 
1.9 Adenovirus 
 
Adenoviruses were isolated in 1953 from human adenoid tissue samples 
in culture undergoing “spontaneous” regression, and were dubbed adenoidal—
pharyngeal—conjunctival viruses based on their capacity to induce disease 
symptoms in experimentally infected humans (Rowe et al. 1953). The 51 
distinct serotypes of human adenovirus have been classified into six groups 
(A–F) based on sequence homology and their ability to agglutinate red blood 
cells (Shenk 1996). Most studies have been carried out on adenovirus serotype 
2 (Ad2) and 5 (Ad5). Human adenoviruses contain a linear, double stranded 
DNA genome of 30-36 Kb, and present an icosahedral symmetry. The hexon, 
penton base, and knobbed fiber, are the most important capsid proteins for gene 
delivery. Adenovirus infection occurs through binding of the adenoviral fiber 
to cellular receptors such as the coxsackie-adenovirus receptor (CAR) or 
integrins.  
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Figure 1. Adsorption and entry of adenovirus into the cell 
Attachment of adenovirus to cell surface receptor (on the left) and receptor-mediated 
endocytosis (on the right). 
 
 
After the virus internalization through endocytosis the virus escapes the 
endosome and translocates to the nuclear pore complex, where the viral DNA 
is released into the nucleus and transcription begins. Transcription, replication 
and viral packaging take place in the nucleus of the infected cell. A complex 
series of splicing accompanies transcription, and genes are transcribed from 
both strands. Adenoviral transcription occurs in two phases: early and late 
(Fields et al. 1996).  
During the early phase, the host cell is transformed into an efficient producer of 
the viral genome. The first gene that is transcribed in the viral genome is E1A. 
The adenovirus E1A protein is encoded by several alternatively spliced 
mRNAs, with the predominant forms being the 12S and 13S mRNAs (Heise et 
al. 2000). Two regions of conserved sequence among E1A proteins of different 
adenovirus types are conserved regions 1 and 2 (CR1 and CR2). CR1 and CR2 
contribute to E1A-induced cell cycle progression and transformation (Fueyo et 
al. 2000, Rodriguez et al. 1997). During infection, the primary mechanism by 
which E1A forces quiescent cells to actively cycle is by interfering with 
proteins of the retinoblastoma (Rb) pathway (Harlow et al. 1986; Moran 1993) 
and this interaction is mediated primarily by CR2. Rb acts as a tumor 
suppressor via binding to E2F, a transcriptional activator that promotes 
expression of genes necessary for driving the cell into S phase (Nevins 1995). 
The E1A product is able to sequester Rb and release repression of E2F, 
allowing it to activate its target genes. E1A proteins have also been shown to 
modulate the activity of p107 and p130, two members of the Rb family that are 
also involved in regulating cell cycle progression (Parreno et al. 2001). In 
addition to binding to Rb, E1A also binds to p300, an important nuclear 
integrator of diverse signalling pathways that possesses intrinsic histone 
acetyltransferase (HAT) activity and is implicated in the activation of genes 
that maintain cell differentiation and inhibit the cell cycle. p300 regulates and 
activates transcription by acetylating multiple other transcription factors, E2F 
and p53 being two important examples. E1A has been shown to repress 
directly the HAT activity of p300 and to inhibit p300-dependent transcription 
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(Hamamori et al. 1999; Chakravarti et al. 1999). All these actions of E1A result 
in the accumulation of p53. p53 is a cellular growth suppressor that acts as a 
G1 checkpoint control and in response to viral challenge, p53 may induce a G1 
growth arrest by inducing genes such as the cyclin-dependent kinase inhibitor 
p21/WAF1/Cip1 gene (El-Deiry et al. 1993, Xiong et al. 1993) or apoptosis by 
inducing genes such as Bax1 (Miyashita and Reed 1995). The induction of 
apoptosis is inhibited by the products of the E1B gene. The E1B transcription 
unit encodes two proteins, E1B-55kDa and E1B-19kDa. The E1B-19kDa 
protein is a functional homologue of the proto-oncogene-encoded Bcl-2 and 
prevents apoptosis by similar mechanisms (Debbas et al. 1993; Rao et al. 
1992). The E1B-55kDa protein complexes with the amino-terminal end of p53 
and inhibits its activity as a transcription factor (Kao et al. 1990; Yew and Berk 
1992; Yew et al. 1994). It is thought that these mechanisms for inhibiting 
apoptosis keep the cell alive as long as possible in order to maximize viral 
yields (Rao et al. 1992). In addition to its antiapoptotic functions, the E1B-
55KDa protein facilitates the transport of nuclear viral mRNAs to the 
cytoplasm during the late stages of infection (Pilder et al. 1986). The E2 region 
encodes proteins necessary for replication of the viral genome: DNA 
polymerase, preterminal protein, and the 72-kDa single-stranded DNA-binding 
protein (De Jong et al. 2003). Products of the viral E3 region function to 
subvert the host immune response and allow persistence of infected cells. The 
immune system has evolved a number of mechanisms for destroying virus-
infected cells, including cell lysis by cytotoxic T lymphocytes and activation of 
receptor-mediated apoptotic pathways by chemokines. 
The E4 transcription unit encodes a number of proteins that have been known 
to play a role in cell cycle control and regulation of DNA replication. The viral 
structural proteins and the proteins necessary for assembly of the virion are 
encoded by genes expressed during the late phase of viral replication. Once 
viral progeny assembly is complete, new viral particles are released by 
cytolysis (figure 2).  
 
 
 
Figure 2. Adenoviral genome. 
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Adenoviruses have become the most widely used and most extensively studied 
viruses for gene delivery/therapy purposes, being easy to manipulate and very 
safe in vitro and in vivo. Numerous pre-clinical studies were conducted using 
adenoviral vectors to transfer tumor suppressor genes or as oncolytic viruses 
(Alemany et al. 2000). In China, oncolytic adenovirus mutants in combination 
with chemotherapy have been accepted as a standard treatment form for 
refractory nasopharyngeal cancer.  
Oncolytic adenoviruses are genetically manipulated human adenoviruses that 
acquired a replication phenotype in tumor cells, but show a more restricted 
phonotype in normal cells. Several features of wild type adenoviruses can be 
modified to acquire tumor replication properties (Chiocca 2002).  
There are different ways in order to developing tumor specificity in oncolytic 
adenoviruses:  
- by altering viral genes that attenuate replication in normal tissue but 
not in tumor cells;  
- by placing viral genes that initiate viral replication under the control 
of promoter sequences that are active only in tumor cells;  
- by the modification of viral coat proteins that function in host cell 
infection. 
The most widely-used strategy consists in the creation of replication-
conditional adenoviruses genetically modified such as dl1520 and dl922-947. 
Mutant adenovirus dl1520 (also known as ONYX-015) contains a deletion in 
the E1B gene, preventing the formation of a functional E1B-55kDa protein. 
With this mutation, dl1520 was expected to replicate only in p53-deficient cells 
(Bischoff et al. 1996). For example, by altering a region of the E1B gene, the 
adenovirus can selectively replicate in p53-deficient (i.e. tumour) cells and 
leave p53-competent cells intact. In addition to its role in the degradation of 
p53, the E1B-55kDa protein has several other important late-phase functions. 
E1B-55KDa mediates late-viral RNA transport and the loss of E1B-55KDa 
restricts the viral replication to tumor cells capable of taking over the RNA 
export function of the viral gene product (O’Shea et al. 2005). 
The second strategy concerns the regulation of viral replication via cellular 
promoters that are overactive in certain tumor cells, sometimes referred to as 
“tumor-specific” promoters. Certain tumor types, such as germ cell tumors, 
prostate cancer, and hepatocellular carcinoma, express proteins that are not 
normally present in the human body after fetal development. Oncolytic 
adenoviruses have been created to take advantage of the expression of these 
tumor markers or dependence on normally secreted hormones by placing the 
E1A gene under the control of the promoters derived from the genes of interest 
(Hallenbeck et al. 1999; Rodriguez et al. 1997; Matsubara et al. 2001; Hsieh et 
al. 2002). The last strategy used to create oncolytic adenovirus is to alter the 
structural viral envelope proteins to retarget the virus to tumor cell surfaces and 
direct the virus away from its normal receptor (Dmitriev et al. 2000). 
The safety and antitumor efficacy of dl2520 have been tested in numerous 
phase I and II clinical trials (Kirn 2001). In all this trials adenovirus was 
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administered alone and this monotherapy has demonstrated limitations in 
efficacy. Its limited efficacy has highlighted the need for oncolytic 
adenoviruses with higher replication efficiency and killing activity. 
A second generation adenoviral mutant has been generated. dl922-947 is an 
E1A mutant oncolytic adenovirus, which bears a 24-bp deletion in E1A 
Conserved Region 2 (CR2) therefore, is unable to induce progression from G1 
into S-phase of quiescent cells. The G1-S checkpoint is critical for cell growth 
progression and is lost in almost all cancer cells as a result of mutations or 
deletions of the RB or CDKN2A genes, amplification and overexpression of 
Cyclin D, and amplification, overexpression or mutation of the CDK4 gene 
(Sherr 2000, Roussel 1999). The in vitro efficacy of dl922-947 was 
demonstrated in a range of a cancer cell lines and this efficacy exceeded that of 
adenovirus 5 wild-type (Ad5wt) and dl1520 (Heise et al. 2000). A similar 
adenovirus, ∆24, with the same deletion in E1A-CR2, has shown activity in 
preclinical models of glioma (Fueyo et al. 2000). dl922-947 has also an 
impressive in vitro activity in ovarian carcinoma and was able to produce some 
long-term survivors in an aggressive xenograft model (Lockley et al. 2006). 
 
1.10 Oncolytic adenovirus and cell death 
 
Although oncolytic viruses have been tested in clinical trials, so far 
oncolytic virus-induced cell death mechanisms remain to be delucidated. In 
order to find drugs that could be used for the development of novel therapeutic 
strategies based on the use of oncolytic viruses, elucidations of the molecular 
mechanisms of virus-induced cell death are necessary.  
The cell death pathways activated by the infection with OVs are only partially 
understood, however several evidences indicate that they are cell type 
depending. We have obtained data confirming this hypothesis. The infection 
with dl922-947 activates in glioma cells a survival pathway, autophagy and the 
block of autophagy with pharmacological inhibitors induces a switch toward 
apoptosis (Botta et al. under review). Conversely, in ATC cells, dl922-947 
infection leads to a programmed cell death lacking the features of classical 
apoptosis, but showing some apoptotic markers, such as subG1 accumulation 
and caspase-3 activation. We did not observe upon dl922-947 infection 
autophagy or mitotic catastrophe in ATC cells (Libertini et al. 2011) and we 
have also obtained data indicating that dl922-947 in ATC cells induces G2/M 
accumulation and block of cell division, as suggested by the observed 
poliploidy.  
Adenovirus-induced cell death was long presumed to be classically apoptotic 
(Hall et al. 1998). E1A induces potent apoptosis in many cell systems (Rao et 
al. 1992), while E4-ORF4 can induce caspase-dependent cell death (Robert et 
al. 2002). Adenoviruses also express several proteins that inhibit cell death 
early after infection; for example, E1B-19KDa is the viral homologue of Bcl2 
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(Chiou et al. 1994) and E1B-55KDa, in concert with E4-ORF6, targets p53 for 
proteasomal destruction (Steegenga et al. 1998) (figure 3).  
 
 
  
 
Figure 3. Adenovirus induced cell death pathway.  
E1A proteins bind to the cell cycle checkpoint protein pRb105 (pRb)—the retinoblastoma 
susceptibility gene product—releasing bound transcription factors, such as E2F1 and other E2F 
family members. E2F1 transactivates pl4ARF, the alternative splice product encoded by the 
p16INK4A locus. P14ARF then binds MDM2 thereby neutralizing its activity. MDM2 
normally binds p53 and targets it for proteolysis via the ubiquitin pathway. Disruption of 
MDM2 function by p14ARF allows p53 levels to rise, which is a prerequisite for induction of 
cell death by p53, but, although necessary, it is not always sufficient. The increase in p53 level 
is usually accompanied by posttranslational modification, most often phosphorylation, in order 
to ‘activate p53’ to become functional (Braithwaite and Russell 2001). 
 
 
Two groups have made more systematic attempts to monitor the cell death 
mechanism induced by selectively replicating viral mutants in human cancer 
cells. One used ∆24 and ∆24RGD in H460 non-small cell lung carcinoma cells 
(Abou El Hassan et al. 2004). Both these vectors contain the same 24-bp E1A 
CR2 deletion as dl922-947, but ∆24 is entirely E3 deleted (Fueyo et al. 2000), 
whereas ∆24RGD has an intact E3 region and an RGD motif in the fibre knob 
to redirect binding to αv integrins (Fueyo et al. 2003). The second group used a 
mutant with a wild-type E1A region under the control of the human telomerase 
reverse transcriptase (hTERT) promoter in telomerase-positive cancer cells (Ito 
et al. 2006). Their conclusions were dramatically different; Abou El Hassan 
used the term ‘necrosis-like programmed cell death’ to describe the actions of 
∆24 viruses, whereas Ito concluded that autophagy contributed significantly to 
the death of glioma cells. Baird et al. (2008) clearly shown that classical 
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apoptosis is not the mechanism by which replicating adenoviruses cause cell 
death. Some apoptotic morphological features are found, but there are 
dramatically fewer than with cisplatin treatment.  
Replicating adenovirus-induced cell death may therefore be described as a 
strongly virus-controlled version of non-classical cell death, one that has not 
been fully characterized before.  
 
1.11 Oncolytic viruses in cancer therapies 
 
Oncolytic viruses are currently under investigation in phase I-III 
clinical trials (Table 1).  
 
 
 
Table 1. Clinical development of oncolytic viral vectors 
The table summarized the different oncolytic viruses that have been tested in preclinical and 
clinical trials, and their developmental status (Parato et al. 2005). 
 
 
Most studies have focused on the direct antitumor properties of these viruses, 
although there is now an increasing body of evidence that the host immune 
response may be critical to the efficacy of oncolytic virotheraphy. Oncolytic 
viruses represent prime candidate to enhance the immunogenicity of the tumor 
microenvironment. However, the role of the immune system is controversial. 
Oncolytic viruses can be administered locally, by direct intratumoral 
inoculation, or systemically, by intravascular administration. The immune 
system could antagonize the effectiveness of oncolytic viruses administered 
VIRUS MECHANISM OF TUMOR TARGENTING PHASE OF DEVELOPMENT RESULTS
Adenovirus Targets to tumor antigens; Phase III conducted Greater response in patients 
conditionally replicating who received a combination
of virus therapy and chemotherapy
than in patients who received 
chemotherapy alone
Reovirus Selectively infects RAS-transformed cells Phase I conducted Currently in trials to compare
intratumoral administration with
cutaneous administration
in patients with melanoma;
 also in trials for patients with 
malignant glioma and intravenous 
administration
Herpes simplex virus 1 Only replicates in tumor cells Phase I conducted,  G207 and HSV1716 vectors were
additional trials planned found to be well-tolerated when 
given by intratumoral injection in 
patients with glioma
NDV Selectively replicates in interferon Phase I conducted PV701 vector was found to be well
defective cells tolerated when given intravenously;
some patients had anti-tumor 
response
Vaccinia virus Gains access to tumor by vascular leakiness Phase I conducted, JX-594 vector was found to be well
Phase II planned tolerated in phase I clinical trial when
given by intratumoral injection into 
melanomas; trials are being planned 
to test intravenous delivery
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intravascularly by limiting viral delivery to the tumor while, on the other hand, 
once the virus has reached its target and begins replicating within and 
destroying tumor cells, the immune response can theoretically augment tumor 
reduction by redirecting the cytotoxic T lymphocytes response from viral 
antigens to tumor antigens, also against distal metastasis. In fact, viruses 
administered by direct intratumoral inoculation elicit a systemic immune 
response that prevents tumor formation and causes regression of existing 
tumors at distant sites (Todo et al. 1999).  
A number of clinical trials have already been conducted that are based on 
oncolytic viruses, including those that are naturally selective for tumor cells, 
such as reovirus and Newcastle disease virus, and those that have been made 
selective by genetic manipulation, such as adenovirus and herpes simplex virus 
(Parato et al. 2005).  
Although the number of different types of oncolytic viruses that have been 
tested in preclinical trials is increasing, only a few have made the transition 
into the clinic. Only 8 years ago, the first patients were treated in the first bona 
fide clinical trials of oncolytic virus therapy with dl1520. When dl1520 was 
given to patients intravenously or intra-arterially, it was well tolerated and was 
associated with tumor shrinkage and/or disease stabilization in some patients 
(Reid et al. 2002; Reid et al. 2001). So, oncolytic viruses seem to have limited 
side effects that are less debilitating than those that are associated with many 
standard cancer therapies, and are beginning to show some signs of efficacy.  
A modification of dl1520, H101, is the only oncolytic virus to be tested in a 
phase III study to date (Xia et al. 2004), and is now the only approved world’s 
first oncolytic virus therapy for cancer treatment. In this trial H101 was given 
by intratumoral injection to patients who received cisplatin-based 
chemotherapy. The response rate was significantly higher (78%) in patients 
who received the combination of viral therapy and chemotherapy than in 
patients who were treated with chemotherapy alone (39%) (Xia et al. 2004; 
Wakimoto et al. 2004). 
 
1.12 Oncolytic adenoviruses in combination cancer therapies 
 
Preclinical and clinical studies have clearly shown the antineoplastic 
potential of oncolytic viruses, at least for local treatment. In all cases safety 
was demonstrated, with the most common associated toxicity being flulike 
symptoms. Some of the most encouraging data were obtained from a phase II 
study using intratumoral administration of dl1520 in patients with advanced 
head and neck squamous cell carcinoma (Nemunaitis et al. 2000). In this trials 
adenovirus administered alone as a mono-therapy has demonstrated limitations 
in efficacy. The best chance for complete tumor eradication lies in a 
multimodal cancer therapy approach utilizing oncolytic virus in combination 
with chemotherapy, radiotherapy, or drugs that could improve oncolytic 
viruses’ activity. The rationale for combination therapy was that a greater 
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antitumor effect was expected with combination treatment compared with 
single therapies. The therapies have different toxicity profiles and may result in 
enhanced efficacy without increased adverse events; moreover, no overlapping 
resistance between oncolytic viruses and chemotherapy and/or radiotherapy 
was anticipated; and it may be possible to lower treatment doses. 
 dl1520 has been used in conjuction with chemotherapeutic agents in clinical 
trials with evidence for potential synergistic antitumor activity. The use of 
dl1520 in conjuction with cisplatin (causes intrastrand DNA cross-links that 
block DNA replication), and 5-fluorouracil (pyrimidine antagonist that inhibits 
DNA synthesis) has been examined in a phase II clinical trial involving head 
and neck carcinoma patients. dl1520 has been used in combination with 
leucovorin and 5-fluorouracil in a phase II trial in patients with gastrointestinal 
carcinoma metastatic to the liver and with gemcitabine in a phase I/II trial in 
patients with unresectable pancreatic carcinoma (Kruyt and Curiel 2002; Post 
et al. 2003). All these studies have shown that combined treatments increase 
the therapeutic effects of the virus.  
The lack of knowledge about the mechanisms relevant for the oncolytic 
activity impedes the choice for the best drug to use in the combined treatment. 
The association of viruses with specific drugs, not only able to directly kill 
tumor cells but also to increase viral oncolytic activity, would increase the 
efficacy of the treatment of human neoplasia. It is well known that one of the 
major obstacle to the successful application of therapeutic strategies based on 
replicating oncolytic viruses is represented by the poor distribution of viral 
particles throughout the tumor mass, probably due to physical barriers or to 
tumor vessels, which are structurally and functionally abnormal and highly 
disorganized. We have demonstrated that the pre-treatment with Bevacizumab, 
a recombinant humanized monoclonal antibody to the VEGF, probably 
decreasing the interstitial pressure or normalizing tumor vessels, improves the 
delivery and the distribution of the virus into tumor mass and enhances the 
effects on the inhibition of tumor growth (Libertini et al. 2008).  
It has been also hypothesized that the cell cycle may influence the outcome of 
Ad infection, and it has also been reported that the block in G2/M phase 
improves viral entry and replication (Seidman et al. 2001). So interfering with 
the G2/M phase, with drugs that block cells in this phase of the cell cycle, could 
be a potential therapeutic tool to potentiate the effects of oncolytic virus. We 
have demonstrated that AZD1152, a specific Aurora B kinase inhibitor, is 
active against ATC cells, inducing G2/M accumulation, polyploidy and 
subsequent cell death by mitotic catastrophe. We have also demonstrated that 
the drug is able to enhance the anti-neoplastic effects of dl922-947 oncolytic 
virus in both in vitro and in vivo models of ATC (Libertini et al. 2011).  
The appeal of combining OVs with radiation therapy continues to grow as the 
relationship between these two therapies is better understood. Through either 
radiation-mediated enhancement of viral oncolysis or virus-mediated 
sensitization of cells to radiation therapy, combination of these two treatments 
has resulted in synergistic antitumor effects in numerous preclinical models. 
  
22 
 
Combined oncolytic adenovirus therapy and external beam radiotherapy (XRT) 
has shown significantly improved results over individual therapies in 
preclinical models (Nandi et al. 2008; Idema et al. 2007; Lamfers et al. 2002; 
Geoerger et al. 2003; Bieler et al. 2008; Chen et al. 2001; Dilley et al. 2005). 
Treatment with Onyx-015, Ad∆24, Ad∆24-p53 (Idema et al. 2007) or 
Ad∆24RGD (Lamfers et al. 2002) in combination with radiation in a 
subcutaneous glioma model resulted in 50-100% long-term survival (Ottolino-
Perry et al. 2010). Many studies looking at combination of adenovirus and 
XRT therapy have hypothesized that the radiation-mediated increase in 
oncolysis is due in part to an increase in viral replication rates. Unfortunately, 
little information about the underlying molecular mechanism has been 
uncovered. Increased viral titers correlated with a synergistic cytotoxic effect 
in vitro. In vivo combination therapy significantly inhibited tumor growth 
relative to individual therapies (Chen et al. 2001; Dilley et al. 2005). 
 
1.13 OVs and IR: understanding the molecular mechanism. Role of the 
DNA damage pathway 
 
Ionising radiation is used as a primary treatment for many types of 
cancer. Consequently, there is an emphasis in preclinical and clinical studies 
toward using adenoviruses as part of a combination treatment strategy with 
radiotherapy (Hingorani et al. 2007). It has been hypothesized that the block in 
G2/M phase could enhance viral replication and subsequently the oncolytic 
effects of the virus.  
It is well known that after exposure to ionising radiations, two distinct G2/M 
checkpoints are activated:  
• the early G2 checkpoint that prevents the progression of cells irradiated 
in G2 into mitosis;  
• the G2/M accumulation that blocks in G2 cells in earlier phases of the 
cell cycle at the time of irradiation (Metting and Little 1995) 
The combination of viruses and external beam radiation therapy (EBRT) has 
shown additive or synergistic therapeutic effects in preclinical studies in vitro 
and in subcutaneous prostate, head and neck, lung, colon, thyroid and 
cholangio-carcinomas, as well as melanoma and malignant glioma (Freytag et 
al. 2008; Swisher et al. 2003; Immonen et al. 2004; Mundt et al. 2004; Teh et 
al. 2004; Freytag et al 2007; Harrington et al 2010; Portella et al. 2003). Phase 
I and II clinical trials investigating the combination of EBRT and viruses have 
been completed and published. These studies have demonstrated excellent 
safety and some preliminary evidence of efficacy for adenovirus, HSV and 
reovirus.  
The main results from these studies are summarized in Table 2.  
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Table 2. Main results from phase I and II clinical trials investigating the combination of 
EBRT and viruses 
 
 
Although there is a clear evidence that combinations of oncolytic viruses and 
radiation can enhance viral replication and possibly anti-tumor efficacy when 
compared with single modality therapy, relatively little is known about the 
mechanisms involved in enhancing tumor cell death. 
Ionising radiation produces a wide variety of lesions in DNA, including base 
damage, single- and double-strand breaks (DSB) and DNA–DNA or DNA- 
protein crosslinks (Prise et al. 2005). These lesions can be topographically 
grouped and clustered within the same region of DNA to comprise so-called 
‘‘complex damage’’ (Goodhead 1994).  
The DNA damage checkpoint can be defined as a network of interacting 
pathways operating in concert to recognize damage in the DNA and elicit the 
response (Elledge 1996; Zhou and Elledge 2000; Nyberg et al. 2002). It shares 
characteristic of a signal transduction pathway, and the participating proteins 
can be formally divided into sensors, transducers and effectors. Sensor proteins 
Author/clinical phase Patients Treatment Comments
Freytag et al. 2003 15 patients with newly Intraprostatic injection of an oncolytic No dose limiting toxicity
Phase I diagnosed non metastatic adenovirus encoding the cytosine deaminase/ Intratumoral transgene expression demonstrated 
prostate adenocarcinoma HSV-TK gene up to 3 weeks after viral injection
Combination with prodrugs 5-fluorocytosine and Mean PSA half-life in patients having received
valganciclovir, and 70-74 Gy conformal radiation more than 1 week of prodrug therapy shorter
therapy than patients having received only 1 week of 
prodrug therapy (0.6 vs 2 months)
Swisher et al. 2003 19 patients with non 3 intratumoral injections of a replication defective Antitumoral efficacy after 3 months assessed with
Phase II metastatic non-small cell adenovirus encoding wild type p53 gene clinical findings. CT scan (16 patients) and biopsies
lung cancer who were not Combination with 60 Gy radiation therapy (15 patients)
eligible for surgery or 
chemoradiation
Immonem et al. 2004 36 patients with operable Patients were randomized to receive standard Well tolerated treatment
Phase II/III malignant glioma treatment alone (surgical excision followed by Significantly increased mean survival time in 
radiation therapy) (19 patients) or in combination experimental arm (39.0 ± 19.7 vs 70.6 ± 52.9 weeks),
with local injection of adenovirus encoding the median survival (62.4 vs 37.7 weeks)
HSV-Tk gene in the tumor cavity after resection,
followed by intravenous ganciclovir injections for
14 days (17 patients)
Mundt et al 2004 14 patients with soft tissue 3 escalating doses of TNF-erade, an adenovirus No dose limiting toxicity
Phase I sarcoma encoding the TNF-α gene under the control of a Response assessment in 13 patients
radio-inducible promoter Of the 11 patients subsequently treated by surgery,
Combination with 36-50.4 Gy radiation 10 patients had a pathological response 
Senzer et al. 2004 36 patients with solid tumors Intratumoral injection of TNF-erade No dose limiting toxicity
Phase I Combination with 30-70 Gy radiation five patients had synchronous lesions, allowing
the comparison between irradiated only lesion and
lesions treated by radiation and virus. Four patients
had a greater response in the injected lesion
Teh et al. 2004 59 patients with low to high Intratumoral injection of adenovirus encoding All patients without pelvic nodes disease had 
Phase I/II risk prostate cancer HSV-TK, followed by valacyclovir injections negative biopsy results after 2 years and biochemical
Combination with 76 Gy radiation therapy control (PSA) at last follow-up. 
Combination with hormonal therapy for high risk Three out of 4 patients with lymph node disease
patients relapsed
Freytag et al. 2007 9 patients with non metastatic Intraprostatic injection of an oncolytic adenovirus No dose limiting toxicity
Phase I prostate adenocarcinoma encoding the cytosine deaminase/HSV-TK gene 8 patients had post treatment prostate biopsies;
combination with prodrugs 5-fluorocytosine and 7 were negative at last follow-up (6 or 12 months
valganciclovir, and 74 Gy intensity-modulated after treatment)
radiotherapy
Harrington et al. 2010 17 patients with stage III, IVa or Intratumoral injections of herpes simplex virus No dose limiting toxicity
Phase I/II IVb squamous cell cancers of encoding the GMCSF gene Specific disease survival 82.4% at a median 
the head and neck Combination with 70 Gy radiation and cisplatin follow-up of 29 months (range, 19-40 months)
Harrington et al. 2010 23 patients with advanced solid Intratumoral injection of reoviru No dose limiting toxicity
Phase I tumors Combination with 20 Gy or 36 Gy radiation 14 patients evaluable for response
  
24 
 
recognize DNA damages, directly or indirectly, and function to signal the 
presence of these abnormalities and initiate the biochemical cascade. 
Transducers are typically protein kinases that relay and amplify the damage 
signal from sensors by phosphorylating other kinases or downstream target 
proteins. Effector proteins include the ultimate downstream targets of the 
transducer protein kinases. Modification of effector proteins by upstream 
kinases, directly or indirectly, mediates the inhibition in cell cycle progression. 
The effector stage is where the DNA damage checkpoint interphases with the 
cell cycle machinery (Iliakis et al. 2003).   
DNA damage detection occurs as an early event after the DNA lesion has 
occurred. The Mre11-Rad50-Nbs1 (MRN) heterotrimeric protein complex acts 
as a DSB sensor and localizes to DNA breaks very rapidly, binding DNA free 
ends (de Jager et al. 2001; Lisby et al. 2004). Relaxation of the chromatin, 
increasing the accessibility of the DSB to the repair machinery, is also an early 
event (Downs et al. 2007; Halicka et al. 2009; Kim et al. 2009). Mre11 has 
both single-stranded endonuclease and 3’-5’ exonuclease activity and can 
process the ends of the DNA lesion to yield regions of microhomology that are 
between 1 and 5 nucleotides (nt) in length (Paull and Gellert 2000). Rad50 is 
proposed to be involved in holding the two ends of DNA together by 
dimerization through the coiled-coil domains (Moreno-Herrero et al. 2005). 
Rad50 has ATPase activity that is important for regulating DNA binding and 
Mre11 nuclease activity (Bhaskara et al. 2007; de Jager et al. 2002; Hopfner et 
al. 2000). Nbs1 is important in directing the localization of the MRN complex. 
In cells that lack Nbs1, which contains a nuclear localization signal, Mre11 and 
Rad50 remain cytoplasmic (Desai-Mehta et al. 2001). Also, the forkhead-
associated and BRCA1 C-terminal domains of Nbs1 are involved in binding to 
γH2AX and retaining the MRN complex at the site of the lesion (Kobayashi et 
al. 2004). DNA-PK and DNA ligase IV/XRCC4 are involved in ligating the 
DNA ends together to repair the DSB (Baker et al. 2007). When a DSB occurs 
in the cellular genome due to a multitude of causes, ranging from ionising 
radiation (Maser et al. 1997) to viral infection, the MRN complex recognizes 
the lesion and recruits the protein kinases ataxia-telangiectasia mutated (ATM) 
and ATM-Rad3 related (ATR) to the site of the break to initiate the process of 
non-homologous end joining (NHEJ) (Uziel et al. 2003). ATM and ATR are 
central players in activation of the cellular DNA damage response. Through 
intermolecular auto-phosphorylation, ATM is phosphorylated on S1981, 
resulting in the dissociation of dimers into monomers and enzymatic activation 
(Bakkenist and Kastan 2003). ATM activation leads to the direct or indirect 
phosphorylation of more than 30 substrates including p53, NBS-1, Structural 
Maintenance of Chromosomes 1 (SMC-1), E2F1, Checkpoint kinase 1 (Chk1), 
Chk2, Breast Cancer Susceptibility Gene 1 (BRCA1), DNA-dependent protein 
kinase (DNA-PK) and H2AX (Darzynkiewicz et al. 2009; Lavin et al. 2006). 
Large foci form at the site of the DNA break due to the accumulation of 
γH2AX, the phosphorylated form of the histone variant H2AX. γH2AX 
recruits, among other proteins, Mdc1 (mediator of DNA damage checkpoint 1), 
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which serves as a bridge to sustain protein-protein interactions at the DNA 
lesion (Stucki and Jackson 2006). SMC-1 is a member of the cohesion complex 
that holds sister chromatids together during the homologous recombination 
process (Watrin and Peters 2006). SMC-1 is recruited to the site of DSB and 
promotes DNA repair in G2 phase (Bauerschmidt et al. 2010). E2F1 induces 
ATM- and NBS-1 dependent Chk2 phosphorylation and promotes apoptosis by 
cooperating with p53 (Powers et al. 2004; Zhang et al. 2010). Following DNA 
damage, Chk1 is mainly responsible for the G2/M cell cycle checkpoint but 
also mediates cell cycle arrest in S phase. Active Chk1 phosphorylates 
Cdc25C, inhibiting Cdc25C-mediated activation of cyclin-dependent kinase 2 
(Cdk2), a mitosis promoter (Xiao et al. 2003). Activation of Chk2 leads to 
phosphorylation and degradation of Cdc25A which, in turn, leads to silencing 
of Cdk2 activity (Falck et al. 2001). Chk2 also phosphorylates and inhibits 
Cdc25C, providing a further brake on cell cycle progression (Matsuoka et al. 
1998). In response to DNA damage, Chk2 phosphorylates many other 
substrates including p53 and BRCA1 (Darzynkiewicz et al. 2009). 
Phosphorylated BRCA1 plays a role in promoting both HR and in restricting 
error-prone NHEJ repair (Zhang and Pwell 2005). DNA-dependent protein 
kinase plays a major role in NHEJ repair (Lieber 2008). This MRN-ATM 
pathway is illustrated in figure 4. 
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Figure 4. Mre11-Rad50-NBS1 and ATM pathway, in response to a DNA double strand 
break. The Mre11-Rad50-NBS1 complex localizes to DNA breaks and recruits ataxia 
telangiectasia mutated (ATM) protein kinase. The relaxation of the chromatin is an early event, 
initially independently of H2AX and ATM. ATM activation leads to the direct or indirect 
phosphorylation of more than 30 substrates including p53, E2F1, Checkpoint kinase 1 (Chk1), 
Chk2, BRCA1, DNA-dependent protein kinase (DNA-PK) and H2AX, controlling apoptotic 
pathways, cell cycle arrest, and DNA repair pathways.  
 
 
DSBs play an important role in cell death induced by radiation. Two major 
mechanisms of repair of DSBs have been described: the non homologous end-
joining (NHEJ) mechanisms and homologous recombination (HR) (Jackson 
2002). After detection of DNA damage, repair pathways are activated which 
arrest cell cycle progression at an appropriate cell cycle checkpoint. In normal 
cells, with an intact p53 signaling, this will occur at the G1/S checkpoint for 
cells in G0 or G1 of the cell cycle or at the G2/M checkpoint for cells already in 
S or G2 phase at the time of DNA damage. The cell cycle arrest allow cells to 
assess the extent of DNA damage and to attempt its repair. In case the DNA 
damage is irreparable, the cell triggers its own death through apoptosis. In 
cancer cells, a number of the cell cycle checkpoints are deranged and these 
mechanisms may not operate effectively, allowing neoplastic cells survival.  
A number of viral proteins, such as E4-ORF3 and E4-ORF6 products, interact 
with cellular proteins involved in the DNA damage response (Chaurushiya and 
Weitzman 2009; Zhou et al. 2009).  
Moreover, these viral proteins have found to be key components also in 
supporting viral DNA replication. In mutant viruses lacking E4-ORF3 and E4-
ORF6, early viral transcription and gene expression are normal; however, a 
significant delay and reduction in viral DNA replication (Halbert et al. 1985; 
Weinberg and Retner 1986) has been observed. An important function of these 
Ad E4 proteins is the inhibition of the Mre11-Rad50-Nbs1 (MRN) complex 
(Lilley et al. 2007;Weitzman and Ornelles 2005).  
The role of the MRN complex in NHEJ is relevant to an Ad infection due to 
the fact that MRN could perceive the linear, double-stranded Ad DNA 
genomes as DSBs. Following infection with a mutant virus that lacks both E4-
ORF3 and E4-ORF6, the cell senses the DNA damage through the sensor 
complex, ATM is phosphorylated, checkpoint signaling occurs, and the 
genomes are eventually ligated together to form large concatemers (Lilley et al. 
2007; Weitzman and Ornelles 2005). These concatemers are too large to be 
packaged into virus particles. The origins of replication are located at the 
termini of the viral genome, therefore mutant viruses would be inefficiently 
replicated due to the lack of a free terminus in internal genomes. Moreover the 
junctions of the concatemers also have deletions (Weiden and Ginsberg 1994), 
suggesting that the ends of the Ad genome are degraded.  
Adenoviruses have evolved several mechanisms to counteract the detrimental 
effects of NHEJ, two of which specifically target the MRN complex. The E4-
ORF3 protein can redistribute Mre11, Rad50, and Nbs1 from their normal 
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diffuse nuclear localization into large nuclear and cytoplasmic accumulations 
during infections or E4-ORF3 transfection (Evans and Hearing 2005; Stracker 
et al. 2002; Stracker et al. 2005). This effectively sequesters the MRN complex 
away from the viral genomes, which are located at the replication centers and 
do not colocalize with redistributed MRN proteins (Evans and Hearing 2005; 
Stracker et al. 2005) (figure 5).  
 
 
 
 
 
 
Figure 5. Role of viral E4-ORF3 protein  
The E4orf3 protein can redistribute Mre11, Rad50, and Nbs1 from their normal diffuse nuclear 
localization into large nuclear and cytoplasmic accumulations during infections and 
transfection. 
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The E4-ORF6 protein interacts with another viral protein, E1B-55KDa, to form 
an E3 ubiquitin ligase complex with the cellular proteins Rbx1, Cullin 5 
(CUL5), and elongins B and C (Harada et al. 2002; Querido et al. 2001). This 
complex targets specific proteins, such as p53, Mre11, and DNA ligase IV, for 
proteasome-dependent degradation (figure 6) (Baker et al. 2007; Harada et al. 
2002; Querido et al. 2001). E1B-55KDa and E4-ORF3 also are involved in 
relocalizing Mre11 to cytoplasmic aggresomes (Araujo et al. 2005; Liu et al. 
2005).  
 
 
 
Figure 6. Role of viral E4-ORF6 protein 
E4-ORF6 protein interacts with another viral protein, E1B-55K, to form an E3 ubiquitin ligase 
complex with the cellular proteins Rbx1, Cullin 5 (CUL5), and elongins B and C. This 
complex targets specific proteins, such as p53, Mre11, and DNA ligase IV, for proteasome-
dependent degradation 
 
 
With either a virus that lacks E4-ORF6 or E4-ORF3 alone, checkpoint 
signaling and concatemer formation are inhibited, but the deletion of both of 
these Ad gene products results in checkpoint signaling induction, concatemer 
formation, and a significant decrease of viral DNA replication (Lilley et al. 
2007; Weitzman and Ornelles 2005).  
It is not clear if the infection with adenoviruses is sufficient to trigger the 
DSBR response or if viral DNA replication is required. This second hypothesis 
is more likely to occur since it has been observed that E4-ORF3 protein causes 
the redistribution of the MRN complex by 6h postinfection (hpi), before viral 
DNA replication begins (Evans and Hearing 2005). In the absence of the E4-
ORF3 protein, when MRN activity is solely inhibited by E4-ORF6/E1B-
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55KDa-induced degradation, MRN protein levels are not reduced until later 
after infection (Liu et al. 2005; Stracker et al. 2002). 
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2. AIM OF THE STUDY 
 
Replication selective oncolytic viruses (OVs) are a rapidly expanding 
therapeutic platform for the treatment of aggressive human malignancies, such 
as anaplastic thyroid carcinoma (ATC). OVs are characterized by genetic 
alterations that ablate critical viral protein functions essential for viral 
replication in normal cells, but non essential in tumor cells, thus targeting viral 
replication to tumor cells. OVs show several advantages for the therapy of 
cancer: viral replication leads to host cell destruction, and to an amplification 
of the viral load in a single replicative cycle (Chiocca 2002). Furthermore, OVs 
lack cross-resistance with current clinical therapies and represent a promising 
anti-cancer approach (Kumar et al. 2008).  
Preclinical and clinical studies have clearly shown the antineoplastic potential 
of oncolytic viruses, at least for local treatment, but have also highlighted the 
need to find associations that could improve their activity. The association of 
viruses with specific drugs, not only able to directly kill tumor cells but also to 
increase viral oncolytic activity, would represent a powerful therapeutic tool 
for the treatment of human neoplasia.  
ATC is one of the most aggressive human malignancies, responsible for up to 
40% of mortality from thyroid cancer. Although multimodality treatments are 
successfully applied for well-differentiated thyroid carcinomas, ATC survival 
rates have not been improved for decades: after diagnosis, patients have a 
median survival time of 4-6 months (Smallridge et al. 2009). Development and 
evaluation of novel therapeutic strategies are, therefore, desperately required. 
In fact, the actual palliative treatment of ATC consists of irradiation plus 
chemotherapeutic drugs, known DNA damaging agents. In order to identify 
novel therapeutic approach for the treatment of ATC, during my PhD project I 
have studied the effects of ionising radiations in combination with dl922-947 in 
vitro and in vivo, in particular focusing my attention on which type of cell 
death is activated by the combined treatment. Therefore, to identify novel 
drugs able to enhance the effects of OVs, I have also studied the effects of 
dl922-947 on the DNA damage pathway and the effects of the combination 
between dl922-947 plus ATM inhibitor on cytotoxic activity of the virus on 
ATC models.  
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3. MATERIALS AND METHODS 
 
3.1 Cell lines and drug 
 
Human ATC cell lines, FRO and BHT101-5 have been authenticated as shown 
previously (Schweppe et al. 2008). This two ATC cell lines have a non-
functional p53 gene: in BHT101-5 cells, a 251 Ile/Thr substitution has been 
reported, while FRO cells are p53 null (Schweppe et al. 2008). FRO cells were 
obtained by Dr. Juillard (University of California LA), while BHT101-5 cells 
were established by Dr. Palyi (National Institute of Oncology, Hungary). Both 
cell lines were grown in DMEM medium supplemented with 10% FBS, 100 IU 
of penicillin/ml and 100 IU of streptomycin/ml in humified CO2 incubator.  
ATM kinase inhibitor KU55933 (sc-202963, Santa Cruz) was dissolved in 
DMSO to a final concentration of 10 mM and stored at -20°C.  
 
3.2 Preparation of adenoviruses 
 
dl1520 (ONYX-015), a gift from Dr. A. Balmain and Dr. I. Ganly, is a 
chimaeric human group C adenovirus (Ad2 and Ad5) that has a deletion 
between nucleotides 2496 and 3323 in the E1B region that encodes the 55-KDa 
protein. In addition, there is a C to T transition at position 2022 in region E1B 
that generates a stop codon at the third codon of the protein.  
dl922-947 is a second generation adenoviral mutant that has a 24-bp deletion in 
E1A Conserved Region 2 (CR2) therefore, is unable to induce progression 
from G1 into S-phase of quiescent cells.  
Ad5wt is a non-mutant adenovirus used as control adenovirus.  
AdGFP is a non replicating E1-deleted adenovirus encoding green fluorescent 
protein.  
Viral stocks were expanded and tittered in human embryonic kidney cell line 
HEK-293, which expresses the E1 region. Stocks were stored at -80°C after the 
addition of glycerol to a concentration of 50% vol/vol. Virus titer was 
determined by plaque-forming units (pfu) on the HEK-293 cells.  
 
3.3 Viability assay 
 
For the evaluation of the cytotoxic effects of dl922-947 in combination with 
ionising radiation, FRO and BHT101-5 cells were seeded in 96-well plates, 
24h later increasing concentration of dl922-947 were added to the incubation 
medium, and after additional 24h cells were irradiated with increasing doses of 
ionising radiation, or viceversa. For the evaluation of the cytotoxic effects of 
dl922-947 in combination with ATM kinase inhibitor, cells were seeded in 96-
well plates, and 24h later were treated with increasing concentration of viruses 
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in combination or not with the drug. Six days later, cells were fixed with 50% 
TCA and stained with 0.4% sulforhodamine B in 1% acetic acid. The bound 
dye was solubilized in 100 µl of 10 mM unbuffered Tris HCl solution and the 
optical density was determined at 495 nm in a microplate reader (Biorad). The 
percent of survival rates of cells exposed to adenovirus vectors were calculated 
by assuming the survival rate of untreated cells to be 100%. 
 
3.4 Quantitative PCR of adenovirus 
 
To quantify the amount of viral genomes, cells were infected with dl922-947 
(0-0.5-1-2.5-5-7.5-10 pfu/cell) and 24h later were irradiated, or viceversa. 
After 48h of treatment, cell media was collected and viral DNA extracted using 
a High Pure Viral Nucleic Acid Kit (Roche) and then quantified by Real-Time 
PCR using assay-specific primer and probe. Real time-based assay was 
developed using the following primers: 5’-GCC ACC GAG ACG TAC TTC 
AGC CTG -3’ (Upstream primer) and 5’- TTG TAC GAG TAC GCG GTA 
TCC T -3’ (Downstream primer) for the amplification of 143 bp sequence of 
the viral hexon gene (from bp 99 to 242 bp). For quantification, a standard 
curve was constructed by assaying serial dilutions of dl922-947 ranging from 
0.1 pfu to 100 pfu. To quantify the amount of viral genomes in cells 
undergoing the combined treatment (virus plus ATM inhibitor), FRO and 
BHT101-5 cells were infected with increasing concentration of the virus (0-1-
5-10 pfu/cell) in combination with increasing concentration of the drug (0-600-
800-1000 nM), or were pre-treated for 24h with the drug and then infected with 
the virus. After 48h of treatment, cell media was collected and viral DNA 
extracted using a High Pure Viral Nucleic Acid Kit (Roche) and then 
quantified by Real-Time PCR using assay-specific primer and probe. To 
quantify the amount of dl922-947 virus genome in tumor xenografts, viral 
DNA was extracted from 50 mg of each sample using a High Pure Viral 
Nucleic Acid Kit. DNA was resuspended in 200 µL of eluition buffer and 2 µL 
used for the Real Time PCR-based assay. For each experiment the DNA was 
extracted from three different samples of each treatment group.  
 
3.5 AdGFP infection  
 
For the evaluation of adenoviral infectivity in human thyroid carcinoma cell 
lines after the combined treatment (virus plus IR), cells were detached, 
counted, and plated in 6 well plate at 70% cell density. After 24h, cells were 
infected with a green fluorescent protein (GFP)-transducing adenovirus 
(AdGFP), a non replicating E1-deleted adenovirus encoding GFP, diluted in 
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growth medium at different multiplicity of infection (MOIs) (0-25-50 pfu/cell). 
After additional 24h cells were irradiated with increasing doses of IR (0-2-4-8 
Gy). Cells were trypsinized 48h after the combined treatment and then washed 
and resuspended in 300 µL PBS and analysed for GFP emission in FITC 
channel. Samples were acquired with a CYAN flow cytometer (DAKO 
corporation, San Jose, CA, USA) and analysed using SUMMIT software.  
 
3.6 Cell cycle analysis 
 
Adherent FRO and BHT101-5 cells detached with trypsin–EDTA were 
collected, fixed with 70% ethanol, and stained with a 10% propidium iodide 
solution (cellular DNA flow cytometric analysis reagent set; Roche) according 
to the manufacturer’s instructions. DNA content was analyzed with a FACScan 
flow cytometer. 
 
3.7 FACS analysis: P-H2AX and cell cycle 
 
Cells treated with IR, virus or both were harvested by trypsinization, fixed in 
70% cold-ethanol over night. The fixed cells were washed with PBS and 
permeabilized 15 min in 10% FBS/TBS tween 0.1%. TBS tween 0.1% washed 
pellet was incubated 2h in 50 µL of anti-phospho-histone H2AX antibody 
diluted 1:50 in 4% FBS/TBS tween 0.1%. After washing with TBS tween 
0.1%, cells were incubated 1h in anti-rabbit IgG FITC conjugated antibody 
diluted 1:100 in 4% FBS/TBS tween 0.1%. The immunostained cells were then 
washed with TBS tween 0.1% and stained 20 min with 1 mg/ml propidium 
iodide plus 500µg/ml RNase A in 400 ml PBS. All incubations were performed 
at room temperature, the last two ones were also performed in the dark. 
Incubation with H2AX and without primary antibody was performed to assess 
the specificity of the observed signal. Samples were acquired with a CYAN 
flow cytometer (DAKO Corporation, San Jose, CA) and analyzed using 
SUMMIT software. 
 
3.8 Western blot  
 
Cells were homogenized directly into lysis buffer (150 mM NaCl, 1% NP-40, 
0,5% sodium deoxycholate, 50 mM Tris pH 8). The lysates were clarified by 
centrifugation at 14,000 rpm for 20 min. Protein concentrations were estimated 
by an assay (Bio-Rad) and boiled in Laemmli buffer [60 mM Tris-HCl (pH 
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6.8), 9,2% SDS, 40% glycerol, 20% 2-mercaptoethanol, and 0.00125% 
bromophenol blue] for 5 min before electrophoresis. Proteins were subjected to 
SDS-PAGE (7,5-10-15% polyacrylamide) under reducing conditions. After 
electrophoresis, proteins were transferred to nitrocellulose membranes 
(Immobilon, Millipore Corp., Bedford, MA); complete transfer was assessed 
using trans-blot SD semi-dry transfer cell (BioRad). After blocking with 5% 
milk solution, the membranes were incubated with the primary antibodies over-
night at 4°C. Membranes were then incubated with the horseradish peroxidase-
conjugated secondary antibody (1:2000) for 45 min (at room temperature), and 
the reaction was detected with an enhanced chemiluminescence system 
(PIERCE, Thermo scientific) with Chemidoc XRS (BioRad). 
 
3.9 Antibodies for western blot 
 
Mouse monoclonal [31A1067] to active + procaspase 3 (ab13585; 1:1000, 
abcam), anti-actin H-300 (sc-10731; 1:500, Santa Cruz, CA, USA), anti-tubulin 
(650951; 1:1000, ICN Biomedicals), anti-ATR (09-070; 1:1000, Millipore), 
anti-NBS1 clone Y112 (04-236; 1:1000, Millipore), anti-phospho-ATM 
(Ser1981) (10H11.E12) (4526S; 1:1000, Cell signaling technology), anti-
phospho-Chk1 (Ser345) (133D3) (2348; 1:1000, Cell signaling technology), 
anti-adenovirus-2/5 E1A (13 S-5) (sc-430; 1:1000, Santa Cruz, CA, USA), 
anti-MRE11 (49959; 1:1000, Millipore), anti-phospho-Chk2 (Thr68) (2661; 
1:1000, Cell signaling technology), anti-phospho-histone H2A.X (Ser139) 
(20E3) (9718; 1:2000, Cell signaling technology), anti-RAD50 (07-1781; 
1:1000, Millipore), anti-ATM (07-1286; 1:1000, Millipore), anti-integrin β3 
(sc:20058; 1:1000, Santa Cruz, CA, USA), anti-CAR (H-300) (sc-15405; 
1:1000, Santa Cruz, CA, USA) are the antibodies used for western blot.  
 
3.10 Tumorigenicity assays  
 
Experiments were performed in six-week-old female athymic mice (Charles-
River, Italy). All mice were maintained at the Dipartimento di Biologia e 
Patologia Animal Facility, in accordance with accepted standards of animal 
care and with the Italian regulations for the welfare of animals used in studies 
of experimental neoplasia. The studies were approved by Ethic Committee on 
animal care of the University Federico II Napoli. FRO cells (8x106) were 
injected into the right flank of  60 athymic mice. The animals were monitored 
for the appearance of tumors and tumor latency evaluated. After 20 days, when 
tumors were clearly detectable, tumors volumes were evaluated and the 
animals were randomised into four groups (15 animals/group) (T=0) with 
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similar average tumour size: untreated, treated with IR, dl922-947, or both. 
Two groups were irradiated with a single radiation dose (10Gy), on the tumor 
volume at a distance of 80 cm with a bolus interposition to avoid lower doses 
at the tumor external edge. Virus was administered three times per week by 
intratumoral injection to avoid first pass effect. A low viral dose (1x106 pfu) 
was used to better evaluate the effects of the combined treatment. The control 
group was injected with saline solution. Tumors diameters were measured with 
calipers and tumors volumes (V) were calculated by the formula of rotational 
ellipsoid: V=AxB2/2 (A=axial diameter, B=rotational diameter). Experiment 
was stopped when tumors reached 1 cm3 in volume and/or symptomatic tumor 
ulceration occurred. To evaluate the genome equivalent copies of dl922-947 in 
tumor xenografts, 10 mice were irradiated with a single radiation dose and 24h 
after the virus was inoculated intratumorally. After additional 48h animals 
were sacrified, the tumor mass excised, DNA extracted and viral replication 
evaluated by Real Time PCR. To evaluate viral distribution in tumor mass after 
the combined treatment,  FRO cells (8x106) were injected into the right flank of 
10 athymic mice, and after 20 days, when tumors were clearly detectable, 
animals were randomized into two groups (5 animals/group). Only one group 
was irradiated with a single radiation dose (10 Gy). AdGFP (1x107 pfu) was 
injected intratumorally in both groups 24h after. After additional 48h, animals 
were sacrificed, and tumors were excised, snap frozen in liquid nitrogen, and 
cut with a cryostat in thick sections for microscopic investigation. Sections 
were mounted onto untreated slides and coverslipped in slow-fade antifade 
(Molecular Probes) for microscopic investigation. Ten sections were sampled 
across the entire tumor mass to ensure they were representative of the 
distribution of GFP-positive signal into the tumor mass. For each slice, 10 
images at high resolution were sampled from the periphery to the core of the 
section. Images were acquired using a ZeissLSM510 Meta argon-krypton laser 
scanning confocal microscope, with fluorescence excitation lines at 488 nm 
and emission filter BP505-550, 20x (Plan Apochromat; numerical aperture, 
1.4; Zeiss), pixel depth of 12 bit, fixed box sizes of 512x512 pixels, and 
pinhole below 1 Airy unit. Four images from each optical section were 
averaged to improve the signal-to-noise ratio. The color scheme used was 
green for GFP-labeled structures.  
 
3.11 Statistical analysis   
 
Comparisons among different treatment groups in the in vivo experiment were 
made by the ANOVA method and the Bonferroni post hoc test using a 
commercial software (GraphPad Prism 4). Assessment of differences among 
rate of tumor growth in mice was made for each time point of the observation 
period. The analysis of the cell killing effect in vitro was also made by 
ANOVA method and the Bonferroni post hoc test. For all the other 
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experiments comparisons among groups were made by ANOVA method and t 
test.  
 
3.12 Micronuclei counting  
 
FRO and BHT101-5 cells were grown on cover slips and treated with 
increasing doses of IR (0-4-8-16 Gy). After 24-48h cells were fixed 15’ in 3% 
paraformaldehyde, permeabilized with 0.2% Triton X-100 10’ and then stained 
5’ with Hoechst 33258 (1 µg/ml, Sigma-Aldrich). The washes were followed 
by mounting the cover slips onto glass slides with glycerol:PBS 1:1. 
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4. RESULTS 
 
4.1 Ionising radiation enhances the effects of the oncolytic adenovirus 
dl922-947 
 
It has been demonstrated in preclinical studies that ionising radiation 
enhances the efficacy of first generation oncolytic viruses (Portella et al. 2003; 
Stanziale et al. 2002; Rajecki et al. 2009). To evaluate whether ionising 
radiation (IR) could enhance oncolytic activity of a second generation 
oncolytic virus, dl922-947, FRO and BHT101-5 cells, were seeded in 96-well 
plates and infected with different multiplicity of infection (MOIs) of dl922-947 
(0-0.1-0.5-1-2.5-5 pfu/cell), expressed as plaque forming unit (pfu/cell) and 
irradiated with increasing doses of IR (0-2-3-4-5 Gy), and cell survival was 
evaluated after seven days. In previous studies it has not been clearly evaluated 
the best timing for this combined treatment. In order to identify the most 
appropriate timing, ATC cells (FRO and BHT101-5) have been infected with 
growing concentration of dl922-947 and after 24h irradiated or viceversa. The 
results are shown in figure 7 (A-B).  
Viability assays show that ionising radiation enhances the effects of dl922-947 
against ATC cells. Both combinations lead to an enhanced effect, although our 
data clearly show that the most effective treatment is infection followed after 
24 hours by irradiation. All combination points show a significant difference 
with respect to the single treatments. On the contrary, in cells irradiated and 
then infected an effect is evident only at the higher concentration of the virus. 
In particular, in cells treated with 7.5 pfu/cell of the virus plus 4 Gy, we can 
observe a 2.6 fold increase in cells mortality with respect to the single 
treatments, versus the 1.3 fold increase observed in IR pre-treated cells. 
 
 
A 
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Figure 7. Effects of the combined treatment:dl922-947/IR on ATC cell lines. 
FRO and BHT101-5 cell lines were infected with increasing concentration of dl922-947 and 
24h after irradiated with different doses of ionising radiation (A) or viceversa (B). After seven 
days cells were analyzed by viability assay. The percentage of survival rates of cells exposed to 
combined treatment were calculated by assuming the survival rate of untreated cells to be 
100%. 
 
To explore the possibility that ionising radiation improves viral replication in 
ATC cells, I have performed a Real-Time PCR based assay to evaluate the 
genome equivalent copies of dl922-947 in ATC cells undergoing the combined 
treatment.  
FRO and BHT101-5 cells were irradiated with increasing doses of IR (0-2-3-4-
5 Gy) and 24h later infected with different concentration of dl922-947 (0.5-1-
2.5-5-7.5-10 pfu/cell). After additional 48h, viral DNA was extracted and 
genome equivalent copies analyzed by Real-Time PCR. As shown in figure 
8A, a clear increase in viral replication was observed in both cell lines.  
Next I have verified whether ionising radiations increase viral genes 
expression, analyzing expression levels of early E1A viral gene in irradiated or 
untreated cells.  
FRO cells were irradiated (0-2-6 Gy) and then infected with 10 and 25 pfu/cell 
of dl922-947. E1A levels were analyzed by western blot at two different 
experimental times (16-24h). As shown in figure 8B, E1A levels increase in a 
dose dependent manner. 
This results clearly show that ionising radiation induces an increase of viral 
replication and enhances the expression of early viral genes in a dose-
dependent manner. 
 
B 
  
39 
 
 
 
 
Figure 8. Effects of IR on viral life cycle and gene expression 
A. FRO and BHT101-5 cells were irradiated with increasing doses of IR (0-2-3-4-5 Gy) 
and 24h later infected with different concentration of dl922-947 (0.5-1-2.5-5-7.5-10 
A. 
B. 
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pfu/cell). After additional 48h, viral DNA was estracted and genome equivalent 
copies analyzed by Real-Time PCR. A clear increase in viral replication was observed 
in both cell lines. 
B. FRO cells were irradiated (0-2-6 Gy) and then infected with 10 and 25 pfu/cell of 
dl922-947. E1A levels were analyzed by western blot at two different experimental 
times (16-24h). E1A levels increase in a dose dependent manner. 
 
4.2 Ionising radiation does not increase viral entry upon infection 
 
It has been proposed that radiation can enhance viral oncolytic activity 
by increasing viral entry in target cells, probably enhancing the expression of 
the coxsackie and adenovirus receptor (CAR) on the membrane of infected 
cells or the expression of αv/β3/5 integrin subunits, acting as low affinity co-
receptors. To monitor this step, FRO cells were irradiated and 24h later 
infected with a non-replicating reporter adenovirus transducing green 
fluorescent protein (AdGFP). After additional 48h, GFP emission was 
evaluated by cytofluorimetric analysis. The percentage of GFP cells was not 
modified by radiation, although a positive shift in FITC channel was observed. 
This increase is apparent since IR treatment enlarges the cells enhancing basal 
fluorescence. Indeed, the analysis of FITC ratio in irradiated and unirradiated 
cells infected or not with AdGFP showed no significant differences (Fig. 9A). 
Similar results were obtained with BHT101-5 cells (data not shown).  
To confirm that IR do not increase viral entry upon infection, I have also 
analyzed the expression levels of CAR and αv/β3 integrin subunits. FRO cells 
were irradiated with different doses of IR (0-2-4-6-8 Gy) and 24h later infected 
with 10 pfu/cell of dl922-947. Twenty-four hours after infection CAR and 
integrin levels were analyzed by western blot. As shown in figure 9B ionising 
radiation do not increase CAR and integrin levels upon infection. The increase 
of CAR levels in cells undergoing the combined treatment with respect to the 
untreated cells, was due to the viral infection, as previously observed by us 
(unpublished observation). 
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Figure 9. Effects of ionising radiation on viral entry 
A. FRO cells were irradiated and 24h after infected with a non replicating reporter 
adenovirus transducing green fluorescent protein (AdGFP). After additional 48h, GFP 
emission was evaluated by cytofluorimetric analysis. The percentage of GFP cells was 
not modified by radiation.  
B. FRO cells were irradiated with different doses of IR (0-2-4-6-8 Gy) and 24h later 
infected with 10pfu/cell of dl922-947. Twenty-four hours after infection CAR and 
integrin levels were analyzed by western blot. IR do not increase CAR and integrin 
levels upon infection. 
 
 
 
A. 
B. 
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4.3 IR induces G2 accumulation and caspase-3 activation: effects of the 
combined treatment on ATC cell cycle and cell death 
 
It is well known that after exposure to ionising radiations, two distinct 
G2/M checkpoints are activated: the early G2 checkpoint prevents the 
progression of cells irradiated in G2 into mitosis; the G2/M accumulation 
blocks in G2 the cells that had been in earlier phases of the cell cycle at the 
time of irradiation (Metting and Little 1995).  
To confirm IR effects on ATC cells, FRO and BHT101-5 were irradiated with 
different doses (0-4-8-16 Gy) for 24-48-72-96h and by propidium iodide 
staining, the effects of IR on cell cycle were evaluated. As shown in figure 10, 
a dose and time dependent increase in polyploid cells was observed. After 24h 
of treatment, a G2/M accumulation was observed, and after 48h also an 
increase in the percentage of cells in subG1 fraction was observed.  
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Figure 10. Effects of IR on ATC cell cycle 
FRO and BHT101-5 were irradiated with different doses (0-4-8-16 Gy) for different times (24-
48-72-96h) and by propidium iodide staining, the effects of IR on cell cycle were evaluated. A 
dose and time dependent increase in polyploid cells was observed. In particular, after 24h of 
treatment, a G2/M accumulation was observed in both cell lines at the higher doses of IR (8-16 
Gy), and after 48h of treatment also an increase in the percentage of cells in subG1 fraction 
was observed. 
 
The increase of cells with >4N DNA content and a subsequent subG1 suggest 
that IR treated cells could die through mitotic catastrophe, a form of 
programmed cell death resulting from aberrant mitosis. Caspase-3 activation 
has been frequently observed in mitotic catastrophe.  
I have also analyzed caspase-3 activation in irradiated ATC cells. FRO and 
BHT101-5 cells were irradiated with increasing doses of IR (0-2-4-8-16 Gy for 
FRO cells; 0-4-8-16 Gy for BHT101-5 cells) and were collected at different 
experimental time points (24-48-72-96h) to analyze by western blot the effects 
of the treatment on caspase-3 activation. As shown in figure 11, a decrease of 
procaspase-3 was observed 48h after the treatment, followed by caspase-3 
cleavage and activation.  
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Figure 11. IR activates caspase-3 in ATC treated cells 
FRO and BHT101-5 cells were irradiated with increasing doses of IR (0-2-4-8-16 Gy for FRO 
cells; 0-4-8-16 Gy for BHT101-5 cells) and were collected at different experimental time 
points (24-48-72-96 h). A decrease of procaspase-3 was observed 48h after the treatment, 
followed by caspase-3 cleavage and activation. 
 
Mitotic catastrophe is a form of cell death resulting from aberrant mitosis. Such 
mitosis does not produce proper chromosome segregation and cell division, 
and leads to the formation of large non-viable cells characterized by 
micronuclei (Castedo et al. 2004). Micronuclei are nuclear envelopes around 
clusters of missegregated chromosomes (examples in figure 12).  
To verify whether ionising radiation induces the formation of micronuclei, 
FRO and BHT101-5 cells were irradiated with increasing doses of IR (0-4-8 
Gy) and the number of micronucleated cells was quantified by 
immunofluorescence analysis. As shown in figure 13, a clear dose- and time-
dependent increase in the number of micronucleated cells was observed.  
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Figure 12. Ionising radiation induces mitotic catastrophe on ATC treated cells 
Hoechst staining of FRO and BHT101-5 cells irradiated or not with 4 or 8 Gy. The same 
magnification (40x) was used in the images.  
 
 
Figure 13. Ionising radiation induces mitotic catastrophe on ATC treated cells 
FRO and BHT101-5 cells were irradiated with increasing doses of IR and the number of 
micronucleated cells was quantified by immunofluorescence analysis. The cells with ≥ 3 
micronuclei were counted as positive. 
 
The cell death pathways activated by the infection with OVs are only partially 
understood, however several evidences indicate that they are cell type 
depending. In glioma cells, the infection with dl922-947 activates an 
autophagic pathway (Botta et al; under review) while, in ATC cells, dl922-947 
infection does not induce autophagy but rather a programmed cell death, that 
lacks the features of classical apoptosis, but presents some apoptotic markers 
such as subG1 accumulation and caspase-3 activation (Libertini et al. 2011). 
In order to evaluate which type of cell death occurs in ATC cells upon 
combined treatment, cell cycle profiles in infected/irradiated cells were 
performed. FRO cells were irradiated (0-4-8 Gy) and then infected with 10 
pfu/cell of dl922-947. Starting from 24h of treatment, cells were collected and 
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cell cycle analyzed by PI staining and FACS analysis. The combination 
between IR and virus increased the percentage of cells in subG1 fraction 
compared with single treatments (figure 14). 
 
Figure 14. dl922-947 and IR induce subG1 phase population in treated cells 
FRO cells were irradiated and then infected with 10 pfu/cell of dl922-947. Cells were collected 
at different times and cell cycle analyzed by PI staining and FACS analysis. The combination 
treatment  increased the percentage of cells in subG1 fraction compared with single treatments.  
 
Since in ATC cells, dl922-947 infection leads to programmed cell death 
lacking the features of classical apoptosis, but showing some apoptotic 
markers, such as subG1 accumulation and caspase-3 activation, I have also 
analyzed caspase-3 activation in cells undergoing the combined treatment.  
As shown in figure 15, in the combined treatment, an earlier decrease of 
procaspase-3 with respect to virus treatment alone was observed. This 
observation suggests that ionising radiations could enhance viral induced cell 
death by accelerating the activation of caspase-3 pathway. 
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Figure 15. dl922-947 and IR induce caspase-3 activation   
FRO cells were irradiated with 8 Gy and then infected with 10 pfu/cell of the virus. Starting 
from 24h, cells were collected and caspase-3 levels analyzed by western blot. In the combined 
treatment, an earlier decrease of procaspase-3 with respect to virus treatment alone was 
observed. 
 
4.4 Ionising radiation in combination with dl922-947 reduced the 
growth of ATC tumor xenografts 
 
In order to demonstrate that the combined treatment ionising radiation 
and dl922-947 could potentially yield improved clinical efficacy, I have 
evaluated the effects of ionising radiation treatment in vivo.  
Sixty athymic mice were inoculated subcutaneously with FRO cells (8x106). 
After 20 days, when tumors were clearly detectable, the animals were 
randomized into four groups. Two groups were irradiated with a single 
radiation dose (10 Gy), on the tumor volume. Virus was administered three 
times per week by intratumoral injection to avoid first pass effect. A low viral 
dose (1x106 pfu) was used to better evaluate the effects of the combined 
treatment. The control group was injected with saline solution. As shown in 
figure 16, a significant difference was observed in the combined treatment 
group with respect to single treatments.   
 
 
* 
* 
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Figure 16. Tumor growth 
Two groups were irradiated with a single radiation dose (10 Gy), on the tumor volume; virus 
was administered three times per week by intratumoral injection to avoid first pass effect. The 
control group was injected with saline solution. The combined treatment, IR plus dl922-947, is 
able to reduce tumor growth with a higher efficiency with respect to the virus or ionising 
radiation alone (*p<0.05 up to T=20).  
 
Next, by Real Time PCR, I have evaluated the genome equivalent copies of 
dl922-947 in animals treated with IR and dl922-947. Figure 17 reports the 
amount of viral DNA copies in the group treated with dl922-947 alone and in 
the group treated with dl922-947 plus IR. The combined treatment induces a 
viral replication twenty fold higher with respect to the virus alone.  
 
 
 
 
Figure 17. Effects of IR/virus combination 
FRO cells were inoculated into the right flank of 10 athymic mice. When tumors were clearly 
detectable, animals were divided in two groups. One group of animals was irradiated with a 
single radiation dose (10 Gy) and 24h after the virus was injected intratumorally in both 
groups. After additional 48h animals were sacrified, the tumor excised, DNA extracted and 
viral replication evaluated. The combined treatment induces a viral replication twenty fold 
higher with respect to the virus alone. 
 
I have then evaluated viral distribution in tumor tissues. Figure 18 reports 
images of confocal microscopy. Fluorescence is more diffuse and intense in 
AdGFP injected and irradiated tumors with respect to the AdGFP injected 
tumors. This observation indicate that together with the effects observed in 
vitro, IR contributes to a better diffusion of the virus within the tumor mass, 
further confirming the efficacy of this combination.  
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Figure 18. Effects of IR/dl922-947 combination 
FRO cells (8x106) were injected into the right flank of 10 athymic mice, and after 20 days, 
when tumors were clearly detectable, animals were randomized into two groups (5 
animals/group). Only one group was irradiated with a single radiation dose (10 Gy). AdGFP 
(1x107 pfu) was injected intratumorally in both groups after 24h. After additional 48h, animals 
were sacrificed, and tumors were excised. On the left the distribution of AdGFP alone is 
represented, on the right there is the AdGFP distribution after the pre-treatment with IR. The 
fluorescence is more diffuse and intense in animal tissues treated with AdGFP plus IR with 
respect to the tissues treated with the virus alone. 
 
I have also evaluated the activation of caspase-3 in ATC xenografts after the 
combined treatment. Interestingly, there is a higher activation of caspase-3 in 
the animals undergoing the combined treatment (figure 19). 
 
 
Figure 19. Activation of caspase-3 in ATC xenografts 
Proteins were extracted from ATC tumors and caspase-3 activation levels were analyzed by  
western blot. As shown in the blot, in the animals undergoing the combined treatment there is a 
higher activation of caspase-3, indicative of a higher tumor cell death. 
 
 
All these results demonstrated that the pre-treatment with IR is able to improve 
the therapeutic effect of dl922-947 adenovirus against ATC. 
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4.5 dl922-947 modulates the DNA damage signaling pathway to 
enhance ionising radiation effects 
 
It is well known that ionising radiation induces DNA damage and 
activates the damage signaling pathway. It has been hypothesized that Ad OVs  
interact with cellular DNA damage response pathways to avoid the formation 
of the concatemers and to better replicate in target cells (Evans and Hearing 
2005; Stracker et al. 2002; Stracker et al. 2005; Baker et al. 2007).  
To verify whether the infection with oncolytic viruses could modify the 
response to DNA damage IR-induced, FRO cells were infected with a panel of 
adenoviral mutants: dl922-947, dl1520 bearing a deletion of E1B-55KDa, 
Ad5wt a non-mutant adenovirus used as control adenovirus, and AdGFP a non 
replicating E1-deleted adenovirus encoding GFP. After 1-3-6-16h cells were 
collected and DNA damage pathway proteins levels analyzed by western blot. 
As shown in figure 20, starting from 1hpi (hours post infection), dl922-947 and 
dl1520 induce the phosphorylation of ATM on Ser1981, an early step of 
activation of DNA damage signaling pathway. Interestingly, dl922-947 and 
dl1520 also induce the activation by phosphorylation on Ser139 of histone 
H2A.X, a downstream effector of the activation of ATM. Moreover, dl922-947 
induces the activation of Chk1/2 by phosphorylation on Ser345 and Thr68, 
respectively. Starting from 3hpi, in cells infected with dl922-947 I observed a 
reduction of the MRN proteins, which was more evident after 6 and 16 hours 
of treatment. It is worth to note that dl1520, lacking a functional E1B-55KDa, 
does not modify MRN protein levels. Ad5wt does not affect MRN protein 
expression at the time points evaluated. This effect is probably due to the 
different replication kinetic of Ad5wt with respect to dl922-947.   
 
 
  
  
51 
 
 
 
 
 
 
  
52 
 
 
 
Figure 20. Effects of viral infection on DNA damage signaling pathway 
FRO cells were infected with a panel of adenoviral mutants: dl922-947, dl1520, Ad5wt and 
AdGFP. Cells were collected at different times (1-3-6-16hpi) and DNA damage pathway 
protein levels were analyzed by western blot. 
 
To confirm that the infection with dl922-947 induces a cellular DNA damage 
in ATC cells, I have also analyzed the activation of histone H2A.X by FACS 
analysis. FRO cells were infected with two different concentration of the virus 
(10 and 25 pfu/cell), collected at two different times (6 and 24 hpi) (figure 21). 
After 6h of treatment the activation of histone H2A.X was observed, as 
previously demonstrated also by western blot analysis. Interestingly, the 
activation of the H2A.X persists after 24h of infection, suggesting that the 
damage was not repaired. The same results were confirmed by western blot 
(figure 22).  
I can conclude that the infection with dl922-947 induces the activation of the 
DNA damage signaling pathway, through the activation of the most important 
sensors of the damage (ATM and histone H2A.X), likely because the host cells 
recognize the viral genome as a DSB. Moreover, the virus targets the MRN 
complex proteins, causing its degradation and probably relocalization to avoid 
the formation of the concatemers.  
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Figure 21. dl922-947 induces the activation of histone H2A.X 
FRO cells were infected with two different concentration of the virus and the P-H2A.X 
positivity was analyzed by FACS analysis. As shown in the figure, is evident the shift in the 
FITC channel with respect to the control cells, and also the increasing of the P-H2A.X 
positivity in cells infected with dl922-947.  
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Figure 22. dl922-947 induces the activation of histone H2A.X 
FRO cells were infected with different viral mutants and expression levels of P-H2A.X, Rad50 
and MRE11 were evaluated by western blot after 24 and 48h of treatment. Also at 24-48h the 
virus induces the activation of H2A.X and the reduction of Rad50 and MRE11, suggesting that 
the damage is not repaired.   
 
It is well known that ionising radiation produces a wide variety of lesions in 
DNA, including base damage, single- and double-strand breaks. I have also 
shown that the virus targets the DNA damage signaling pathway. Therefore, I 
have analyzed the effects of the combined treatment on DNA damage signaling 
pathway.  
FRO cells were infected with dl922-947 (10 pfu/cell) and then irradiated (0-4 
Gy). Cells were collected at different times (3-6-24h) to analyze the effects of 
the combined treatment on DNA damage signaling pathway proteins (figure 
23). Starting from three hours of treatment an increase in the phosphorylation 
of ATM, histone H2A.X, Chk1 and Chk2 was observed in irradiated cells. This 
effect is increased in infected cells or in cells undergoing the combined 
treatment. A decrease of MRN proteins levels was observed only in infected 
cells or undergoing the combined treatment. This reduction is more evident 
after 16h and 24h of treatment, suggesting that the DNA damage was not 
repaired, as also confirmed by the permanent activation of P-H2A.X, P-Chk1 
and P-Chk2. In irradiated cells the MRN complex is activated.   
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Figure 23. Effects of the combined treatment (virus plus IR) on DNA damage pathway 
FRO cells were infected with dl922-947 (10 pfu/cell) and then irradiated with two different 
doses (0-4 Gy). Cells were collected at different times (3-6-24h) to analyze, by western blot, 
the effects of the combined treatment on DNA damage signaling pathway proteins. 
 
 
It has been recently published (Connell et al. 2011) that oncolytic virus dl922-
947, that bears a functional E4 gene, can induce a DNA damage response in 
ovarian cancer cells, and that Chk1 inhibition can increase the oncolytic 
potential of dl922-947. To evaluate the role of DNA damage pathway on OVs 
activity and to assess the possible use of drugs affecting DNA damage response 
in ATC cell lines, FRO and BHT101-5 cells were infected in combination with 
a specific inhibitor of ATM kinase (KU55933).  
FRO and BHT101-5 cell lines were infected with increasing concentration of 
the virus (0-5-7.5-10-25-50 pfu/cell for FRO cells; 0-1-2.5-5-7.5-10 pfu/cell for 
BHT101-5 cells) in combination with two different concentrations of the drug 
(0-2-8 µM for FRO cells; 0-1-4 µM for BHT101-5 cells). As shown in figure 
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24, in both cell lines the combination treatment potentiate the cytotoxic effects 
of the virus, suggesting that the drug accelerates viral-induced cell death.  
 
 
 
 
Figure 24. ATM inhibitor potentiates the effects of dl922-947 
FRO and BHT101-5 cell lines were infected with increasing concentration of the virus (0-5-
7.5-10-25-50 pfu/cell for FRO cells; 0-1-2.5-5-7.5-10 pfu/cell for BHT101-5 cells) in 
combination with two different concentrations of the drug (0-2-8 µM for FRO cells; 0-1-4 µM 
for BHT101-5 cells). After seven days cells were analyzed for viability assay. In both cell lines 
ATM inhibitor enhances cytotoxic effects of dl922-947. All experimental points, in both cell 
lines, show a significant difference with respect to the single treatments. 
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To explore the possibility that the higher cytotoxic effects was due to an 
increase in viral replication, I have evaluated genome equivalent copies of 
dl922-947 in ATC cells undergoing the combined treatment, both in 
combination or with a 24h pre-treatment with the drug.  
A clear increase in viral replication was observed in both cell lines (figure 25), 
although the combination treatment was more effective with respect to 24h pre-
treatment.  
 
Figure 25. ATM inhibitor increases viral replication 
FRO and BHT101-5 cells were infected with increasing concentration of the virus (0-1-5-10 
pfu/cell) and treated with different concentration of the drug (0-600-800-1000 nM), in 
combination (A), or with a 24h pre-treatment with the drug (B). A clear increase in viral 
replication was observed in both cell lines, and in both experiments. 
 
Next, I have evaluated the effects of the combined treatment on the activation 
of ATM kinase, histone H2A.X, Chk1 and Chk2.  
The combined treatment reduces P-ATM levels, whereas in infected cells a 
clear activation was observed. A similar effect was also observed for P-H2A.X, 
P-Chk1 and P-Chk2. 
Interestingly, the MRN complex protein levels were reduced in cells 
undergoing the combined treatment, indicating that the block of ATM 
activation does not prevent viral induced degradation of MRN complex.  
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Figure 26. Effects of the combination dl922-947 plus ATM inhibitor on DNA damage 
signaling pathway proteins 
FRO cells were infected with 10 pfu of dl922-947 in combination or not with ATM inhibitor at 
two different concentrations (0-600-800 nM). After 24-48-72h, cells were collected and 
expression levels of P-ATM, P-H2A.X, P-Chk1, P-Chk2 and MRN complex proteins analyzed 
by western blot. 
 
I have also monitored cell death mechanisms induced in the combined 
treatment.  
FRO cells were pre-treated for two hours with the drug (10µM) and then 
infected with dl922-947 (25 pfu/cell). Cells were collected at different times 
(6-16-24-48-72h) and cell cycle analyzed by FACS analysis. As shown in 
figure 27, after 6 and 16h of treatment the drug alone does not affect cell cycle 
profile and the effects in the combined treatment were due only to the virus. 
Starting from 24h in the cells treated with the drug I can observe an increase in 
the subG1 fraction and an increase in the percentage of polyploid cells, while in 
cells undergoing the combined treatment there is a little increase in the 
percentage of cells in subG1 fraction compared to the virus alone. It is also 
worth noting that, in the combined treatment, the slight increase in subG1 
fraction at later time points is associated with a decrease in polyploidy 
fractions, as we have already demonstrated (Libertini et al. 2011).  
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Figure 27. Effects of the combination between dl922-947 and ATM inhibitor on ATC cell 
cycle 
FRO cells were pre-treated for two hours with the drug (10µM) and then infected with dl922-
947 (25 pfu/cell). Cells were collected at different times (6-16-24-48-72h) and cell cycle 
analyzed by FACS analysis. 
 
 
The data obtained treating in vitro ATC cells with ATM inhibitor and dl922-
947 demonstrate that the drug enhances the effects of the virus, accelerating 
viral induced cell death and increasing viral replication, confirming that the 
inactivation of the DNA damage pathway is important to enhance the cell 
killing activity of dl922-947.   
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5. DISCUSSION 
 
ATC is one of the most lethal human neoplasia and leads to death in a 
very short time. Active therapies are not available, making the development of 
novel therapeutic strategies a necessity (Smallridge et al. 2009).  
Oncolytic viruses are emerging as new therapeutic tools for the treatment of 
cancer, and we have previously demonstrated that the mutants dl1520 and 
dl922-947 are active against ATC in vitro and in vivo (Libertini et al. 2007; 
Libertini et al. 2008).  
It is increasing recognized that combining viral therapies with EBRT represents 
a promising approach. In fact, enhanced antitumor efficacy has been observed 
with oncolytic adenoviruses when combined with chemotherapeutic agents or 
radiation in several tumor models (Yoon et al. 2006; DeWeese et al. 2001; 
Portella et al. 2002). Phase I and II trials investigating combinations of 
oncolytic viruses and EBRT have been published, paving the way for ongoing 
phase III trials (Touchefeu et al. 2011). 
The previous studies performed with ionising radiation and oncolytic viruses 
(Portella et al. 2003) and the observation that drugs able to block cells in G2/M 
or inhibit cytokinesis could enhance the effects of oncolytic viruses (Seidman 
et al. 2001), have persuaded me to evaluate whether this combination could 
positively affect dl922-947 activity against ATC.  
The data presented in this thesis demonstrate the efficacy of this combination. 
In particular, ionising radiation enhances the effects of the oncolytic 
adenovirus dl922-947 both in vitro and in vivo.  
I have identified the most appropriate timing showing that the most effective 
treatment is infection followed after 24 hours by irradiation. In cells 
undergoing this treatment, all experimental points show a significant difference 
with respect to the single treatments. On the contrary, in cells irradiated and 
then infected a synergistic effect is evident only at the higher concentration of 
the virus. 
A number of potential mechanisms of interaction between viruses and radiation 
have been described. Radiation can increase viral uptake, probably enhancing 
the expression of the coxsackie and adenovirus receptor (CAR) on the 
membrane of infected cells or the expression of αv/β3/5 integrin subunits acting 
as low affinity coreceptors, viral gene expression and replication.  
I monitored viral entry upon radiation treatment. The data obtained show that 
IR does not affect viral entry in ATC cells.  
It has been demonstrated that synchronization or blocks in G2/M phase led to 
elevated Ad binding and transgene expression, since expression of high-affinity 
(coxsackie and adenovirus receptor, CAR) and low-affinity (αv integrins) Ad 
receptors showed a significant increase (Seidman et al. 2001). Although IR-
treated cells accumulate in G2/M phase, membrane levels of CAR and its co-
receptors integrins αvβ3 do not increase after IR treatment in ATC cells. The 
increase of CAR levels in cells undergoing the combined treatment with 
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respect to the untreated cells, was due to the viral infection, as previously 
observed by us (unpublished observation). 
This observation is in agreement with Geoerger et al. (2003) who reported that 
radiation do not increase CAR or integrin αv expression in glioma cell lines and 
Bieler et al. (2008), who showed no increase in CAR expression in 
glioblastoma cell lines infected with adenoviruses.  
In this work I have demonstrated that ionising radiation increases viral 
replication also in ATC cell lines in a dose-dependent manner. Moreover, IR 
increases viral gene expression, as demonstrated by the dose-dependent 
increase of E1A levels.  
Some publications report enhanced viral replication following EBRT, both in 
vitro and in vivo. This phenomenon has been described with adenoviruses in 
prostate (Chen et al. 2001; Dilley et al. 2005; Liu et al. 2010), lung (Adusumilli 
et al. 2005) and glioblastoma models (Bieler et al. 2008). However, in contrast, 
a smaller number of studies have failed to find evidence that radiation increases 
viral replication. It is possible that radiation-mediated effects on viral 
replication may be cell line-dependent.  
dl922-947 infection in ATC cells induces a G2/M accumulation with 
subsequent polyploidy. It is also well known that after exposure to ionising 
radiation a G2/M accumulation blocks in G2 the cells that had been in earlier 
phases of the cell cycle at the time of irradiation (Metting and Little 1995). To 
better understand the effects of the combined treatment on ATC cell death, I 
have previously analyzed the effects of radiation treatment alone on ATC cell 
lines. 
It has been shown that cells treated with ionising radiation die through mitotic 
catastrophe (Dodson et al. 2007), a form of cell death resulting from aberrant 
mitosis. Such mitosis does not produce proper chromosome segregation and 
cell division, and leads to the formation of large non-viable cells characterized 
by micronuclei: nuclear envelopes around clusters of missegregated 
chromosomes (Castedo et al. 2004).  
The increase of 4N DNA content and subG1 accumulation together with 
caspase-3 activation has been observed in mitotic catastrophe. In ATC cells 
treated with increasing concentration of IR a decrease of procaspase-3 was 
observed, followed by caspase-3 cleavage and activation, as well >4N DNA 
and subG1 accumulation. Moreover, a clear dose- and time-dependent increase 
in the number of micronucleated cells was observed, confirming mitotic 
catastrophe as cell death mechanism activated in irradiated ATC cells. 
It has been already demonstrated that dl922-947 induces in ovarian carcinoma  
and ATC cells, a non-apoptotic programmed cell death. This type of death 
shares some features with apoptosis such as caspase-3 activation and subG1 
accumulation (Baird et al. 2008; Libertini et al. 2011).  
The association with IR induces a cell death closely resembling the viral non 
apoptotic programmed cell death. Moreover, the appearance of cleaved 
caspase-3 and the increase of cells in subG1 phase is accellerated.  
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It is possible to exclude death by mitotic catastrophe in the combined treatment 
since, upon infection, cells detach, a feature not observed in mitotic 
catastrophe. Moreover, in the few adhering cells, we have not observed the 
presence of micronuclei (data not shown). 
These data indicate that in the combined treatment the viral induced cell death 
mechanism is dominant. 
In order to demonstrate that the combined treatment ionising radiation and 
dl922-947 could potentially yield improved clinical efficacy, I have also 
evaluated the effects of ionising radiation treatment in vivo.  
The results of in vivo experiments showed that the combined treatment 
enhanced the antineoplatic effects of the virus against ATC xenografts, 
confirming the data obtained in vitro. Accordingly with in vitro experiments, in 
vivo I have observed an increase of viral replication and caspase-3 activation. 
Moreover, the analysis of viral distribution showed that ionising radiation pre-
treatment improved viral distribution within the tumor, since a more intense 
GFP staining was observed in all tumor tissues, indicating that in vivo other 
mechanisms contribute to the enhancement of viral activity, along with those 
observed in in vitro experiments.   
Recent data suggest that viruses have evolved with the ability to interact with 
cellular DNA damage response and repair pathways. A deeper understanding 
of these interactions could explain the enhanced effect observed in the 
combined treatment, and should lead to innovative combination strategies 
involving viral therapy combined with DNA repair inhibitors.  
It is well known that ionising radiation induces DNA damage and activates the 
DNA damage signaling pathway. When a DSB occurs the MRN complex 
recognizes the lesion and recruits the protein kinases ATM and ATR to the site 
of the break. Once activated, ATM leads to the direct or indirect 
phosphorylation of different substrates, such as NBS-1, Chk1, Chk2, BRCA1 
and H2AX (Darzynkiewicz et al. 2009; Lavin et al. 2006).  
Virus infection presents an assault on the host cell. While the virus tries to 
commandeer the cellular machinery to aid its own replication, the host cell 
responds with defense systems that create obstacles for the virus. Viral 
infection and replication present the host cell with large amounts of exogenous 
genetic material, much of which may possess unusual DNA secondary 
structures. It is therefore likely that viral genomes will represent targets for 
cellular proteins that recognize and respond to abnormal and damaged DNA. 
Accordingly, viruses have been shown to be capable of interacting with cellular 
DNA damage response pathway to avoid the formation of the concatemers and 
to better replicate in target cells (Evans and Hearing 2005; Stracker et al. 2002; 
Stracker et al. 2005; Baker et al. 2007).  
Adenoviruses have evolved different mechanisms to counteract the detrimental 
effects of NHEJ, two of which specifically target the MRN complex. The E4-
ORF3 protein can redistribute Mre11, Rad50, and Nbs1 from their normal 
diffuse nuclear localization into large nuclear and cytoplasmic accumulations 
during infections or E4-ORF3 transfection (Evans and Hearing 2005; Stracker 
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et al. 2002; Stracker et al. 2005). The E4-ORF6 protein interacts with another 
viral protein, E1B-55KDa, to form an E3 ubiquitin ligase complex with the 
cellular proteins Rbx1, Cullin 5 (CUL5), and elongins B and C (Harada et al. 
2002; Querido et al. 2001). This complex targets specific proteins, such as p53, 
Mre11, and DNA ligase IV, for proteasome-dependent degradation (Baker et 
al. 2007; Harada et al. 2002; Querido et al. 2001). 
To verify whether the infection with oncolytic adenoviruses could modify the 
MRN protein levels in our model, FRO cells were infected with a panel of 
adenoviral mutants: dl922-947, bearing a deletion of 24-bp in the CR2 of E1A, 
dl1520 an E1B-55KDa deleted virus, Ad5wt a non-mutant adenovirus used as 
control adenovirus, and AdGFP a non-replicating E1-deleted adenovirus 
encoding GFP.  
Starting from 1 hpi (hour post infection), dl922-947 and dl1520 induce the 
phosphorylation of ATM on Ser1981, an early step of activation of DNA 
damage signaling pathway. Interestingly, dl922-947 and dl1520 also induce the 
phosphorylation on Ser139 of histone H2A.X, a downstream effector of the 
activation of ATM. Moreover, dl922-947 induces the activation of Chk1/2 by 
phosphorylation on Ser345 and Thr68, respectively. Starting from 3 hpi, in 
cells infected with dl922-947 I observed a reduction of the MRN proteins, 
which was more evident after 6 and 16 hours of treatment.  
It is well known that ionising radiation produces a wide variety of lesions in 
DNA, including base damage, single- and double-strand breaks. Moreover, I 
have observed that the virus targets the DNA damage signaling pathway to 
better replicate, therefore I have analyzed the effects of the combined treatment 
(virus/IR) on the DNA damage signaling pathway. 
At three hours post treatment an increase in the phosphorylation of ATM, 
histone H2A.X, Chk1 and Chk2 was observed in irradiated cells; this effect 
was more evident in infected cells or in cells undergoing the combined 
treatment.  
A decrease of MRN proteins levels in cells undergoing the combined treatment 
was also observed. This reduction was more evident at longer time (in 
particular 16h and 24h), suggesting that the DNA damage was not repaired, as 
confirmed by the permanent activation of histone H2A.X, Chk1 and Chk2. In 
control irradiated cells no reduction in MRN complex levels were observed. 
Our data are in agreement with a recently published study by Connell and 
colleagues (2011), showing that oncolytic virus dl922-947 induces a DNA 
damage response in ovarian cancer cells, and that Chk1 inhibition increases the 
oncolytic potential of dl922-947.  
In order to better understand the role of DNA damage pathway on OVs activity 
and replication as well as to assess the possible use of drugs affecting DNA 
damage response in ATC cell lines, I have combined dl922-947 with a specific 
inhibitor of ATM kinase. 
The drug potentiates the cytotoxic effects of the virus; interestingly, an increase 
in viral replication was observed in both cell lines. 
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I have then investigated the effects of the combined treatment (dl922-947/ATM 
inhibitor) on the activation of DNA damage pathway, showing in cells 
undergoing the combined treatment a clear reduction of MRN complex 
proteins. 
These data confirm that the virus needs to target DNA damage pathway for its 
own replication. Interestingly, despite drug induced block of ATM 
phosphorylation, MRN complex in cells undergoing the combined treatment is 
degraded, further confirming the importance of this step for viral life cycle.  
In conclusion the data presented here demonstrate that ionising radiation 
potentiates the oncolytic activity of dl922-947. This data could be useful for 
the development of novel therapeutic strategies for the treatment of ATC.  
Moreover, I have shown that the virus targets the DNA damage pathway 
through the degradation of the MRN repair complex and that this effect is not 
modified by the combination with ionising radiation or ATM inhibitor, 
indicating a dominant effect of the virus. The enhancement in viral replication 
together with an accumulation of unrepaired DNA lesions could explain the 
increase in cell killing observed in the combined treatment.  
This observation suggest that the targeting of DSB repair could represent a 
novel mechanism to increase the oncolytic activity of dl922-947. 
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6. CONCLUSION 
 
Anaplastic thyroid carcinoma is one of the most lethal human neoplasia, 
that leads to death in few months. Surgery, radiotherapy and chemotherapy 
have no effects on its prognosis. Therefore, novel therapeutic approaches are 
required. Replication selective oncolytic viruses (OVs) are a rapidly expanding 
therapeutic platform for cancer treatment.  
In this study I propose a novel therapeutic approach based on the use of 
oncolytic adenovirus and in particular of a second generation adenoviral 
mutant, dl922-947. I have demonstrated that ionising radiation enhances the 
oncolytic activity of dl922-947 both in vitro and in vivo. Furthermore, I have 
shown that ionising radiation acts on viral gene expression, enhancing viral 
replication, but does not affect membrane CAR or integrin levels and does not 
increase viral entry.  
A single radiation dose of 10 Gy enhances dl922-947 oncolytic effect and viral 
replication in vivo, and also improves the distribution within the tumor since a 
more intense GFP staining was observed in all tumor tissues.   
I have also shown that dl922-947 modulates the DNA damage signaling 
pathway, by inducing the degradation of the MRN complex proteins to avoid 
the formation of viral concatemers and to better replicate. To evaluate the 
possible use of such drugs affecting DNA damage response in ATC cell lines, I 
have decided to combine dl922-947 with a specific inhibitor of ATM kinase to 
verify whether the combined treatment could potentiate the cytotoxic effects of 
the virus, since the drug blocks the ATM pathway. The combination treatment 
potentiate the cytotoxic effects of the virus, suggesting that the drug increases 
viral replication.  
In conclusion, the results described in this study encourage the use of dl922-
947 for new therapeutic protocols for the treatment of ATC and in particular a 
combination between the virus and ionising radiation could represent a better 
option for virotherapy against this aggressive carcinoma. Moreover, also the 
modulation of the DNA damage signaling pathway, and in particular the 
inhibition of the ATM kinase could represent a novel therapeutic tool for the 
enhancement of the oncolytic activity of dl922-947 in ATC models.  
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Aurora/Ipl1-related kinases are a conserved family of proteins that are essential for the regulation of chromosome segregation and
cytokinesis during mitosis. Aberrant expression and activity of these kinases occur in a wide range of human tumours and have been
implicated in mechanisms leading to mitotic spindle aberrations, aneuploidy, and genomic instability. Previous studies of our group have
shown that Aurora B expression is restricted to specific germinal cells. In this study, we have evaluated by immunohistochemical analysis
Aurora B expression in post-puberal testicular germ cell tumours (22 seminomas, 2 teratomas, 15 embryonal carcinomas, 5 mixed
germinal tumours with a prominent yolk sac tumour component and 1 choriocarcinoma). The Aurora B protein expression was detected
in all intratubular germ cell tumours, seminomas and embryonal carcinomas analysed but not in teratomas and yolk sac carcinomas. The
immunohistochemical data were further confirmed by Western blot analysis. In addition, the kinase Aurora B was vigorously expressed in
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DOI: 10.1002/jcp.21875Post-puberal testicular germ cell tumours (TGCTs) represent
the most common malignancy in males between 15 and 34 years
of age, and represent a major cause of death attributable to
cancer in this age group (Oosterhuis and Looijenga, 2005).
TGCTs can be subdivided into seminoma and non-seminoma
germ cell tumours (NSGCTs) including embryonal cell
carcinoma, choriocarcinoma, yolk sac tumour and teratoma,
both recognizing a unique histological precursor, the
intratubular testicular germ cell tumour (ITGCT).
Neoplasms containing more than one tumour history are
referred to as mixed germ cell tumours. Seminomas and
NSGCTs do not only present distinctive clinical features, but
they also show significant differences as far as therapy and
prognosis are concerned (Chieffi, 2007).
Mitosis, the process by which a complete copy of the
duplicated genome is precisely segregated by the microtubule
spindle apparatus into two daughter cells, is an extraordinarily
complex biological process. Serine threonine kinases of Aurora
family (Aurora A, Aurora B and Aurora C) are key mitotic
regulators required for genome stability and for the
progression through the M phase and it is well known that the
products of the Aurora genes are expressed in proliferating
cells and are overexpressed in neoplastic cells (Tanaka et al.,
1999). Expression and activity of Aurora B in proliferating
tissues are cell cycle regulated: its expression peaks at G2-M
transition and the kinase activity is maximal during mitosis.
Aurora B is a one of the component of the chromosomal
passenger complex (CPC). CPC contains three non-enzymatic
subunits, all of which are essential for the activity, localization,
stability and substrate specificity of Aurora B. In human cells,
these non-enzymatic subunits are Survivin, the inner
centromere protein (INCENP), and Borealin. Aurora B is
involved in chromosome segregation, spindle-checkpoint and
cytokinesis, and alteration of each of these steps could induce
aneuploidy, that is commonly found feature of cancer cells
(Adams et al., 2001; Carmena and Earnshaw, 2003). 2 0 0 9 W I L E Y - L I S S , I N C .Aurora B expression has been studied in different human
cancer and it has been shown that its expression directly
correlates with malignancy in several human lesions such as
non-small cell lung carcinoma (Smith et al., 2005; Vischioni et al.,
2006), mesothelioma (Lo´pez-Rı´os et al., 2006), glioblastoma
(Araki et al., 2004; Zeng et al., 2007), oral cancer (Qi et al.,
2007), hepatocellular carcinoma (Kurai et al., 2005), and thyroid
carcinomas (Sorrentino et al., 2005). High expression levels of
Aurora B were detected in primary human colorectal cancers at
various pathologic stages with a tendency to group in higher
grades of malignancy (Katayama et al., 1999), and Aurora B
expression directly correlates with Gleason grade in prostate
cancer (Chieffi et al., 2006). However, it is not clear whether
the observed overexpression of Aurora B is a mere reflection
of the high proliferative index of cancerous cells or whether it is
indeed causally related to tumourigenesis. It has been reported
a direct link between Aurora B and carcinogenesis (Ota et al.,
2002) and Aurora B kinase activity augments Ras-mediated cell
436 E S P O S I T O E T A L .transformation, suggesting that the overexpression of Aurora B
may contribute to the generation of a transformed phenotype
(Kanda et al., 2005).
It has been previously shown that Aurora B is present, among
germ cells, in mitotic cells (spermatogonia and primary
spermatocytes) (Chieffi et al., 2004; Kimmins et al., 2007); the
aim of the present study is to evaluate Aurora B expression in
TGCTs to assess correlation with differential histological
diagnosis and to validate Aurora B as a potential therapeutic
target.
Materials and Methods
Tissue samples and cell culture
As source of neoplastic tissues, the tissue Bank of National Cancer
Institute ‘‘G. Pascale’’ provided 45 cases of cryopreserved tissue
from 22 seminomas, 2 teratomas, 15 pure embryonal carcinomas, 5
mixed tumours with a prevalent component of yolk sac tumour and
1 choriocarcinoma. To analyse the intratubular germ cell tumours
(ITGCTs) we evaluated ITGCTs carcinomas areas in 15 of 22
examined seminomas. Ethical Committee approval was given in all
instances. The GC-1 cell line were cultured in Dulbecco’s modified
Eagle’s Medium (D-MEM) supplemented with 10% foetal bovine
serum (FBS) (Gibco BRL, Milan, Italy), and grown in a 378C
humidified atmosphere of 5% CO2 (Hofmann et al., 1992). Tcam-2
cells were grown at 378C in a 5% CO2 atmosphere in RPMI 1640
(LONZA, Milan, Italy) supplemented with 10% FBS (de Jong
et al., 2008).
Antibodies
Antibodies were purchased from the following sources: (1)
polyclonal rabbit antibody anti-Aurora B (#611082; BD
Transduction Laboratories, San Diego, CA); (2) polyclonal rabbit
antibody anti-Aurora B (#36–5200, Invitrogen, Carlsbad, CA); (3)
mouse monoclonal antibody against recombinant PCNA (#M-
0879, Dako Corp., Glostrup, Denmark); (4) polyclonal goat
antibody anti-vinculin (#sc-7649, Santa Cruz Biotechnology Inc.,
Santa Cruz, CA); (5) polyclonal rabbit antibody anti-b-actin (Sigma,
Milan, Italy); (6) polyclonal rabbit anti-P-H3 histone (#06-570,
Upstate, Lake Placid); (7) polyclonal rabbit anti-histone H3
(#06-755, Upstate); (8) mouse monoclonal antibody anti-Ki-67
(#sc56319, Santa Cruz Biotechnology Inc.).
Histologic analysis and immunohistochemistry
For light microscopy, tissues were fixed in 10% formalin and
embedded in paraffin by standard procedures. Four-micrometer
sections were stained with haematoxylin and eosin or processed
for immunohistochemistry. For each paraffin-embedded sample a
4-mm serial section mounted on slides pretreated for
immunohistochemistry were dewaxed in xylene and brought
through ethanols to deionized distilled water. Before staining for
immunohistochemistry, sections were incubated in a 750 W
microwave oven for 15 min in 10 mM, pH 6.0 buffered citrate to
complete antigen unmasking. The classical Avidin–Biotin
peroxidase Complex (ABC) procedure was used for
immunohistochemistry. In the ABC system, endogenous
peroxidase was quenched by incubation of the sections in 0.1%
sodium azide with 0.3% hydrogen peroxide for 30 min at room
temperature. Non-specific binding was blocked by incubation with
non-immune serum (1% TRIS-bovine albumin for 15 min at room
temperature). Sections were incubated overnight with antibodies
against Aurora B (diluted 1:200), 2) against ki-67 (diluted 1:200).
For Aurora B detection additional antibody was used which gave
similar results (not shown). The following controls were
performed: (1) omission of the primary antibody; (2) substitution of
the primary antiserum with non-immune serum diluted 1:500 in
blocking buffer, (3) addition of the target peptide used to produce
the antibody (106 M); no immunostaining was observed after anyJOURNAL OF CELLULAR PHYSIOLOGYof the control procedures. Peroxidase activity was developed with
the use of a filtered solution of 5 mg of 3-3’-diaminobenzideine
tetrahydrochloride (dissolved in 10 ml of 0.05 M Tris buffer, pH 7.6)
and 0.03% H2O2. We used Mayer’s haematoxylin for nuclear
counterstaining. Sections were mounted with a synthetic medium.
Cases were scored as negative when non-neoplastic cell expressed
Aurora B, at low and high expression when respectively less and
more than 20% of neoplastic cells expressed Aurora B.
Protein extraction and Western blot analysis
Total cell extracts (TCE) were prepared with lysis buffer (50 mM
Tris Hcl pH 7.5, 5 mM EDTA, 300 mM NaCl, 150 mM KCl, 1 mM
dithiothreitol, 1% Nonidet P40, and a mix of protease inhibitors).
Protein concentration was estimated by a modified Bradford assay
(Bio-Rad, Melville, NY). The protein extracts were boiled in
Laemmli sample buffer, separated by sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS–PAGE) and transferred
to Immobilon-P transfer membranes (Immobilon Millipore
Corporation, Bedford, MA). Membranes were blocked with 5%
nonfat milk proteins and incubated with the primary antibody: (1)
against Aurora B (diluted 1:500), (2) against PCNA (diluted
1:1,000), (3) anti-vinculin (diluted 1:1,000), (4) anti-b-actin (diluted
1:500). Also, for Western blot analyses a additional antibody was
used for Aurora B which gave the same results (not shown). Bound
antibodies were detected by the horseradish peroxidase-
conjugated secondary antibodies followed by enhanced
chemiluminescence (Amersham, Life Science, Bucks, UK). As a
control for equal loading of protein lysates, the blotted proteins
were probed with antibodies against vinculin and b-actin proteins.
FACS analysis
GC1 cells treated for 24 h with different amounts of Aurora B
inhibitor were harvested by trypsinization, washed with PBS and
fixed in 70% cold-ethanol over night. The fixed cells were washed
with PBS and permeabilized 15 min in 10% FBS/TBStween 0.1%. PBS
washed pellet was incubated 2 h in 50ml of anti-phospohistone H3
antibody diluted 1:130 in 4% FBS/TBStween 0.1%. After washing
with PBS, cells were incubated 45 min in anti-rabbit IgG FITC
conjugated antibody diluted 1:50 in 4% FBS/TBStween 0.1%. The
immunostained cells were then washed with PBS and stained
20 min with 5 ng/ml propidium iodide plus 2 ng/ml RNase A in 300ml
PBS. All incubations were performed at room temperature, the last
two ones were also performed in the dark. Incubation with H3 and
without primary antibody was performed to assess the specificity
of the observed signal. Samples were acquired with a CYAN flow
cytometer (DAKO Corporation, San Jose, CA) and analysed using
SUMMIT1 software.
Results and Discussion
We evaluated the expression of Aurora B protein in
normal and TGCTs by immunohistochemistry using two
commercially available polyclonal antibodies. These antibodies
are specific for Aurora B protein without cross-reactivity.
Immunohistochemical assays were first performed on sections
of normal human testis (data not shown), in agreement with our
previous results a specific nuclear positivity for Aurora B
was observed in spermatogonia and primary spermatocytes
(Chieffi et al., 2004).
Aurora B expression was examined in a series of post-
puberal TGCTs including 22 seminomas, 15 pure embryonal
carcinomas, 5 yolk sac tumours in mixed tumours, 2 teratoma
component in mixed tumours and 1 choriocarcinoma. Aurora B
expression was also evaluated in 15 ITGCTs areas out of 22
examined seminoma. The results of this analysis, summarized in
the Table 1, showed Aurora B immunoreactivity in ITGCTs,
seminomas, and embryonal carcinomas, ranging from low to
high expression. Conversely, in epithelial and mesenchymal
TABLE 1. Aurora B immunohistochemical data in post-puberal TGCTs
Number of
cases (45)
Mean age, years
(range years)
Aurora B
Low
expression
High
expression
Seminoma 22 34 (20–52) 9 13
EC 15 28 (20–40) 3 12
Teratoma 2 30 (26–35) 2 0
YST 5 31 (22–34) 4 1
CC 1 30 0 1
ITGCT — — 0 15
EC, embryonal carcinoma; YST, yolk sac tumour; CC, choriocarcinoma; ITGCT¼ intra-
tubular germ cell tumour¼ associated areas in 15 cases out of 22 examined seminoma.
High expression, >20% of neoplastic cells; Low expression, <20% expression.
Fig. 2. Immunohistochemistry analysis of Aurora B and Ki-67
expression on serial sections of seminomas. A: Seminoma with low
nuclear positivity of ki-67 (B) and Aurora B (case #2); (C) seminoma
with an intense and diffuse nuclear ki-67 (D) and Aurora B (case #4)
positivity (magnification 40T).
A U R O R A B E X P R E S S I O N I N T G C T s 437areas of teratomas and in yolk sac carcinomas, Aurora B
immunoreactivity was not observed or low. Representative
immunohistochemical data are shown in Figure 1. Mainly in
seminomas Aurora B expression correlates to the proliferative
index, evaluated through Ki-67 expression (Fig. 2). Reflecting
the role of this kinase in mitosis, seminomas with high
proliferative index showed high expression of Aurora B (Fig. 2).
Western blot analysis was performed on the same samples
used showing that Aurora B levels correlates with PCNA levels,
thus confirming immunohistochemical data (Fig. 3).
Aurora B expression has been analysed in GC1 and TCam-2
cell lines, respectively derived from immortalized type B murine
spermatogonia and human seminoma (Hofmann et al., 1992; de
Jong et al., 2008). As shown in Figure 4A, higher Aurora B and
PCNA protein levels were observed in the fast growing GC1
cells, whereas TCam-2 cells, characterized by a slow growth
kinetic, showed lower levels of Aurora B and PCNA
expression. Therefore, we have evaluated on GC1 cells theFig. 1. Immunohistochemistry analysis of Aurora B expression in
TGCTs. A: Aurora B expression in intratubular germ cells tumour in
which an intense nuclear positivity were observed (case #3); (B)
classic seminoma with an intense and diffuse nuclear Aurora B
positivity (case #3); (C) high expression of Aurora B in embryonal
carcinoma (case #23); (D) low expression of Aurora B in yolk sac
tumours (case #40); (E) high nuclear expression of Aurora B in
choriocarcinoma (case #45); (F) absent expression of Aurora B in
mature teratoma (case #38) (magnification 40T).
JOURNAL OF CELLULAR PHYSIOLOGYeffects of Aurora B block induced by a specific inhibitor, a
small molecule similar to the quinazoline derivative:
N-[4-(6,7-dimethoxy-quinazolin-4-ylamino)-phenyl]-
benzamide (Sorrentino et al., 2005). The treatment with
Aurora B inhibitor induced a significant (P< 0.001) decrease in
cell growth at all concentration used (Fig. 4B).
Aurora B is responsible for the mitotic phosphorylation of
Ser10 residue in the tail of H3 histone and of Ser28 in H3 and of
Ser7 in CENP-A. To confirm the specific effects of the inhibitor,
cells were treated for 24 h and then analysed by FACS using a
specific antibody anti-phospho-Ser-10 H3 histone. To quantify
H3 histone phosphorylation (P-H3) with respect to cell cycle
phase, cells were also stained with propidium iodide.
Control cells showed about 3 0.1% of staining with anti-P-
H3 antibody (Fig. 4C lower part). At 5mM, a slight decrease in P-
H3 levels staining was observed (about 2.7 0.1). At higher
concentrations, a more pronounced decrease in P-H3 levels
was observed. Cell cycle analysis (Fig. 4C upper part and
Fig. 4D) showed that Aurora B inhibitor induces an
accumulation in G2/M phase, already after 24 h. Interestingly, atFig. 3. Western blot analysis of Aurora B expression in normal testis
and TGCTs. 40mg of total tissue lysates were resolved on 12% SDS–
PAGE, transferred onto nitrocellulose filters and Western blotted
with anti-Aurora B and anti-PCNA antibodies. Lane NT: normal
testis; Lanes 2–8: seminomas (cases #1–7); lane 9: teratoma (cases
#38); lane 10: yolk sac tumour (case #40); lanes 11–12: embryonal
carcinomas (cases #23, 24). Antibodies toa-vinculin served as loading
control.
Fig. 4. A: Western blot analysis of Aurora B expression in GC1 and Tcam-2 cells. Lysates from Tcam-2 and GC1 cells (50mg) were analysed for
Aurora B and PCNA expression. GC1 cells express higher Aurora B and PCNA levels. Actin was used as loading control. B: Growth curve of GC1
cells treated with Aurora B inhibitor. GC1 (50,000 cells/well) were plated in 12 wells plates and the day after treated with different concentrations
(2.5, 5, 7.5, 10mM) ofAurora B inhibitor. Cell number was evaluated in the following days by counting. The barrepresents the standard deviation of
experiments performed twice in triplicate. C: FACS analysis after 24 h of Aurora B inhibitor treatment. GC1 (50,000 cells/well) were plated in 12
wells plates and the day after treated with different concentrations (2.5, 5, 7.5, 10mM) of Aurora B inhibitor. DNA content and P-H3 amount were
evaluatedbyFACSanalysis.ThepercentagesrepresentthenumberofP-H3positivecells (lowerpart).Theaccumulationoftetraploidcellsandthe
decrease in P-H3 levels became evident starting from 7.5mM. The bars (upper part) represent the gates used to quantify cell cycle phases shown in
(D). D: Quantification of cell cycle changes after 24, 48 and 120 h of treatment with Aurora B inhibitor. G2/M accumulation, polyploidy and subG1
phase increase in dose- and time-dependent manner.
438 E S P O S I T O E T A L .this concentration, cells start to show a decrease in P-H3
staining levels. At 7.5mM, was also observed polyploidy (see
also Fig. 4D) in parallel with a strong decrease in P-H3 positivity.
As shown in Figure 4D, more than 50% of the cells were in sub-
G1 phase after 120 h of treatment. Sub-G1 phase is indicative of
cell death and can be due to the activation of the apoptoticJOURNAL OF CELLULAR PHYSIOLOGYpathway or by necrosis, therefore the block of Aurora B activity
induced cell death.
Testicular tumours are rare, comprising 2% of all cancers in
men; however, post-puberal testicular cancer is the most
common malignancy affecting males aged 15–34 years (Senturia,
1987; Looijenga and Oosterhius, 1999). Because the molecular
A U R O R A B E X P R E S S I O N I N T G C T s 439basis of these cancers needs to be elucidated, identification of
cellular genes involved in testicular tumourigenesis could
increase our understanding of the development of testicular
tumours, thus providing the basis for new targeted therapies.
There are at least three Aurora–related kinases in mammals,
Aurora A (STK-15), Aurora B (AIM-1), and Aurora C (STK-13).
All three mammalian members of this family are overexpressed
in human cancer cells. In the present study, we show that
Aurora B expression is a consistent feature of human
seminomas, where its topological staining pattern is lost, and in
embryonal carcinomas. Aurora B expression levels are
regulated at both mRNA and protein levels, with maximal
mRNA and protein levels occurring during the G2/M phases
(Terada et al., 1998). This cyclical pattern of regulation is
conserved in cancer cells (Tatsuka et al., 1998). This indicates
that the effects of Aurora B overexpression may be of critical
importance during the G2/M phases of the cell cycle. The
sequence of these events is essential for normal mitotic cell
division in spermatogenesis and clearly overexpression of
Aurora B may have implications for the abnormalities in germ
cell maturation, such as those that occur in testicular cancer.
Taken together, our data support a role for Aurora B in the
initiation and/or progression of testicular cancers.
The identification of Aurora B inhibitors is an important
discovery, considering the role of the corresponding gene in
human cancers small molecules can selectively target the
enzymatic activity of kinases by occupying the catalytic ATP-
binding site. Several Aurora kinase inhibitors have been
described, including ZM447439 (Ditchfield et al., 2003; Gadea
and Ruderman, 2005), Hesperadin (Hauf et al. 2003), VX-680
(Harrington et al., 2004), and AZD1152 (Wilkinson et al.,
2007). These inhibitor have already be shown to be specific for
Aurora B, although it has been observed that pharmacological
inhibition and disruption of Aurora B by other means such as
RNA interference (RNAi) are not completely identical, since
residual phosphorylation of histone H3 has been observed
upon specific Aurora B RNAi (Keen and Taylor, 2004).
Preclinical and clinical studies show that these drugs are
usually well tolerated, being the most common adverse effect
neutropenia. The use of a specific Aurora B inhibitor
demonstrates that the block of kinase activity induces the death
of germ cells with a high proliferative rate suggesting its
potential therapeutic role for the treatment of TGCTs.
In conclusion, we have shown that Aurora B is a consistent
feature of human seminomas and embryonal carcinomas.
Although germinal cell tumours are highly responsive to
commonly used chemotherapeutic treatment, cases of acute
toxicity and chronic collateral effects, such as sterility, are
recorded. Therefore, the availability of novel drugs such as
Aurora B inhibitor(s) could represent an escape from
chemotherapy early and late effects.
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PED/PEA-15 Modulates Coxsackievirus–Adenovirus
Receptor Expression and Adenoviral Infectivity
via ERK-Mediated Signals in Glioma Cells
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Abstract
Glioblastoma multiforme (GBM) is the most aggressive human brain tumor, and is highly resistant to chemo-
and radiotherapy. Selectively replicating oncolytic viruses represent a novel approach for the treatment of
neoplastic diseases. Coxsackievirus–adenovirus receptor (CAR) is the primary receptor for adenoviruses, and
loss or reduction of CAR greatly decreases adenoviral entry. Understanding the mechanisms regulating CAR
expression and localization will contribute to increase the efficacy of oncolytic adenoviruses. Two glioma cell
lines (U343MG and U373MG) were infected with the oncolytic adenovirus dl922-947. U373MG cells were more
susceptible to cell death after viral infection, compared with U343MG cells. The enhanced sensitivity was
paralleled by increased adenoviral entry and CAR mRNA and protein levels in U373MG cells. In addition,
U373MG cells displayed a decreased ERK1/2 (extracellular signal-regulated kinase-1/2) nuclear-to-cytosolic
ratio, compared with U343MG cells. Intracellular content of PED/PEA-15, an ERK1/2-interacting protein, was
also augmented in these cells. Both ERK2 overexpression and genetic silencing of PED/PEA-15 by antisense
oligonucleotides increased ERK nuclear accumulation and reduced CAR expression and adenoviral entry. Our
data indicate that dl922-947 could represent an useful tool for the treatment of GBM and that PED/PEA-15
modulates CAR expression and adenoviral entry, by sequestering ERK1/2.
Introduction
Malignant glioma of astrocytic origin, or glioblastomamultiforme (GBM), is the most common primary brain
tumor in adults and the most aggressive human brain tumor
(Furnari et al., 2007; Brandes et al., 2008).
Treatment normally includes tumor resection, radiation,
and chemotherapy; however, GBM cells are largely resistant
to chemo- and radiotherapy. Consequently, only a small mi-
nority of patients with GBM achieve long-term survival (Furnari
et al., 2007; Brandes et al., 2008). Novel treatment strategies are
therefore required in order to increase the therapeutic options.
Selectively replicating oncolytic viruses represent a novel
platform for the treatment of neoplastic diseases and several
studies have been performed showing the feasibility of this
therapeutic strategy in patients with glioblastoma (Haseley
et al., 2009).
dl922-947 is a selectively replicating oncolytic adenoviral
mutant bearing a 24-bp deletion in E1A-conserved region-2
(CR2), necessary for binding and inactivation of the pRb
family of proteins (Heise et al., 2000); dl922-947 mutant is
unable to induce progression from G1 into the S phase of
normal cells, but replicates with high efficiency in cells with
an abnormal G1–S checkpoint.
The G1–S checkpoint is critical for cell growth progression
(Sherr, 2000) and is abnormal in GBM (Solomon et al., 2008);
therefore mutant E1A adenoviruses have been proposed for
the therapy of gliomas and are now in preclinical develop-
ment as antiglioma therapy (Vecil and Lang, 2003).
The efficacy of adenoviral vectors as therapeutic agents
depends on the ability of neoplastic cells to bind and inter-
nalize adenoviruses. Adenoviral infection involves two dis-
tinct virus–cell interactions. First, cell surface attachment is
mediated by binding of the viral fiber protein to the cellular
coxsackievirus–adenovirus receptor (CAR) (Bergelson et al.,
1997; Tomko et al., 2000). CAR is a 46-kDa integral mem-
brane protein and variant isoforms, which differ only at the
C terminus and that most likely result from alternative
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splicing, have also been identified in mice, humans, and rats
(Fechner et al., 1999; Coyne and Bergelson, 2005).
Internalization, via receptor-mediated endocytosis, in-
volves interactions between the viral penton protein and
cellular integrins, such as avb3, avb5, a5b1, and a3b1, that act
as coreceptors (Nemerow, 2000). Low or absent expression of
CAR is seen in many primary tumor tissues (Rein et al., 2006)
and low expression of CAR has been observed in grade IV
gliomas (Fuxe et al., 2003).
However, the molecular mechanisms by which CAR ex-
pression is regulated have been only partially elucidated. In-
terestingly, inhibition of ERK (extracellular signal-regulated
kinase)/MAPK (mitogen-activated protein kinase) pathway
has been reported to upregulate CAR expression (Anders
et al., 2003).
Here we show that, in two glioblastoma cell lines (Hao
et al., 2001; Xiao et al., 2002), the expression of PED/PEA
(phosphoprotein enriched in diabetes/phosphoprotein en-
riched in astrocytes)-15, a protein that binds ERK and pre-
vents its nuclear accumulation (Formstecher et al., 2001; Hill
et al., 2002; Renault et al., 2003; Whitehurst et al., 2004;
Renganathan et al., 2005), correlates with CAR mRNA levels
as well as with the sensitivity to adenoviral infection and
dl922-947 killing activity. Indeed, silencing of PED/PEA-15
promotes ERK nuclear translocation and simultaneously re-
duces CAR expression and adenoviral entry into glioblas-
toma cells.
Materials and Methods
Cell lines, plasmids, and transfections
Glioma cell lines U343MG and U373MG were purchased
from the American Type Culture Collection (Manassas, VA).
All cell lines were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine se-
rum, penicillin (100 IU/ml), streptomycin (100 IU/ml), and
2% l-glutamine in a humidified CO2 incubator.
The pcDNA3 vector carrying PED/PEA-15 cDNA was
obtained as previously described (Condorelli et al., 1998).
Sequences of scramble and antisense oligonucleotides
(Sigma-Aldrich, St. Louis, MO) are as follows:
AS-PED/PEA-15 human: 50-TGACGCCTCTGGAGCTGA
GA-30
Scr-PED/PEA-15 human: 50-GGCAATTTCGAGCGGCAC
GT-30
The plasmid pcDNA3-HA carrying ERK2 cDNA
(pcDNA3-HA-pMAPK2) was kindly provided by M. Chiar-
iello (Istituto di Endocrinologia e Oncologia Sperimentale,
CNR, Naples, Italy).
Transfection of a pcDNA3 vector carrying PED/PEA-15
cDNA, PED antisense and scramble oligonucleotides, or
pcDNA3-HA carrying ERK2 cDNA, was accomplished by
the Lipofectamine (Invitrogen, Carlsbad, CA) method as
previously described (Condorelli et al., 1998).
Preparation of adenoviruses, infection,
and viability assay
dl922-947 is a second-generation adenoviral mutant that
has a 24-bp deletion in E1A conserved region-2 (CR2).
AdGFP is a nonreplicating E1A-deleted adenovirus encoding
green fluorescent protein. Viral stocks were expanded in the
human embryonic kidney cell line HEK-293, and purified, as
previously reported (Portella et al., 2002).
Stocks were stored at 708C after the addition of glycerol
to a concentration of 50% (v/v). Virus titer was determined
by plaque-forming units (pfu) on the HEK-293 cells.
For evaluation of the cytotoxic effects of the dl922-947 vi-
rus, 1103 cells were seeded in the wells of 96-well plates,
and 24 hr later cells were infected with various multiplicities
of infection (MOIs). After 10 days cells were fixed with 10%
trichloroacetic acid (TCA) and stained with 0.4% sulforho-
damine B in 1% acetic acid (Skehan et al., 1990). The bound
dye was solubilized in 200ml of 10 mM unbuffered Tris so-
lution and the optical density was determined at 490 nm in a
microplate reader (Bio-Rad, Munich, Germany). The percent
survival rates of treated cells were calculated by assuming
the survival rate of untreated cells to be 100%.
For the evaluation of infectivity cells were detached,
counted, and plated in 6-well plates at 70% cell density. After
24 hr cells were infected with AdGFP diluted in growth
medium at various MOIs; medium was replaced after 2 hr.
Cells were washed 24 hr postinfection and then trypsinized
and analyzed for GFP expression with a flow cytometer
(Dako, Carpinteria, CA) and Summit version 4.3 software
(Dako).
Quantitative PCR of dl922-947
To quantify the amount of dl922-947 viral genome, cells
were infected with dl922-947 at various MOIs (0.1, 1, and
10 pfu/cell). At 48 hr postinfection, cell supernatant was
collected and viral DNA was extracted with a QIAamp DNA
mini kit (Qiagen, Valencia, CA) and then quantified by real-
time PCR, using assay-specific primer and probe. A real
time-based assay was developed with primers 50-
GCCACCGAGACGTACTTCAGCCTG-30 (upstream primer)
and 50-TTGTACGAGTACGCGGTATCCT-30 (downstream
primer) for amplification of a 143-bp sequence of the viral
hexon gene (from bp 99 to 242). For quantification, a stan-
dard curve was constructed by assaying serial dilutions of
dl922-947 virus ranging from 0.1 to 100 pfu/cell to quantify
the input dose.
Detection of cell surface CAR and mRNA quantification
Cells were grown in 6-well plates. After 48 hr cells were
detached in phosphate-buffered saline (PBS)–10 mM EDTA,
washed with PBS, and then incubated with mouse anti-CAR
monoclonal antibody RmcB (Hsu et al., 1988) and a second-
ary antibody (polyclonal rabbit anti-mouse antibody conju-
gated to fluorescein isothiocyanate [FITC]; Sigma-Aldrich),
and analyzed for CAR expression with a flow cytometer
(Dako) and Summit version 4.3 software (Dako). Background
emission was subtracted and FITC emission was normalized
to control emission.
To block CAR, cells were pretreated with increasing con-
centrations of the mouse anti-CAR monoclonal antibody
RmcB, anti-insulin-like growth factor-1 receptor b subunit
(IGF-1R) (Upstate Cell Signaling Solutions/Millipore, Lake
Placid, NY), and anti-actin (Santa Cruz Biotechnology, Santa
Cruz, CA) antibodies (diluted 1:100, 1:250, and 1:500), for
1 hr at room temperature before addition of virus. Cells were
harvested and analyzed as previously described.
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To analyze CAR mRNA levels cells were harvested and
total RNA was isolated and digested with DNase, using an
RNeasy mini kit (Qiagen) according to the manufacturer’s
recommendations. One microgram of tissue or cell RNA
from each sample was reverse transcribed, using SuperScript
II reverse transcriptase (Invitrogen). PCR products were an-
alyzed with SYBR green mix (Invitrogen). Reactions were
performed with Platinum SYBR green qPCR SuperMix-UDG,
using an iCycler iQ multicolor real-time PCR detection sys-
tem (Bio-Rad). All reactions were performed in triplicate, and
b-actin was used as an internal standard.
The primer sequences were as follows: Cxadr forward (50-
ATGAAAAGGAAGTTCATCAACGTA-30) and Cxadr re-
verse (50-AATGATTACTGCCGATGTAGCTT-30), generating
an amplicon of 93 nucleotides scattered among exons 6 and
7; and b-actin forward (50-GCGTGACATCAAAGAGAAG-
30) and b-actin reverse (50-ACTGTGTTGGCATAGAGG-30).
The conditions used for PCR were 10 min at 958C and then
45 cycles of 20 sec at 958C and 1 min at 608C. To calculate the
relative expression levels, we used the 2–DDct method, where
DDCt¼DCt, sample  DCt, reference.
Protein extraction, cell subfractionation,
and Western blot analysis
In all experiments, 70% confluent cells were used. Sub-
cellular fractionation was performed by a previously de-
scribed method (Ruvolo et al., 1998). Briefly, cells were broken
in ice-cold hypotonic HEPES buffer (10 mM HEPES [pH 7.4],
5 mM MgCl2, 40 mM KCl, 1 mM phenylmethylsulfonyl fluo-
ride, aprotinin [10 g/ml], leupeptin [10 g/ml]). Broken cells
were centrifuged at 200g to pellet the nuclei. The resulting
supernatants were centrifuged at 10,000g to pellet the heavy
membrane fraction. The last supernatant represented the cy-
tosolic fraction. The nuclear membranes were isolated by
centrifugation of the nuclei through a 2 M sucrose cushion at
150,000g. For protein extraction cells were homogenized
directly into lysis buffer (50 mM HEPES, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 1 mM
phenylmethylsulfonyl fluoride, aprotinin [1 (g/ml], 0.5 mM
sodium orthovanadate, 20 mM sodium pyrophosphate). The
lysates were clarified by 20 min of centrifugation at 14,000g.
Protein concentrations were estimated by a Bio-Rad assay,
and then proteins were boiled in Laemmli buffer for 5 min
before electrophoresis. Proteins were subjected to sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE) (10% polyacrylamide) under reducing conditions.
After electrophoresis, proteins were transferred to nitrocel-
lulose membranes (Immobilon; Millipore). After blocking
with Tris-buffered saline–bovine serum albumin (TBS–BSA),
the membrane was incubated with primary antibody: poly-
clonal rabbit antibody against CAR (SC-15-405, diluted
1:250; Santa Cruz Biotechnology), rabbit anti-PED serum
(diluted 1:2000; previously described [Condorelli et al., 1998]),
rabbit antibody against ERK1 and ERK2 (diluted 1:1000),
rabbit anti-IGF-1R (diluted 1:1000; Upstate Cell Signaling
Solutions/Millipore), or rabbit anti-H1 histone (diluted 1:1000;
Upstate Cell Signaling Solutions/Millipore), or with the rab-
bit antibody against actin (diluted 1:2000; Santa Cruz Bio-
technology) for an overnight incubation.
Membranes were then incubated with horseradish per-
oxidase-conjugated secondary antibody (diluted 1:2000) for
45 min (at room temperature) and the reaction was detected
with an enhanced chemiluminescence (ECL) system (GE
Healthcare Life Sciences, Chalfont St Giles, UK).
Densitometric analysis was performed with Scion Image
(Scion, Frederick, MD). All data were expressed as means
 SD.
Results
U373MG and U343MG cells show different
sensitivities to adenoviral infection
First, we evaluated the antineoplastic activity of the se-
lectively replicating oncolytic adenovirus dl922-947 against
U373MG and U343MG glioma cell lines (Fig. 1A).
Cells were infected with various MOIs of dl922-947 and
cell survival was evaluated after 7 days. The U373MG cell
line displayed higher sensitivity to dl922-947, with a 50%
inhibitory concentration (IC50) at an MOI of 0.0001 pfu/cell,
whereas for U343MG the IC50 was observed at an MOI of
0.1 pfu/cell (Fig. 1A).
Our data indicate that both glioma cell lines are sensitive
to dl922-947, although displaying different sensitivities to its
oncolytic activity. Genome equivalent copies analysis
showed that both cell lines sustain the replication of dl922-
947 (Fig. 1B).
To study whether this difference could be due to dissim-
ilar infection efficiency, we used a nonreplicating reporter
adenovirus encoding the green fluorescent protein (AdGFP),
as previously reported (Watanabe et al., 2006). Cells were
infected with various MOIs of AdGFP and 24 hr postinfec-
tion the amount of GFP-positive cells was quantified by flow
cytometric analysis.
At 1 pfu/cell of AdGFP 80% of U373MG cells showed pos-
itivity for GFP expression, whereas a higher viral dose (10 pfu/
cell) was required to obtain the same percentage of GFP-
positive U343MG cells. Starting from 10 pfu/cell no further
increase in GFP-positive cells was observed in either cell line.
These differences in infection efficiency could explain the
differences in viral replication, because at 0.1 and 1 pfu/cell a
highly significant difference ( p< 0.001) in genome copies of
dl922-947 was detected in U373MG compared with U343MG.
Conversely, at 10 pfu/cell the differences in genome
equivalent copies of dl922-947 were less evident ( p< 0.05).
Infectivity of U343MG and U373MG cells is mediated
by coxsackievirus–adenovirus receptor
It has been reported that CAR is the main mediator of
adenoviral entry (Bergelson et al., 1997; Nemerow, 2000;
Tomko et al., 2000; Arnberg, 2009). Therefore, we analyzed
CAR expression by Western blot and cytofluorimetric
analysis in U343MG and U373MG cell lines. Two CAR-
specific bands of 44 and 46 kDa, respectively, were detected
in all samples (Fig. 2A), as previously reported (Cohen et al.,
2001; Libertini et al., 2007).
U373MG cells displayed higher total levels (Fig. 2A) and
membrane levels (Fig. 2B) of CAR, compared with U343MG
cells; this observation parallels the higher viral entry and
sensitivity to the oncolytic activity of dl922-947. To evaluate
whether CAR may play a direct role in infection efficiency,
U343MG and U373MG cells were pretreated for 1 hr with
increasing amounts of the blocking anti-CAR monoclonal
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antibody RmcB and infected with AdGFP at 25 pfu/cell. We
also pretreated cells with two control antibodies: anti-IGF-1R
and anti-actin. Significant decreases in GFP emission were
observed in U373MG cells ( p< 0.005) and U343MG cells
( p< 0.001), upon treatment with RmcB, but not upon treat-
ment with anti-IGF-1R or anti-actin antibodies (Fig. 2C and
D). These data confirm that CAR plays a crucial role in in-
fection efficiency in both cell lines.
ERK modulates U373MG cell line infectivity
by regulating CAR expression
It has been described that ERK signaling regulates CAR
levels in cancer cell lines (Anders et al., 2003). Therefore, we
evaluated ERK1/2 phosphorylation and subcellular localiza-
tion in U373MG and U343MG cells. No difference in ERK1/2
phosphorylation was detected in the two cell lines (Fig. 3A).
However, in U373MG cells, ERK1/2 cytosolic content was
higher than in U343MG cells. Conversely, U343MG cells dis-
played higher levels of ERK1/2 in the nucleus than did
U373MG cells (Fig. 3B), suggesting that ERK1/2 nuclear lo-
calization might contribute to downregulate CAR expression.
Next, a plasmid carrying ERK2 cDNA (pcDNA3-
HA-pERK2) was transiently transfected into U373MG cells, in
order to force ERK into the nucleus. Transfection efficiency
was evaluated by Western blot (Fig. 3C). ERK2 overexpression
was paralleled by increased detection of ERK2 in the nuclei
and by a reduction of CAR total and membrane levels (Fig.
3C). CAR mRNA levels, evaluated by reverse transcription
(RT) real-time PCR, also showed a reduction of about 80%
(Fig. 3D), thus suggesting that an ERK nuclear shift down-
regulates CAR gene expression. Accordingly, a significant
reduction in GFP emission was observed in ERK2-transfected
U373MG cells, after infection with AdGFP (Fig. 3E).
PED/PEA-15 modulates ERK localization
and CAR expression
PED/PEA-15 is a death effector domain-containing pro-
tein, which is involved in the regulation of apoptotic cell
death (Hao et al., 2001; Xiao et al., 2002). PED/PEA-15 is
highly expressed in cells of glial origin (Hao et al., 2001; Xiao
et al., 2002; Sharif et al., 2004). Moreover, it has been reported
that PED/PEA-15 inhibits nuclear translocation and activity
of ERK1/2 (Formstecher et al., 2001; Hill et al., 2002; Renault
et al., 2003; Whitehurst et al., 2004; Renganathan et al., 2005).
As previously reported (Hao et al., 2001), PED/PEA-15
levels were higher in U373MG cells than in U343MG cells
(Fig. 4A). To assess whether PED/PEA-15 may control ERK
localization and CAR expression, a PED/PEA-15 antisense
oligonucleotide (PED-As) was transfected into U373MG
cells, using a scrambled oligonucleotide (PED-Scr) as control,
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FIG. 1. Comparison of the cell-killing activity, replication of
dl922-947, and infectivity in U343MG and U373MG glio-
blastoma cell lines. (A) Cytotoxic effects of the oncolytic ad-
enovirus dl922-947 were evaluated on U343MG and U373MG
glioma cells. The percent survival rates of cells exposed to
adenovirus were calculated by assuming the survival rate of
untreated cells to be 100%. dl922-947-infected U373MG cells
showed significant or highly significant differences in viral
sensitivity compared with U343MG cells. A highly significant
difference ( p< 0.001) in cell survival was observed at all
points with respect to the control for both cell lines: *sig-
nificance compared with equally infected U343MG cells;
#significance compared with uninfected cells. The differences
observed were at least significant (*p< 0.05; **p< 0.001).
Shown are mean percentages of untreated cells and SD from
three different experiments. Standard deviations (error bars) were calculated. (B) Replication was assessed by real-time PCR
genome equivalent analysis. Cells were infected with dl922-947 at various MOIs (0.1, 1, and 10 pfu/cell). At 48 hr postin-
fection, cell medium was collected and viral DNA was extracted and quantified. At an MOI of 0.1 and 1 pfu/cell the
difference in dl922-947 replication between U343MG and U373MG levels was highly significant (**p< 0.001), whereas at an
MOI of 10 pfu/cell the difference was significant (*p< 0.05). Shown are mean percentages of untreated cells and SD from three
different experiments. Standard deviations (error bars) were calculated. (C) Cells were seeded in 6-well plates and infected
with AdGFP at various MOIs (1, 10, 25, 50, and 100 pfu/cell). At 24 hr postinfection, cells were collected and the percentage of
GFP-positive cells was quantified by FACS analysis. Data represent the mean of three different experiments.
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and PED/PEA-15 levels in transfected cells were evaluated
by Western blot.
After PED-As transfection, a decrease in CAR total levels
was observed (Fig. 4B) and the nuclear-to-cytosolic ratio of
ERK distribution was shifted toward the nucleus (Fig. 4C).
To further confirm the role of PED/PEA-15 in the ex-
pression of CAR, U343MG cells were transfected with a
plasmid carrying PED/PEA-15 cDNA, showing an increase
in CAR total levels (Fig. 4D).
Downregulation of PED/PEA-15 decreases CAR
levels, adenoviral infectivity, and sensitivity
to dl922-947 in U373MG cells
Downregulation of PED/PEA-15 was accompanied by a
reduction in total (Fig. 4B) and membrane (Fig. 5A) CAR
levels, respectively. Transfection of U373MG cells with the
scrambled oligonucleotide (PED-Scr) led to a slight reduction
(about 30%) of CAR membrane levels, compared with un-
transfected cells. However, PED-As-transfected cells showed
a significant decrease in CAR membrane levels with respect
to PED-Scr-transfected cells ( p< 0.05).
RT real-time PCR experiments showed an approximately
50% reduction of CAR mRNA levels ( p< 0.05) (Fig. 5B) after
transfection with PED-As and a significant decrease in GFP
emission was observed in PED-As-transfected cells after in-
fection with AdGFP at 25 pfu/cell ( p< 0.05) (Fig. 5C).
These data indicate that PED/PEA-15 plays a role in
controlling the regulation of CAR expression and in adeno-
viral infectivity in glioma cells. To confirm that the down-
regulation of PED/PEA-15 reduces sensitivity to the
oncolytic virus dl922-947, U373MG cells were transfected
with PED-As or PED-Scr.
U373MG cells were also transfected with pcDNA3-HA
pERK2 or pcDNA3-HA plasmid as controls. Forty-eight
hours after transfection cells were infected with dl922-947
FIG. 2. Coxsackievirus–adenovirus receptor
(CAR) in U343MG and U373MG cells. (A)
Western blot analysis of CAR expression in
glioma cells. b-Actin was used as loading
control. U373MG cells displayed higher levels
of total CAR expression. (B) Cytofluorimetric
analysis of CAR expression on the membrane
of glioma cell lines. U343MG and U373MG
cells were harvested and incubated with an
anti-CAR (RmcB) monoclonal antibody or
fluorescein isothiocyanate (FITC)-labeled
mouse antibody alone. FITC-labeled cells
were used as basal fluorescence control. The
first curve represents FITC-labeled secondary
antibody in the absence of primary antibody.
U373MG cells showed about 60% CAR-
positive cells, whereas only 8% of U343MG
cells stained positive with anti-CAR anti-
body. In all experiments, 70% confluent cells
were used. (C) U343MG and U373MG cells
were pretreated for 1 hr with increasing con-
centrations (1:100, 1:250, and 1:500) of the
mouse anti-CAR monoclonal antibody RmcB,
using anti-insulin-like growth factor-1 recep-
tor b subunit (IGF-1R) and anti-actin anti-
bodies as controls, and then infected with
AdGFP (25 pfu/cell). At 24 hr postinfection
GFP emission was analyzed by cytofluori-
metric analysis. Standard deviations (error
bars) of three different experiments were
calculated. GFP emission decreased in a dose-
dependent manner (>50%) after preincuba-
tion with RmcB, but not with anti-IGF-1R or
anti-actin antibodies, in both cell lines. Data
represent the mean of three different experi-
ments.
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FIG. 3. ERK pathway regulates CAR expression in glioma cells. (A) U343MG and U373MG cells were analyzed for the
expression of phospho-ERK1/2 by Western blot, using ERK1/2 total levels as loading control. (B) Subcellular fractionation
(nuclear and cytoplasmic) of U343MG and U373MG cells was performed as described in Materials and Methods, and proteins
were extracted and subjected to SDS–PAGE and immunoblotted with anti-ERK1/2 antibody. b-Actin and H1 histone were
used as loading control for the cytosolic and nuclear fractions, respectively. Blots were revealed by ECL and autoradiography
(left). Autoradiographs of the experiment were subjected to densitometric analysis. The graph on the right represents the ratio
of the values obtained for nuclear and cytosolic ERK immunodetection, after normalizing each fraction for H1 histone and
b-actin levels, respectively. Standard deviations (error bars) of three different experiments were calculated. (C) U373MG cells
were transiently transfected with the plasmid pcDNA3-HA carrying ERK2 cDNA (ERK2) or pcDNA3-HA plasmid as a
control. Total lysates, membrane enrichments, and nuclear fractions were obtained 48 hr after transfection. b-Actin, IGF-1R,
and H1 histone levels were used as loading control and as markers for total, membrane and nuclear lysates, respectively. (D)
CAR mRNA levels were quantified in U373MG cells by RT real-time PCR 24 hr after transfection with 5mg of ERK2 plasmid
or pcDNA3-HA control plasmid. Expression levels were normalized to the expression of b-actin. Data represent the mean of
three experiments. ERK2 overexpression greatly reduced CAR mRNA levels. (E) Effect of ERK2 transfection on infectivity of
glioma cells. U373MG cells were transfected with 5mg of ERK2 plasmid or pcDNA3-HA control plasmid, and 48 hr post-
transfection were infected with AdGFP (25 and 50 pfu/cell). GFP expression was analyzed by cytofluorimetric analysis. Data
represent the mean of three experiments. Standard deviations (error bars) of three different experiments were calculated. The
differences observed were highly significant (**p< 0.001).
1072
(10 pfu/cell) and after 48 hr cell survival was analyzed
(Fig. 5D). A highly significant ( p< 0.001) increase in cell
survival after infection was observed in PED As- and ERK2-
transfected cells with respect to untransfected or transfected
controls ( p< 0.001).
Discussion
GBM is surgically incurable in the vast majority of patients
(Brandes et al., 2008), with median survival duration of about
9–15 months (Furnari et al., 2007). The protocol of adjuvant
therapy, radiation followed by chemotherapy, administered
after surgery, has demonstrated only a moderate increase in
survival (Argyriou et al., 2009). Therefore novel therapeutic
approaches are required. Genetically engineered, condition-
ally replicating viruses are promising therapeutic agents for
cancer and several oncolytic viruses have already been tested
in preclinical or clinical studies for the treatment of gliomas
( Jiang et al., 2007).
In the present study, we have observed that dl922-947 is
active against two glioblastoma cell lines, U343MG and
U373MG, reinforcing the concept that the therapy of glio-
blastoma could benefit from the use of oncolytic viruses.
However, a differential sensitivity to the oncolytic activity of
dl922-947 was evidenced in the two cell lines, with U343MG
cells being more resistant to the virus.
This difference could potentially be due to factors affecting
the viral life cycle (such as attachment, entry, viral gene ex-
pression, etc.). It is generally accepted that poor adenoviral
entry in neoplastic cells represents the most important ob-
stacle for an effective therapy based on replicating oncolytic
adenoviruses (Va¨ha¨-Koskela et al., 2007).
Coxsackievirus–adenovirus receptor (CAR) is the primary
receptor for adenoviruses, and loss or reduction of CAR
greatly decreases adenoviral entry (Bergelson et al., 1997;
Nemerow, 2000; Tomko et al., 2000; Rein et al., 2006). Higher
levels of CAR expression were observed in U373MG cells, as
compared with U343MG cells, and this was paralleled by
increased infection efficiency. However, a significant reduc-
tion was observed in both cell lines blocking the receptor
with an anti-CAR antibody.
Although complete abrogation of adenoviral entry was
not obtained, possibly because of residual entry via alterna-
tive pathways (Arnberg et al., 2009) or subtotal blockade
with the antibody, our data are consistent with the hypoth-
esis that CAR-mediated internalization plays a major role in
both cell lines.
It has been demonstrated that disruption of signaling
through the Raf/MEK (MAPK/ERK kinase)/ERK pathway
by MEK inhibitors (U0126 and PD184352) upregulates CAR
expression (Anders et al., 2003). Interestingly, U373MG cells
displayed higher ERK1/2 cytosolic localization, compared
with U343MG cells, in which ERK1/2 was mostly nuclear.
Because nuclear translocation is a crucial step for ERK-
mediated regulation of gene expression, we hypothesized that
ERK nuclear activity could control CAR expression. Indeed,
overexpression of ERK2 in U373MG cells was accompanied
by forced nuclear localization and decreased CAR mRNA and
protein levels, leading to a reduction in infection efficiency.
PED/PEA-15 is a death effector domain-containing pro-
tein involved in the regulation of apoptotic cell death and
highly expressed in cells of glial origin (Hao et al., 2001;
FIG. 4. PED/PEA-15 antisense (PED As) transfection. (A)
Differential expression of PED/PEA-15 in glioma cell lines.
U343MG and U373MG cells were analyzed for the expres-
sion of the antiapoptotic protein PED/PEA-15 on Western
blot, using b-actin levels as loading control. (B) Effect of
PED/PEA-15 downregulation on CAR. U373MG cells were
transiently transfected with PED/PEA-15 antisense oligo-
nucleotides (PED As) and PED/PEA-15 scrambled oligonu-
cleotides (PED Scr). PED/PEA-15 and CAR total levels were
analyzed 48 hr after transfection. (C) Effect of PED/PEA-15
downregulation on ERK1/2 localization. U373MG cells were
transiently transfected with PED/PEA-15 antisense (PED
As), or with a scrambled oligonucleotide (PED Scr) as con-
trol. Subcellular fractionation (nuclear and cytoplasmic) of
PED As-transfected U373MG cells was performed, and
ERK1/2 expression was analyzed in both fractions. b-actin
and H1 histone were used as a loading control for cytosolic
and nuclear fractions, respectively. (D) Effect of PED/PEA-
15 upregulation on CAR expression. U343MG cells were
transiently transfected with 5 mg of the plasmid pcDNA3
carrying PED/PEA-15 cDNA (PED/PEA-15) or pcDNA3
plasmid as a control. PED/PEA-15 and CAR total levels
were analyzed 48 hr after transfection, using b-actin levels as
loading control.
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FIG. 5. Transfection with PED/PEA-15 antisense (PED As) reduces CAR levels, infectivity, and sensitivity in U373MG cells.
(A) U373MG cells transfected with PED As or PED Scr oligonucleotides were analyzed for expression of CAR by surface
labeling. Forty-eight hours after transfection, cells were harvested and incubated with anti-CAR or secondary FITC-labeled
anti-mouse antibody alone. Labeled cells were analyzed for CAR expression by cytofluorimetric analysis. A strong reduction
in CAR membrane levels was observed in PED As-transfected cells. The difference observed was significant (*p< 0.05).
Standard deviations (error bars) of three different experiments were calculated. (B) CAR mRNA levels were quantified on
U373MG cells by real-time PCR 24 hr after transfection. Expression levels were normalized to the expression of b-actin. PED
As-transfected cells displayed lower CAR mRNA levels. The difference observed was significant (*p< 0.05). Standard de-
viations (error bars) of three different experiments were calculated. (C) U373MG cells were transfected with PED/PEA-15
antisense or scrambled sequence and 48 hr post-transfection were infected with AdGFP (25 pfu/cell). GFP expression was
analyzed by cytofluorimetric analysis; PED As transfection significantly reduced GFP emission (*p< 0.05). Standard devia-
tions (error bars) of three different experiments were calculated. (D) U373MG cells were transfected with PED/PEA-15
antisense (PED As), scrambled sequence (PED Scr), ERK2 plasmid, or pcDNA3-HA control plasmid. Forty-eight hours after
transfection cells were infected with dl922-947 (10 pfu/cell). Cell survival was analyzed 48 hr postinfection. ERK2- and PED
As-transfected cells displayed lower sensitivity to the virus compared with cells transfected with control plasmids. The
differences observed were highly significant (**p< 0.001). Standard deviations (error bars) of three different experiments were
calculated.
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Xiao et al., 2002). PED/PEA-15 regulates the ERK/MAPK
pathway by binding ERK1/2 and preventing its nuclear ac-
cumulation and activity (Formstecher et al., 2001; Hill et al.,
2002; Renault et al., 2003; Whitehurst et al., 2004; Renga-
nathan et al., 2005). Moreover, abrogation of ERK1/2 binding
as a result of point mutations in PED/PEA-15 restores
normal ERK1/2 function (Whitehurst et al., 2004). We have
hypothesized that PED/PEA-15 could be involved in CAR
regulation and adenoviral infectivity by controlling ERK
subcellular distribution. Indeed, PED/PEA-15 levels are
higher in U373MG cells than in U343MG cells and positively
correlate with the relative ERK cytosolic abundance, CAR
levels, adenoviral infectivity, and dl922-947 killing capacity.
In U373MG cells genetic silencing of PED/PEA-15 with a
specific antisense oligonucleotide enhanced ERK1/2 nuclear
distribution and led to a reduction of CAR levels and sen-
sitivity to the oncolytic adenovirus dl922-947. Conversely,
overexpression of PED/PEA-15 increased CAR total levels in
U343MG cells.
Our data show that PED/PEA-15 levels correlate with
infectivity and sensitivity to oncolytic adenoviruses and sug-
gested that, in association with CAR, the evaluation of PED/
PEA-15 levels could represent a useful tool to guide patients
with glioblastoma toward specific therapeutic options.
It is important to note that PED/PEA-15 is involved in the
regulation of apoptotic cell death (Hao et al., 2001; Condorelli
et al., 2002; Xiao et al., 2002) and it has been demonstrated that,
in glioma cell lines, the apoptotic cascade activated by tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) is
negatively regulated by PED/PEA-15 (Hao et al., 2001; Xiao
et al., 2002; Song et al., 2006). Moreover, overexpression of
PED/PEA-15 induces a marked resistance against glucose
deprivation-induced apoptosis in glioma cells (Eckert et al.,
2008). Glioma cells overexpressing PED/PEA-15 also show a
marked resistance to radiotherapy (G. Perruolo, G. Botta, and
G. Portella, unpublished data) and it has been reported that
PED/PEA-15 may contribute to the resistance to chemothera-
peutic agents in breast cancer cells (Stassi et al., 2005) and B-cell
chronic lymphocytic leukemia cells (Garofalo et al., 2007), and
in human non-small cell lung cancer (Zanca et al., 2008).
These findings indicate that PED/PEA-15 increases the
resistance to apoptotic agents, and that PED/PEA-15 ex-
pression could predict resistance to apoptosis. It is possible
to hypothesize that patients with high PED/PEA-15 levels
should not benefit from therapy based on these agents,
whereas our data indicate that these patients could benefit
from adenovirus-based therapy.
Therefore, PED/PEA-15 expression levels could play a dual
predictive role: as a marker of resistance to chemo- and radio-
therapy for its antiapoptotic activity and as a marker of sensitivity
to adenovirus-based therapies, for its role on CAR expression.
In conclusion, our data show that adenoviral infectivity is
mostly CAR-mediated in glioblastoma cells and that PED/
PEA-15 upregulates CAR expression, by preventing ERK
nuclear translocation. Further studies are required to clearly
assess the role of PED/PEA-15 as a predictive marker in
glioblastoma.
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Abstract: The Aurora Kinases are highly related serine-threonine kinases, essential for accurate and equal segregation of 
genomic material during mitosis. A large number of studies have linked the aberrant expression of Aurora kinases to 
cancer, leading to the development of specific Aurora kinases inhibitors. Several small molecules inhibit with a similar 
efficacy both Aurora A and Aurora B, however, in most cases the effects resemble Aurora B disruption by genetic 
methods, indicating that Aurora B represents an effective therapeutic target. These drugs are currently under preclinical or 
clinical evaluation and are reviewed in this article. The relevant patents are discussed. 
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INTRODUCTION 
Aurora Kinases 
 Mitosis is an extraordinarily complex biological process, 
by which a complete copy of the duplicated genome is pre-
cisely segregated into two daughter cells. All mitotic phases 
are strictly controlled by phosphorylation events performed 
by several evolutionary conserved serine-threonine kinases, 
known as mitotic kinases, such as cyclin-dependent kinases, 
NIMA-related kinases and Aurora-Ipl1 related kinases [1]. 
 Mammalian genomes contain three genes encoding 
Aurora kinases, denoted Aurora A, Aurora B, and Aurora C 
[2]. The three Aurora kinases are serine-threonine protein 
kinases that together form a small kinase family phylo-
genetically related to the branch of the AGC (protein kinase 
A/protein kinase G/protein kinase C family) protein kinases 
[3]. The founding member of the Aurora kinases is the 
Drosophila Aurora kinase that was discovered in a screen to 
identify genes involved in mitotic spindle function [4]. Fungi 
have only one Aurora kinase (Ipl1 in S. cerevisiae [5, 6] and 
Ark1 in S. pombe [7]) that is functionally more related to the 
Aurora B kinases in higher organisms. Mammals have a 
third Aurora gene called Aurora C. Aurora kinase function is 
controlled by several mechanisms. Firstly, gene transcription 
of the Aurora kinases is cell cycle regulated. The promoters 
of Aurora B and Aurora A contain specific sequences 
(CDE/CHR sequences) required for transcription in G2 [8-
10]. Several transcription factors, such as E2F-1, E2F-4, DP-
2 and FoxM1 have been implicated in cell cycle regulated 
transcription of Aurora B [8-11]. The Aurora C gene seems 
to be mainly expressed in meiotically dividing cells, and its 
transcription is at least in part controlled by a testis-specific 
transcription factor called Testis Zinc Finger Protein (Tzfp) 
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[12]. Aurora C, like Aurora B, is capable of binding to the 
IN-box of INCENP. This binding also results in activation of 
Aurora C, in a manner that is most likely similar to the mode 
of activation of Aurora B [13, 14]. Aurora C is the least 
studied of the three mammalian Aurora kinases [15]. It was 
initially discovered in mice as a testis-specific serine/ 
threonine kinase named Aie1 [16]. Protein kinase A (PKA) 
is able to phosphorylate Aurora C on Thr
171
, which is the 
threonine residue that must be phosphorylated for kinase 
activity. When Thr
171
 and Thr
175
 were both mutated to 
alanines, Aurora C showed impaired kinase activity toward 
an as yet undefined 16kDa protein named Aurora C substrate 
1 (ACS-1) [17]. Interestingly, Aurora C appears to share its 
cellular localization and some functions with Aurora B. Both 
Aurora B and C are chromosomal passenger proteins and 
both form complexes with INCENP [14] and survivin [18]. 
INCENP was also found to stimulate the ability of Aurora C 
to phosphorylate histone 3 (H3) [14]. The Aurora C gene is 
expressed at low levels in several tissues and is over-
expressed in some cancer cell lines [13] such as those 
derived from thyroid cancer [19]. Protein expression of 
Aurora C is similar to the two other mammalian Aurora 
kinases in that it peaks during G2/M phases, but it does so 
later in mitosis than Aurora A or B [13]. Either over-
expression of kinase dead Aurora C or knockdown of Aurora 
C causes cells to become multinucleated; this phenotype is 
reminiscent of knockdown of Aurora B. Interestingly, 
Aurora C can rescue Aurora B knockdown and the same is 
true of the reverse scenario [14, 18]. Taken together, the 
similar cellular localization and common knockdown 
phenotypes of Aurora B and C suggest that these two kinases 
may have redundant cellular functions.  
 Both Aurora A and Aurora B are targets of a multi-
subunit E3-ubiquitin ligase called the Anaphase Promoting 
Complex/Cyclosome (APC/C) [20-25]. The APC/C, in 
conjunction with its specificity factor Cdh1, targets these 
proteins for destruction during mitotic exit and as such 
ensures that G1 cells contain low levels of these proteins. 
The cellular consequences of misregulated degradation of the 
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Aurora kinases are unknown, although non-degradable 
Aurora B was shown to be more potent in promoting 
anchorage-independent growth than wild type Aurora B [21]. 
Besides the APC/C, also a Cullin 3(Cul3)-based E3 ligase 
was shown to ubiquitinate Aurora B in vitro and in vivo [26]. 
Ubiquitination was shown to promote dissociation of Aurora 
B from metaphase chromosomes, and recent data indicate 
that degradation-independent ubiquitination of Aurora B 
triggers Cdc48/p97 ATPase-dependent extraction of Aurora 
B from mitotic chromosomes, an event required for timely 
chromosome decondensation during mitotic exit. In addition, 
removal of Aurora B from mitotic chromosomes is required 
for nuclear membrane assembly in telophase. Human Aurora 
A is turned over through the anaphase promoting complex/ 
cyclosome (APC/C)-ubiquitin-proteasome pathway [27]. 
Aurora A degradation is dependent on hCdh1 in vivo, not on 
hCdc20 [20] and involves two different degradation motifs. 
The first corresponds to a N-terminal, D-Box-activating 
motif (RxLxPS). This motif confers functionality to a second 
motif, a D-Box, consisting of the sequence RxxLxxG. The 
D-box is located at the C-terminus of the kinase domain and 
is the target of Fizzy-related proteins [28]. Although Aurora 
B possesses the same D-Box as Aurora A, it is not degraded 
by the same ubiquitin ligase. Instead, Aurora B undergoes 
degradation by binding to the human proteasome ?-subunit 
C8 (HC8) in a proteasome-dependent manner [29]. In 
contrast with Aurora A and B, the mechanism(s) involved in 
Aurora C degradation remain obscure. Certainly, the detailed 
study of Aurora C regulation constitutes an interesting area 
of research [30]. 
 Regulation of Aurora A is complex and involves both 
phosphorylation/dephosphorylation and degradation. Phos-
phorylation stimulates kinase activity. Three phosphory-
lation sites have been identified in Xenopus Aurora A by 
mass spectrometry [31]. Phosphorylation of Thr
295
 (Thr
288
in 
human Aurora A) in the activation loop is essential for 
kinase activity [27]. This residue is in a protein kinase A 
(PKA) consensus motif, and PKA can phosphorylate and 
activate Aurora A in vitro [27]. However, this site also fits 
the consensus phosphorylation sequence that has been 
defined for S. cerevisiae Ipl1 (R/K)X(T/S)(I/L/V) [32]; and 
the equivalent residue (Thr
260
) in yeast Aurora has indeed 
been identified as an autophosphorylation site [32]. Ser
53 
in 
the N-terminal A-box is phosphorylated during M phase and 
might have a role in the regulation of Aurora A degradation. 
Although the third phosphorylation site to be identified -
Ser
349
- is not essential for catalytic activity, S349D mutants 
block kinase activation, which indicates a possible structural 
or regulatory role for this modification [31]. The phosphatase 
PP1 negatively regulates the Aurora kinases. The coun-
teracting effect of PP1, which was first described for yeast 
Ipl1, has also been shown in Xenopus and human cell lines 
[27, 33-36]. The activation of Aurora A by TPX2 is at least 
partly due to antagonism of PP1 [37, 38]. Aurora A is 
degraded in late mitosis/early G1 by the Cdh1/Fizzy-related 
form of the anaphase-promoting complex/cyclosome (APC/ 
C; the APC/C with Cdh1/Fizzy-related as a substrate recog-
nition subunit) [6, 28]. Aurora A has a silent C-terminal D-
box (destruction box), which is also present in Aurora B [24, 
38], but which is only functional in the presence of a N-
terminal A-box (also called the D-box-activating-domain 
(DAD)) [38]. The A-box/DAD is absent from Aurora B and 
C, and their D-boxes are not targeted by the APC/C during 
mitotic exit. Phosphorylation of the A-box seems to make 
the Aurora A resistant to APC/C mediated degradation. 
Interestingly, the D-box is recognized by both the Cdh1/ 
Fizzy-related and Cdc20/Fizzy forms of the APC/C, but 
Aurora A is only targeted by the former. The recently identi-
fied Aurora A-kinase-interacting protein (AIP), a negative 
regulator of Aurora A, is a conserved nuclear protein that 
interacts with the kinase in vivo [39]. AIP was isolated as a 
dosage-dependent suppressor of Aurora A that was ectopi-
cally overexpressed in budding yeast. In mammalian cells, 
AIP might downregulate Aurora through proteasome-depen-
dent degradation [39]. Its normal function is not known [40]. 
 Aurora kinases are involved in multiple facets of mitosis 
and cell division, including centrosome duplication, mitotic 
spindle formation, chromosome alignment upon the spindle, 
mitotic checkpoint activation, and cytokinesis. Errors in 
these processes ultimately lead to aneuploidy or cell death 
[41]. Aberrant expression of Aurora Kinases may disturb 
checkpoint functions, particularly in mitosis, and this may 
lead to genetic instability and trigger the development of 
tumours [42]. The Aurora A and B have emerged as essential 
regulators of cell division. Aurora A is involved in the regu-
lation of mitotic entry, centrosome maturation, and spindle 
assembly. Aurora B is required for correct chromosome 
segregation and cytokinesis; Aurora C plays a role in the 
regulation of cilia and flagella, localizes to centrosomes from 
anaphase to cytokinesis and it is predominantly expressed in 
testis [43, 44]. 
 The protein encoded by the Aurora A, B, and C genes are 
403, 343, and 275 amino acids long, respectively. These 
kinases present a similar domain organization: a N-terminal 
regulatory domain of 39-129 residues in length, a protein 
kinase domain and a short C-terminal catalytic domain of 15-
20 residues. The catalytic domain of these three proteins is 
highly homologous, sharing greater than 70% homology 
among the three Aurora proteins [40, 45-47]. In all three 
kinases ATP binding active site are lined by 26 residues and 
three variants: Leu
215
, Thr
217
, Arg
220
 are specific to Aurora 
A. A PEST-like motif has been identified in Aurora C, and a 
mutation of this motif significantly abrogates Aurora C 
kinase activity [17]. Each Aurora kinase domain contains a 
threonine residue (Thr
288
) within the protein’s activation loop 
that must be phosphorylated for the kinase to be active. The 
N-terminal domain of the Aurora kinases shares low seq-
uence conservation, which determines selectivity during 
protein-protein interactions. Additionally, the Aurora pro-
teins all contain a destruction box, or D-box, at the C-ter-
minal, which is a sequence typically recognized by APC/C, 
mediating the proteasomal degradation of a D-box con-
taining protein. The alignment of Aurora A and B allows the 
identification of one distantly conserved KEN motif, 
spanning 11-18 residues. The KEN motif acts as a Cdh1-
dependent anaphase-promoting complex (APC) recognition 
signal. Destruction also requires a short region in the N-
terminal, which contains a newly identified recognition 
signal, the A-box. The A-box is conserved in vertebrate 
Aurora kinases and contains a Ser
53
, which is phosphorylated 
during M phase. Mutation of Ser
53
 to aspartic acid, which 
can mimic the effects of phosphorylation, completely blocks 
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Cdh1-dependent destruction of Aurora A. The N-terminal 
domain varies widely among the Aurora proteins, and this 
domain is believed to be involved in substrate binding and 
cellular localization Fig. (1) [15, 24, 30, 40, 46]. 
 Despite significant sequence homology, the localization 
and functions of these three Kinases are largely distinct from 
one another. Aurora A is ubiquitously expressed and 
regulates cell cycle events occurring from late S phase 
through M phase, including centrosome maturation [48], 
mitotic entry [49, 50], centrosome separation [51], bipolar-
spindle assembly [38, 52], cytokinesis [53], chromosome 
alignment on the metaphase plate [53-56], and mitotic exit. 
Aurora B is essential for chromosome biorentation, accurate 
chromosomal segregation, correct functioning of the spindle 
assembly checkpoint and cytokinesis [57-61]. Aurora C 
exhibits similar functions to those assigned to Aurora B and 
is required for cytokinesis. A study of 2004 found that direct 
association with INCEP activates Aurora C, suggesting the 
cooperation of Aurora A and B in the regulation of mitotic 
events. Recently, it has been shown that Aurora C can 
complement the functions of Aurora B [44]. 
 The genes encoding the three human Aurora kinases map 
to regions that are affected by chromosomal abnormalities in 
different cancer types, and overexpression of each of the 
human Aurora kinases has been detected in human tumours 
[42].  
Aurora B 
 The Aurora B gene lies on human chromosome 17p13 
and codifies for a 41KDa serine-threonine kinase. Aurora B 
expression and activity in proliferating tissues are cell cycle 
regulated: expression peaks at G2-M transition and kinase 
activity is maximal during mitosis. At the end of mitosis, the 
D-box region of Aurora B is recognized by the anaphase-
promoting complex/cyclosome (APC/C), leading to Aurora 
B ubiquitination and degradation [46]. 
 Aurora B is the enzymatic component of a bigger 
complex called Cromosomal Passenger Complex (CPC) 
[62]. The CPC shows a very dynamic localization during 
mitosis hence its name: it covers the entire chromatin during 
the onset of mitosis, moves from the chromosome arms 
toward the kinetochores during prometaphase, relocalizes to 
the microtubules of the central spindle at the metaphase-
anaphase transition, and finally concentrates at the midbody 
during telophase/cytokinesis. This localization parallels the 
diverse functions of the CPC during mitosis: modifying 
histones at the chromatin, correcting misattachments while at 
the centromere, and regulating cytokinesis at the central 
spindle. The CPC contains three non enzymatic subunits, all 
of which are essential for the activity, localization, stability, 
and substrate specificity of Aurora B. In human cells, these 
non enzymatic subunits are Survivin, the Inner Centromere 
Protein (INCENP), and Borealin [63, 64]. It is believed that, 
during mitosis, two distinct passenger complexes exist: one 
consisting of INCENP and Aurora B, responsible for histone 
H3 phosphorylation and another containing all four CPC 
members, responsible for chromosome alignment and cyto-
kinesis [63, 65]. As such, Aurora B can be considered as a 
histone kinase, a spindle checkpoint kinase and a cytokinesis 
kinase Fig. (2) [62]. 
 Histone kinase -Aurora B kinases are responsible for one 
of the classic modifications of chromatin in mitosis: phos-
phorylation of histone H3 on Ser
10
 [66]. This modification, 
which is conserved from yeast to vertebrates, is carried out 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Human Aurora kinase structure. The Aurora kinases are largely composed of two domains, the N-terminal regulatory domain and 
the C-terminal catalytic domain. In the regulatory domain, Aurora A and B contain an activation domain (A-box) that regulates their 
degradation. Aurora A contains a KEN box similar to that found on cdc20 ubiquitinated in response to APC/CCdh1. In the C-terminal domain 
all three Aurora kinases contain the kinase domain (KD) and a destruction box (D-box). 
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by Ipl1 in budding yeast [67] and Aurora B in metazoans 
[35, 67, 68-72]. Aurora B is also responsible for histone H3 
phosphorylation on Ser
28
 from prophase to metaphase [64, 
73] and for the mitotic phosphorylation of Ser
7
 of the 
kinetocore-specific histone H3 variant centromere protein A 
(CENP-A) [58]. Condensation of chromosomes into compact 
structures is essential for error-free sister chromatid segre-
gation and is driven by the action of Condensin complexes 
(Condensin I and II in human cells) [74, 75]. Aurora B 
contributes to proper condensation and chromosomal 
association of the Condensin I complex in several organisms, 
potentially via direct phosphorylation of the three non-SMC 
subunits [70, 76-80]. It must be noted that Condensin 
loading and condensation show a different dependency on 
Aurora B in different organisms [70, 76-79, 81]. Phosphory-
lation of histone H3 at Ser
10
 during late G2/prophase by 
Aurora B has also been linked with chromosome conden-
sation, also because mutation of this phosphorylation site in 
Tetrahymena thermophila and S. pombe caused chromosome 
condensation and subsequent segregation defects [70, 72, 82-
84]. However, a similar mutation did not cause any mitotic 
defects in the budding yeast Saccharomyces cerevisiae [82]. 
These differences might be explained by differences in 
chromosome structure between these species. In human cells, 
phosphorylation of Ser
10
 histone H3 was suggested to 
displace the HP-1 family of proteins from heterochromatin in 
mitosis [85, 86], but whether this displacement has conse-
quences for chromosome condensation is unknown. Defects 
in chromosome structure and compaction are observed in 
Aurora B depleted Drosophila cells [68, 87], but the 
underlying mechanism is not known. One possibility is that 
Aurora activity might be required for condensin function. 
However, the relationship between the kinase and condensin 
is unclear. The condensin complex [88] does not localize 
properly to chromosomes in Drosophila cells that lack active 
Aurora B [87] or in S. pombe that lacks Ark1 [89]. In C. 
elegans, condensin activity is independent of Aurora B in 
prometaphase, but becomes dependent on the kinase in 
metaphase [90, 91]; in Xenopus extracts, Aurora B is not 
required for condensin binding or chromosome condensation 
[72]. Furthermore, in cells treated with the Aurora B 
inhibitor hesperadin [92], in which Aurora B localizes 
properly but is enzymatically inactive, the condensin 
complex localizes normally. There is no evidence so far that 
any of the condensin subunits is a substrate of Aurora B [40]. 
 Spindle checkpoint kinase -Aurora B also controls 
chromosome cohesion. Cohesion is brought about by a ring-
like Cohesin complex, which is related to the Condensin 
complexes. Cohesion persists between sister chromatids until 
the metaphase to anaphase transition [93]. In vertebrate cells, 
Cohesin is removed in mitosis through two distinct mecha-
nisms [94]. The first, referred to as the prophase pathway, 
removes Cohesin from chromosome arms in a fashion that 
depends on Plk-1 and Aurora B [79, 95, 96]. Aurora B 
functions in this prophase pathway through control of the 
Shugoshin family of centromeric proteins. These proteins 
were identified as regulators of meiotic chromosome 
segregation in Drosophila and budding yeast [97, 98]. The 
human counterpart of these proteins (Sgo1) protects centro-
meric Cohesin during mitosis via recruitment of a PP2A-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Localization and function of human Aurora kinases during mitosis and their inhibitors. 
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phosphatase complex to the centromere [99-104]. Aurora B 
activity confines Sgo1 localisation to centromeric regions 
and upon inhibition or depletion of Aurora B, Sgo1 fails to 
concentrate on centromeres and instead localises diffusely 
along chromosome arms [77, 105, 106]. Displacement of 
Sgo1 from centromeres causes protection of chromosome 
arm-localised Cohesin complexes against removal [99, 100, 
102]. Alternatively, since HP-1 influences Cohesin recruit-
ment to chromatin [107, 108], Aurora B-dependent regu-
lation of HP-1-chromatin retention might be an alternative 
way by which it influences chromosome cohesion.  
 Recently, Aurora B has also been put forward as an 
important regulator of chromatin-induced spindle assembly 
in a pathway functioning in parallel to the Ran-dependent 
pathway. Aurora B is activated on chromatin and depletion 
or inhibition of Aurora B severely perturbs spindle assembly 
in Xenopus extracts [109-111]. Two different Aurora B 
substrates were suggested as downstream targets in this 
pathway. The first is the microtubule-depolymerising kinesin 
MCAK (Mitotic Centromere-Associated Kinesin), since 
depletion of MCAK in Aurora B depleted cells or extracts 
restored the chromosome-driven spindle pathway [110, 112, 
113]. The second is the microtubule-destabilizing protein 
Stahtmin/Op18, whose activity is inhibited by Aurora B 
phosphorylation in the vicinity of chromosomes [109, 114]. 
Kinetochore capture by the mitotic spindle is a stochastic 
process that will give rise to intermediate states of attach-
ment. Non-bipolar attachments in which both kinetochores 
bind microtubules emanating from the same pole (also called 
syntelic attachments) occur during every mitosis and need to 
be corrected to eventually produce biorientation [115-117]. 
These attachments are actively destabilized through the 
activity of Aurora B [116, 118, 119]. Unattached kineto-
chores can now enter a new cycle of microtubule attachment 
until bipolar attachment is obtained. Two important kineto-
chore microtubule-capture factors (the Ncd80/Hec1- and 
Dam1-complexes) are subject to phosphoregulation by 
Aurora B [118]. In addition, Aurora B phosphorylates 
MCAK, and this also contributes to the correction of defec-
tive attachments [120-122]. Phosphorylation of Ndc80/Hec1 
by Aurora B reduces its affinity for microtubules in vitro 
[123] and mutation of the putative Aurora B phospho-
rylation-sites in Ndc80/Hec1 stabilises microtubule-kineto-
chore interactions in vivo [124]. Additionally, several sub-
units of the Dam1-complex are also substrates of the budding 
yeast Aurora B (Ipl1) and mutation of phosphorylation-sites 
within the Dam1-subunit of this complex causes chromo-
some segregation defects similar to those occurring in Ipl1-
mutants [118]. In summary, Aurora B influences the stability 
of microtubule kinetochore interactions by controlling the 
function of key microtubule-capture factors on the kineto-
chore. It is capable of destabilizing defective non-bipolar 
attachments and as such functions as an error correction 
factor that ensures faithful segregation of sister chromatids.  
 Aurora B becomes enriched at centromeres of mero-
telically attached kinetochores where it promotes kineto-
chore microtubule turnover [125, 126] most likely via 
regulation of MCAK. Aurora B influences the function of 
MCAK at different levels. First, Aurora B activity is required 
for the concentration of MCAK on centromeres [120, 121, 
126]. Second, phosphorylation of MCAK within its neck 
region inhibits its microtubule-destabilising activity in vitro 
and expression of phosphodefective MCAK mutants 
(containing serine/threonine to alanine mutations on all 
Aurora B sites) causes clear chromosome alignment defects 
[111, 120]. Third, Aurora B also indirectly influences 
MCAK function. Aurora B interacts with ICIS (inner 
centromere Kin-I simulator), a centromeric protein that can 
stimulate MCAK activity in vitro [127] and Aurora B is also 
required to target Sgo2 to centromeres. Interestingly, Sgo2 
depletion caused a displacement of MCAK from centromeres 
and an increase in the amount of merotelic attachments 
[128]. Clearly, regulation of MCAK by Aurora B is complex 
and has an effect on multiple important processes that 
influence chromosome segregation.  
 Aurora B also plays an essential role in the mitotic 
checkpoint by recruiting BubR1 (Budding Uninhibited by 
Benzimidazoles 1 homolog (yeast)-related kinase or MAD3/ 
Bub1b), Mad2 (Mitotic Arrest Deficient 2) and Cenp-E 
(Centromere Protein E) to unattached kinetochores, thus 
coupling chromosome alignment with anaphase [129]. The 
mitotic checkpoint is compromised by the lack of Aurora B 
activity [130]. 
 Cytokinesis kinase -From anaphase onwards, Aurora B 
localises to both the central spindle/midbody and to the cell 
cortex, to which it is transported via microtubules. Aurora B 
activity is required for efficient execution of anaphase and 
cytokinesis in several organisms [68, 70, 92, 129, 131-133]. 
Localisation of Aurora B to the central spindle contributes to 
the rapid switch in microtubule dynamics during anaphase 
[134] and Aurora B is also required for efficient disassembly 
of the mitotic spindle during telophase [135]. During 
cytokinesis, the cytoplasm is divided into two new daughter 
cells each containing a single nucleus. A cleavage furrow is 
generated by contraction of an actionmyosin ring that encir-
cles the cell equator and eventually divides the cytoplasm 
into two [136]. It is important that the cleavage furrow only 
forms after chromosome segregation and that it is positioned 
correctly between the two daughter nuclei. An essential 
determinant of contractile ring function is the GTPase RhoA 
[137]. Active (GTP-bound) RhoA controls several down-
stream effectors involved in cytokinesis [137]. RhoA 
function during cytokinesis is controlled in part by a central 
spindle-localised complex called centralspindlin. This 
complex, consisting of a GTPase activating protein (GAP) 
(MgcRacGAP/Cyk4) and a kinesin (Mklp-1/ZEN-4), 
influences RhoA by controlling localisation of Ect2, an 
essential Rho-GEF [138-142]. Correct function and locali-
sation of centralspindlin depends on Aurora B activity [143-
145]. Aurora B phosphorylates several other proteins 
involved in cytokinesis, like Vimentin [146], Myosin II 
regulatory light chain [147], Desmin, and GFAP [148]. In 
budding yeast, Ipl1 plays an additional role during cyto-
kinesis by controlling the NoCut pathway that prevents 
abscission (the final step of cytokinesis) when chromosomes 
are present in the direct vicinity of the site of abscission 
[149]. Ipl1 controls the localization of the anillin-related 
proteins Boi1 and Boi2 to the site of cleavage ingression 
where they can function as abscission inhibitors and prevent 
premature abscission and concomitant chromosome breakage 
[149]. 
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Aurora Kinases and Cancer 
 In the last decade, a large number of studies have linked 
the aberrant expression of Aurora kinases to cancer and this 
has lead to a great effort on the development of Aurora 
kinases inhibitors.  
 The role of Aurora A in the development of neoplastic 
lesions was established first, and therefore the search for 
anticancer therapeutic targets was initially centred on Aurora 
A inhibitors. However, most of them react with both Aurora 
A and Aurora B. The studies performed with dual Aurora 
kinase inhibitors have shown that treated cells display 
aberrant mitosis, increase in DNA content (>4N) and cell 
death. These effects closely resemble that of Aurora B 
disruption by genetic methods, suggesting that Aurora B 
represents an effective therapeutic target despite its uncertain 
role in the development or progression of neoplastic lesions. 
 A large number of dual activity Aurora inhibitors are 
currently under clinical evaluation. Therefore, we will also 
discuss the role of Aurora A in cancer. 
Aurora A and Cancer 
 Aurora A is ubiquitously expressed and regulates cell 
cycle events occurring from late S phase through M phase, 
including centrosome maturation, mitotic entry, centrosome 
separation, bipolar-spindle assembly, chromosome alignment 
on the metaphase plate, cytokinesis and mitotic exit [1, 40]. 
Different proteins, TPX2, Ajuba, Bora, HEF1 are known to 
play a role in Aurora A activation and function, however it is 
not been fully understood how these activators relate to each 
other and how their signaling cooperates during cell cycle 
progression [46].  
 The role of Aurora A in cancer development has been 
largely studied and clarified. Aurora A gene is located on 
chromosome 20q13.2, a known hotspot of amplification in 
tumours [150]. The gene was first named BTAK (Breast 
Tumor Activated Kinase), since its mRNA was found to be 
overexpressed in breast tumours and to play a critical role in 
breast tumour cell transformation [151, 152]. Several studies 
have shown amplification of the Aurora A locus and con-
comitant overexpression of Aurora A kinase in a multitude 
of tumours, such as gliomas, breast, endometrial and others 
[151-166]. Accumulating evidences have demonstrated that 
gene amplification and overexpression of Aurora A are 
linked to tumorigenesis, suggesting that Aurora A is an 
oncogene [161, 167-175]. In addition, Aurora A overex-
pression has been used as a negative prognostic marker, 
being associated with resistance to anti-mitotic agents 
commonly used for cancer therapy [161, 169, 171, 172, 176-
184]. Aurora A has been identified as a low-penetrance 
tumour-susceptibility gene [185-187]. A T-to-A polymor-
phism, resulting in a change from phenylalanine 31 (Phe
31
) 
to isoleucine (Ile
31
), has been observed in the Aurora A gene 
and reported to be associated with the degree of aneuploidy 
in human colon tumours [185, 186]. The Phe31Ile variant is 
also preferentially amplified in esophageal squamous cell 
carcinomas, and also in this case correlates with an increase 
in aneuploidy. In particular, the Ile/Ile genotype was 
significantly associated with increased risk of oesophageal 
squamous cell carcinoma occurrence compared with the 
Phe/Phe genotype [186]. Aurora A polymorphisms have 
been associated with increased risk of breast [186, 188-190], 
oesophageal [170, 186], lung [186, 191] and gastric cancer 
[192]. 
 Aurora A overexpression alone is insufficient to induce 
carcinogenesis, and other molecular alterations need to be 
associated with Aurora A amplification/overexpression to 
induce oncogenicity [154, 169, 173, 193]. This hypothesis is 
supported by the observation that transgenic mice over-
expressing Aurora A in an inducible manner in the mammary 
glands do not develop tumours; in mammary epithelium 
tetraploid cells and apoptotic features are observed [194, 
195]. Consistent with this data, the conditional expression of 
Phe31Ile variant in mouse skin alone or treated with the co-
carcinogenetic agent TPA did not result in squamous cell 
carcinoma. However, Phe31Ile transgenic animals presente 
accelerated squamous cell carcinoma (SCC) development 
with greater metastatic activity compared to wild type 
animals, upon skin carcinogenesis treatment. These obser-
vations indicate that Aurora A cannot initiate skin carcino-
genesis but rather promotes the malignant conversion of skin 
papillomas [175]. 
Aurora B and Cancer 
 Aurora B is involved in chromosome segregation, 
spindle-checkpoint and cytokinesis, and alteration of each of 
these steps could induce aneuploidy, one of main features 
and driving force of cancer cells. However, the role of 
Aurora B in cancer development and/or progression has not 
been fully clarified.  
 In vitro studies performed with several Aurora B inhi-
bitors, dominant negative mutants or RNAi, show that 
Aurora B deficiency interferes with cell cycle. Treated cells 
cannot divide after mitosis and become tetraploid, with two 
couples of centrosomes. Moreover, cells expressing 
catalytically inactive Aurora B do not arrest in mitosis in the 
presence of nocodazole or taxol. These observations concur 
with Aurora B presumed roles: spindle checkpoint sup-
pression allows cells to go through mitosis, despite a number 
of chromosomes being oriented in a syntelic manner (both 
kinetocore attached to the same pole), while the lack of 
phosphorylation of cleavage furrow components prevents 
cytokinesis. The effects of longer depletion of Aurora B 
seem to be cell line dependent. Some cells either enter 
additional cell cycles but, because of cell division failure, 
they become massively polyploid, whereas other cell lines 
undergo apoptosis or arrest in a pseudo G1 state. These 
differences are probably due to the p53-dependent post-
mitotic checkpoint. 
 Ota et al. [196] strongly suggest a direct link between 
Aurora B and carcinogenesis. In this report, Chinese hamster 
embryo (CHE) cells, carrying wild type p53 (CHEp53
wt
) or 
an inactivating mutation (CHEp53
-/-
), were transfected with 
Aurora B. The mutation in p53 abrogates the p53-dependent 
G1 checkpoint. Stable clones overexpressing Aurora B were 
isolated and injected in nude mice. Notably, the authors 
could use only CHEp53
-/- 
tranfected cells, since they could 
not isolate any stable clone from CHEp53
wt
. Untransfected 
CHE cells induce tumours when injected in nude mice, but 
they do not metastasize, whereas mice injected with Aurora 
B overexpressing CHEp53
-/-
 cells formed more aggressive 
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tumours that also gave distant metastates [196]. In a recent 
paper, Kanda et at. [197] showed that, although Aurora B 
overexpression is not oncogenic in BALB/c 3T3 A31-1-1 
cells, Aurora B kinase activity augments Ras-mediated cell 
transformation, suggesting that the overexpression of Aurora 
B may contribute to the generation of a transformed pheno-
type, by potentiating oncogene activity during carcino-
genesis. 
 Aurora B is located on chromosome 17p13.1, a chromo-
somal region that has not been frequently associated with 
amplification in tumours, with the exception of glioblas-
tomas [198].  
 Aurora B gene is dramatically up-regulated in highly 
proliferating compared with non-proliferating cells. 
Although Aurora B overexpression has been shown in many 
tumours types, this is not the result of gene amplification, 
and it is still under debate whether the observed overexpres-
sion of Aurora B is a reflection of the high proliferative rate 
of neoplastic cells or whether it is causally related to 
tumorigenesis.  
 Aurora B is overexpressed in several human cancers, 
such as non small cell lung carcinoma [199, 200], mesothe-
lioma [201], glioblastoma [198, 202], oral cancer [203], 
malignant endometrium [159], hepatocellular carcinoma 
[204-206], testicular germ cell tumours [207, 208], ovarian 
[187], thyroid [209], colon [210] and prostate [211]. Aurora 
B expression is positively correlated with poor prognosis and 
displays a tendency to group in higher grade of malignancy 
in different neoplastic lesions. Aurora B expression directly 
correlates with Gleason grade in prostate cancer [212], 
Duke’s grade in colorectal cancer [40] and dedifferentiation 
in ovary and thyroid carcinoma [209]. In thyroid tumours, an 
increase of Aurora B expression has been observed in 
papillary and anaplastic thyroid carcinomas. In the late 
stages of thyroid tumour progression a further increase of 
Aurora B expression was observed indicating that Aurora B 
overexpression might confer a growth advantage to neoplas-
tic cells [19, 209]. 
 In all lesions overexpressing Aurora B, phosphorylation 
of the histone H3 was clearly detectable. 
 Several studies have suggested that commonly occurring 
gene polymorphisms of Aurora B are associated with cancer 
risk see Table 1. Recently, an alternative splicing variant of 
Aurora B (Aurora B-Sv2) has been found frequently 
associated with advanced stages of hepatocellular carcinoma; 
this variant appears to be more frequently associated with 
tumour recurrence and poor prognosis [206]. The inhibition 
of Aurora B kinase has an anti-proliferative effects and 
causes regression in several animal models of human can-
cers, including breast, colon, lung, leukemia, prostate and 
thyroid [46, 130, 208, 209, 211, 213-217]. These obser-
vations strongly suggest Aurora B as a potential therapeutic 
target.  
Aurora Inhibitors 
 To target the enzymatic activity of Aurora kinases, small 
molecules able to occupy the catalytic binding site have been 
identified. In contrast to antimitotic drugs, Aurora(s) 
inhibitors do not bind to microtubules but, acting on proteins 
required for proper mitosis, induce mitotic arrest followed, in 
most cases, by cell death. The number of Aurora inhibitors is 
rapidly increasing: approximately 15 Aurora inhibitors are 
under Phase I/II evaluation and others are in preclinical 
testing [218, 219]. 
 The mechanism of action suggests a potentially high 
therapeutic index. Indeed, Aurora kinases are only expressed 
and active during mitosis, therefore non-proliferating cells 
would not be adversely affected by these drugs. Furthermore, 
cells lacking a p53-mediated post-mitotic checkpoint are 
highly responsive to Aurora(s) inhibition and alteration in 
p53 pathways are common in human cancers [220, 221]. 
Last but not least, since Aurora inhibitors do not bind to 
tubulin, they do not induce neuropathy, that is one of the 
main side effects on classical antimitotic drugs, such as 
nocodazole. 
 Although Aurora A has received most of the attention in 
terms of a link with human cancer, so far few molecules 
capable to selective inhibit Aurora A activity have been 
identified. 
 MLN8054 presents an IC50 of 4 and 172nM for Aurora A 
and Aurora B, respectively [222, 223]. This drug induces 
abnormal spindles, often with unseparated centrosomes, and 
delays progression through mitosis. However, MLN8054-
treated cells are able to exit from mitosis, although with 
segregation errors due to the formation of ectopic poles. The 
long term administration of MLM8054 in vitro and in vivo 
models of human neoplasia induces cell death and tumour 
growth arrest [222, 223]. Preliminay data of a phase I trial 
have shown no profound myelosuppression [224]. 
 MLN8237 inhibits Aurora A with an IC50 value of 1 nM. 
It inhibits growth of various cancer cell lines and treatments 
of animal models induced significant tumor growth inhi-
bition. A recent in vivo study shows that MLN8237 exhibits 
potent anticancer activity in CML and Philadelphia chromo-
some positive acute lymphoblastic leukemia models. Phase I 
clinical trials are ongoing in patients with advanced solid 
tumours and advanced hematological malignancies [219]. 
 Inhibition of Aurora B by specific inhibitors interferes 
with normal chromosome alignment during mitosis and over-
rides the mitotic spindle checkpoint inducing endoredupli-
cation. Aurora A and Aurora B specific inhibitors exert 
different effects in treated cells suggesting that the pathways 
leading to the mitotic block in response to inhibitors are 
distinct. Moreover, Aurora B seems to be more suitable as 
anticancer drug target, since inhibition of Aurora B rapidly 
results in a catastrophic mitosis, leading to cell death. 
 Being the number of Auroras inhibitors rapidly increa-
sing, in Table 2 are summarised the results of the most 
relevant clinical trials with Aurora A and B kinase inhibitors. 
Dual Inhibitors of Aurora Kinases 
 In order to block Aurora B functions, several anti-cancer 
drugs targeting its catalytic binding site have been deve-
loped. However, given the high homology of the catalytic 
domain of Aurora kinases, small molecules do not differen-
tiate between them [225]. The first three small-molecule 
inhibitors of Aurora(s) described include Hesperadin [212], 
VX-680 [226], and ZM447439 [130]. These three drugs have 
similar potency versus Aurora A, Aurora B and Aurora C. 
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Each induces a similar phenotype in cell-based assays, 
characterized by inhibition of phosphorylation of histone H3 
on Ser
10
 and Ser
28
, inhibition of cytokinesis, and develop-
ment of polyploidy.  
 Other drugs such as PHA-680632 [227], PHA-739358 
[228] and Reversine [229] are potent inhibitors of all three 
Aurora kinases. Also in this case, the phenotypic effects 
closely resemble those achieved by selective inhibition of 
Aurora B. 
 The general chemical structures of dual inhibitors are 
shown in Fig. (3). 
 
 The IC50s values of Aurora kinases inhibitors are shown 
in Table 3. 
HESPERADIN 
 Hesperadin (Boehringer Ingelhein) is a novel indolinone 
that inhibits immunoprecipitated Aurora B with an IC50 of 
250nmol/L. Hesperadin has IC50s values in the range of 
1.2μM to A > 10μM for cdk1/cyclin B or cdk2/cyclin E, 
respectively. The inhibitor inserts into the ATP binding 
pocket of both Aurora A and Aurora B [212, 218, 219].  
 HeLa cells treated with 20-100nM of Hesperadin show 
polyploidy and loss of mitotic phosphorylation of histone H3 
on Ser
10 
[212]. Moreover, Hela cells treated with 50nM of 
Hesperadin stop proliferating although do not stop the 
growth, showing an increase in nuclear size that correlates 
 
Table 1. Aurora Kinases A and B Molecular Alterations in Human Cancer 
Alteration Cancer Type  Aurora Kinase  Study 
Overexpression Breast A Miyoshi et al.;Tanaka et al.; Hoque et al.; Royce et al. [161, 166, 169, 180] 
 Lung A-B Xu et al.; Smith et al.; Vischioni et al. [182, 199, 200]. 
 Pancreas A Li et al. [160]. 
 Prostate B Chieffi et al. [168, 176, 211]. 
 Bladder  A Fraizer et al.; Comperat et al. [168, 176]. 
 Esophagus  A Yang et al.; Tong et al. [162, 174].  
 Brain  B Zeng et al.; Araki et al. [198, 202]. 
 Liver  A Jeng et al. [157].  
 Head/Neck  A-B Reiter et al.; Qi et al.; Zhao et al.; Li et al.; [172, 203, 214, 215]. 
 Thyroid  B Sorrentino et al. [209]  
 Ovarian  A Lassman et al.; Landen et al. [178, 183]. 
 Renal  A Kurahashi et al. [158].  
Amplification  Breast  A Sen et al.; Bodvarsdottir et al. [152, 154].  
 Colon  A Bischoff et al.; Nishida et al. [151,171]. 
 Brain A Klein et al.; Reichardt et al.; Neben et al. [163, 164, 216]. 
 Bladder  A Sen et al. [153].  
 Head/Neck  A Tatsuka et al. [173].  
 Endometrium  A Moreno-Bueno et al. [165].  
Polymorphisms  Colon  A Hienonen et al.; Ewart-Toland et al.; Chen et al. [156, 185, 217].  
 Breast  A-B Cox et al.; Lo et al.; Tchatchou et al.; Vidarsdottir et al.; [188-190, 193]  
 Esophagus  A Kimura et al. [170].  
 Lung  A Gu et al. [191].  
 Gastric  A Ju et al. [192].  
 Multiple  A Ewart-Toland et al. [186].  
Splicing Variant  Liver  B Yasen et al. [206] 
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Table 2. Clinical trials with Aurora Kinases Inhibitors 
Drug Tumour Type Title of The Study Phase 
Sponsored 
by 
Clinicaltrials.Gov 
Identifier 
VX-680 
(MK0457) 
ADVANCED CANCER 
A Phase I Dose Escalation Study of MK0457 
Evaluating the Safety, Tolerability, 
Pharmacokinetics and Pharmacodynamics of a 
24-Hour Continuous Infusion Given Every 21 
Days in Patients with Advanced Cancer 
PHASE I MERCK NCT00104351 
VX-680 
(MK0457) 
LEUKEMIA 
A Phase I/II Dose Escalation Study of MK0457 
in Patients with Leukemia 
PHASE I MERCK NCT00111683 
VX-680 
(MK0457) 
CARCINOMA, NON-
SMALL-CELL LUNG 
A Phase IIA Study Evaluating the Efficacy of 
MK0457 as a 5-Day Continuous Infusion in 
Patients with Advanced Non-Small Cell Lung 
Cancer (NSCLC) 
PHASE II MERCK NCT00290550 
VX-680 
(MK0457) 
LEUKEMIA 
A Phase II Study of MK0457 in Patients with 
T315I Mutant Chronic Myelogenous Leukemia 
and Philadelphia Chromosome-Positive Acute 
Lymphoblastic Leukemia 
PHASE II MERCK NCT00405054 
VX-680 
(MK0457) 
CHRONIC 
MYELOGENOUS 
LEUKEMIA, LEUKEMIA 
LYMPHOBLASTIC 
ACUTE 
PHILADELPHIA-
POSITIVE 
A Phase I Dose Escalation of MK0457 in 
Combination with Dasatinib in Patients with 
Chronic Myelogenous Leukemia and 
Philadelphia Chromosome-Positive Acute 
Lymphoblastic Leukemia 
PHASE I MERCK NCT00500006 
AZD1152 
ACUTE MYELOID 
LEUKEMIA 
A Phase I, Open Label, Multi-centre Study to 
assess the Safety, Tolerability, and 
Pharmacokinetics of AZD1152 in Japanese 
Patients with Acute Myeloid Leukaemia 
PHASE I AstraZeneca NCT00530699 
AZD1152 MYELOID LEUKEMIA 
A Phase I/II, Open Label, Multi-Centre Study 
to assess the Safety, Tolerability, 
Pharmacokinetics and Efficacy of AZD1152 in 
Patients with Acute Myeloid Leukaemia 
PHASE I/II AstraZeneca NCT00497991 
 AZD1152 + 
LDAC 
ACUTE MYELOID 
LEUKEMIA 
A Randomised, Open-label, Multi-centre, 2-
stage, Parallel Group Study to Assess the 
Efficacy, Safety and Tolerability of AZD1152 
Alone and in Combination with Low Dose 
Cytosine Arabinoside (LDAC) in Comparison 
with LDAC Alone in Patients Aged ? 60 with 
Newly Diagnosed Acute Myeloid Leukaemia 
(AML) 
PHASE II AstraZeneca NCT00952588 
AZD1152 + 
LDAC 
ACUTE MYELOID 
LEUKEMIA 
A Phase I, Open-Label, Multi-Centre, Multiple 
Ascending Dose Study to assess the Safety and 
Tolerability of AZD1152 in Combination with 
Low Dose Cytosine Arabinoside (LDAC) in 
Patients with Acute Myeloid Leukaemia (AML) 
PHASE I AstraZeneca NCT00926731 
AZD1152 TUMOURS 
A Phase I, Open-Label, Multi-Centre Study to 
Assess the Safety, Tolerability and 
Pharmacokinetics of AZD1152 Given as a 
Continuous 48-Hour Intravenous Infusion in 
Patients with Advanced Solid Malignancies 
PHASE I AstraZeneca NCT00338182 
 
 
228    Recent Patents on Anti-Cancer Drug Discovery, 2010, Vol. 5, No. 3 Libertini et al. 
(Table 2) Contd…. 
 
Drug Tumour Type Title of The Study Phase Sponsored by 
Clinical Trials. 
Gov Identifier 
AZD1152 SOLID TUMOURS 
A Phase I, Open-Label, Multi-Centre Study to Assess the 
Safety, Tolerability and Pharmacokinetics of AZD1152 
Given as a Continuous 7-Day Intravenous Infusion in 
Patients with Advanced Solid Malignancies 
PHASE I AstraZeneca NCT00497679 
AZD1152 SOLID TUMOURS 
A Phase I, Open-Label, Multi-Centre Study to Assess the 
Safety, Tolerability and Pharmacokinetics of AZD1152 
Given as a 2 Hour Intravenous Infusion on Two Dose 
Schedules in Patients with Advanced Solid Malignancies 
PHASE I AstraZeneca NCT00497731 
PHA-739358 LEUKEMIA 
A Pilot Phase II Study of PHA-739358 in Patients with 
Chronic Myeloid Leukemia Relapsing on Gleevec or c-
ABL Therapy 
PHASE II 
Jonsson 
Comprehensive 
Cancer Center 
NCT00335868 
PHA-739358 
METASTATIC 
HORMONE 
REFRACTORY 
PROSTATE 
CANCER 
A Phase II Study of PHA-739358 in Patients with 
Metastatic Hormone Refractory Prostate Cancer 
PHASE II 
Nerviano 
Medical 
Sciences 
NCT00766324 
PHA-739358 
MULTIPLE 
MYELOMA 
An Exploratory Phase II Study of PHA-739358 in 
Patients with Multiple Myeloma Harbouring the t(4;14) 
Translocation with or without FGFR3 Expression 
PHASE II 
Nerviano 
Medical 
Sciences 
NCT00872300 
Website: clinicaltrails.gov 
Table 3. IC50s Values of Aurora Kinases Inhibitors 
Compound  K1Aurora A 
(nmol/L) 
K1Aurora B 
(nmol/L) 
K1Aurora C 
(nmol/L) 
Selcetivity 
Hesperadin Not tested 250 Not tested Inhibits other kinases in vitro (AMPK, LcK, MKK1, MAPKAP-K1, CHK1, PHK 
with a K of 1 ?mol/L 
ZM1 1000 50 250 Do not seems to inhibit other kinases in vitro 
ZM2 800 7,5 Not tested Do not seems to inhibit other kinases in vitro 
ZM3 50 15 Not tested Do not seems to inhibit other kinases in vitro 
VX-680 0,6 18 4,6 Inhibits FLT3 with a Ki of 30 nmol/L 
PHA680632 27 135 120 Inhibits other kinases in vitro, including FLT3, LcK, PLK1, STLK2, VEGFR2, 
VEGFR3 
PHA739358 13 79 61 Inhibits several other kinases in vitro, including ABL, Ret, TRK-A, FGFR 
Reversine 150-400 500 400 Not tested 
CYC116 44 19 65 Inhibits VEGFR2 with a Ki of 69 nmol/L 
SNS-314 9 31 3,4 Not tested 
PF-03814735 5 0,8 Not tested Not tested 
ENMD-2076 14 290 Not tested Inhibits Src, cKit, FAK and VEGFR2 with Ki of 100, 40, 5, and 80 nmol/L 
AT9283 3 3 <10 Inhibits JAK-2 and -3, Tyk2, RSK2 with Ki values less than 10 nmol/L 
R763(AS70316) 4 4,8 6,8 Inhibits FMS-related tyrosine kinase 3 (FLT3) with a Ki of 100nmol/L 
MP529 110 >10000 Not tested Not tested 
GSK1070916 100 3,5 6,5 Do not seems to inhibit other kinases in vitro 
AZD1152 1,369 0,36 Not tested Less activity against a panel of 50 other kinases including FLT3, JAK2 and Abl 
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Fig. (3). Aurora kinase inhibitors. Dual inhibitors of Aurora kinases. Chemical structures of (a) Hesperadin, (b) ZM447439, (c) ZM2, (d) 
ZM3, (e) VX-680, (f) PHA-680632, (g) PHA-739358, (h) Reversine, (i) AT-9283, (j) CYC116, (k) ENMD-2076, (l) MP529, (m) PF-
03814735, (n) SNS-314. 
 
with polyploidization. The phenotypes induced by knocking 
down Aurora B by RNAi and inhibiting its function by 
Hesperadin are highly similar. It is demonstrated that 1?M of 
Hesperadin markedly reduced the activity of other six 
kinases (AMPK, LcK, MKK1, MAPKAP-K1, CHK1, and 
PHK). It has been reported that MKK1 inhibition blocks 
cells in G2 phase, however in vivo experiments show that, at 
the concentration used, inhibition of MKK1 activity was not 
observed [212]. Moreover, it seems that the CDKs are not 
inhibited in vivo, because it is required a high concentration 
of Hesperadin to inhibit them [230]. 
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ZM447439 
 ZM447439 (also known as ZM1), is a quinazoline 
derivative developed by AstraZeneca. It binds both the ATP-
binding site and the adjacent cleft, that it is not present in 
other kinases, thus giving this inhibitor its specificity for 
Aurora Kinases [130]. ZM447439 does not inhibit most 
other kinases tested, including the mitotic regulators CDK1 
and PLK1(IC50 > 10μM). ZM1 inhibits Aurora A, B and C 
with an IC50 of 1000, 50 and 250nM respectively [130].  
 ZM1 induces incorrect microtubule-kinetochore attach-
ments, failure of chromosome biorientation, abrogation of 
the mitotic checkpoint, failure of cytokinesis, and the 
development of tetraploidy. Cells treated with ZM1 shows 
cell cycle arrest at G2/M with subsequent accumulation of 
cells with 4N/8N DNA content, a common defect in cells 
with impaired Aurora B activity. Cells later either underwent 
apoptosis via activation of caspase-3 and PARP cleavage, or 
a G1 arrest possibly induced by a p53-dependent G1 tetra-
ploidy checkpoint [231]. ZM447439 suppressed the 
phosphorylation at Ser
10
 of histone H3. Although ZM447239 
inhibits both Aurora A and Aurora B in vitro, the phenotype 
observed in treated cells suggests a greater inhibition of 
Aurora B, missing the centrosome separation defect or the 
delayed mitotic entry characteristic of Aurora A inhibition 
[130]. 
 ZM2 and ZM3 are two compounds structurally related to 
ZM1, which also inhibit Aurora kinase activity in vitro. ZM2 
inhibits Aurora A and B with IC50s values of 800nM and 
7.5nM respectively and it is ~100 times more selective 
against Aurora B than Aurora A. In addition, in vitro, ZM2 is 
5-10 times more potent against Aurora B than ZM1 and 
induces similar mitotic phenotypes and similar biological 
effects to ZM1 but at lower concentrations. ZM2 signifi-
cantly reduces phosphorylation of histone H3 at 0.1?M, 
whereas 3?M ZM1 is required for extensive inhibition. ZM3 
does appear to be a potent Aurora A inhibitor with an IC50 
value of 50nM, but ZM3 also inhibits Aurora B in vitro with 
an IC50 of 15nM. ZM3 is more potent against both Aurora A 
(20-fold) and Aurora B (~3.3-fold) compared with ZM1 
[130]. 
VX-680 (MK0457) 
 VX-680 is a 4,6 di-amino pyrimidine developed by 
Vertex. It has been reported to be a potent in vitro inhibitor 
of Aurora A, B and C with inhibition constants (Ki) of 0.6, 
18 and 4.6nM respectively [226]. 
 VX-680 shows selectivity for the Aurora kinases over 55 
other kinases tested, the only exception is Fms-related 
tyrosine kinase-3 (FLT-3), that it is inhibited with a Ki of 30 
nM. However, the phenotype described after exposing cells 
to this compound are consistent with the inhibition of Aurora 
B [226]. In fact, the treatment of a variety of tumor cell types 
with VX-680 generates polyploidy through defects in 
cytokinesis and inhibits the phosphorylation of the Aurora B 
substrate histone H3 [231]. Harrington et al. have shown that 
the treatment with VX-680 induces the accumulation of cells 
with 4N DNA content, suggesting DNA replication in the 
absence of cytokinesis [232]. Whether cells arrest with 4N 
DNA content in pseudo-G1 or endoreduplicate with the 
accumulation of >4N DNA content likely depends on the 
integrity of the p53-dependent postmitotic checkpoint; in fact 
the integrity of the p53-p21
Waf1/Cip1
 pathway in the G1 
postmitotic checkpoint governs the response to VX-680, and 
cells with compromised checkpoint function are most likely 
to undergo apoptosis [233]. 
 It is also reported that VX-680 is able to inhibit the 
proliferation of phytohemoagglutinin-stimulated primary 
human lymphocytes (IC50=79nM,), but has no effect on the 
viability of noncycling primary human cells at concentration 
as high as 10?M. This lack of toxicity in resting cells is 
consistent with the fact that expression and activity of 
Aurora proteins are low or undetectable in noncycling cells. 
 In vivo, VX-680 is able to suppress the growth of human 
cancer cell xenografts in nude animals. VX-680 causes a 
marked reduction in tumour size in human acute myelocitic 
leukemia (HL60 cells) xenograft model. VX-680 is well 
tolerated, with a small decrease in body weight observed 
only at the highest doses. This small molecule also induces 
tumour regression in pancreatic and colon xenograft models 
[232]. Moreover, VX-680 has a potent antitumor activity 
when infused i.v. in nude rats bearing established colon 
(HCT116 cells) tumours. In this model, a fall in neutrofil 
counts, that recovers to normal levels at the end of the 
treatment, was observed. The inhibition of tumour growth is 
paralleled by a reduction in histone H3 phosphorylation and 
a significant increase in apoptosis [231].  
 VX-680 also binds to wild-type Abl kinase and Abl 
mutants and reduces cell proliferation of cells with Bcr-Abl 
mutations, with an IC50 value ranging from 100 to 200nM 
[193]. A phase I clinical trials in patients with chronic 
myeloid leukemia (CML) or acute lymphocytic leukemia 
(ALL(Ph
+
)) with T315I Bcr-Abl mutation has been 
performed [194-196]. Positive effects were observed with no 
major side effects; grade 1 nausea in one patient and grade 1 
alopecia in four patients were reported. Enrollment in Phase 
I/II clinical trials of VX-680 has been suspended, on the base 
of preliminary safety data, due to the observation of QTc 
prolongation in one patient [219]. 
 Compared to ZM447439, much lower concentrations of 
VX-680 are required to significantly suppress histone H3 
phosphorylation, inhibit mitotic progression and the spindle 
assembly checkpoint (0.5?M for VX-680 with respect to 5 
?M for ZM1). These differences could be explained in part 
by the increased potency of Aurora inhibition by VX-680, 
but in some cases are also due to additional Aurora A 
inhibitory effects. However, VX-680 is significantly more 
cytotoxic than ZM447439 when compared side-by-side in 
the human colon carcinoma cell line DLD-1, in fact the LD50 
for VX-680 is some 30-fold lower than that for ZM447439 
[226, 232].  
 VE-465 is a low molecular weight pan-Aurora kinase 
inhibitor. It is an analog of VX-680 that has been evaluated 
against multiple myeloma cell lines [234]. 
PHA-680632 
 PHA-680632 was developed by Nerviano Medical 
Sciences as an ATP competitive compound and is a deri-
vative of a 1,4,5,6-tetrahydropyrrolo [3,4-c] pyrazole 
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scaffold [227]. It was shown to be a potent inhibitor of all 
three Aurora kinases with IC50s of 27, 135, and 120nmol/L 
for Aurora A, B and C respectively [227]. This compound 
has been tested over a panel of 29 additional kinases and it 
has been found to be active against 6 of these kinases 
including FLT3, LCK, PLK1, STLK2, VEGFR2 and 
VEGFR3, whose IC50s are much higher than that of Aurora 
A (30 to 200 fold). PHA-680632 has potent antiproliferative 
activity in a wide range of cell types with an IC50 in the range 
of 0.06 to 7.15?mol/L. PHA-680632 induces a biological 
response consistent with an Aurora B inhibition, such as 
decreased histone H3 phosphorylation, endoreduplication 
and polyploidy [227]. It has been also demonstrated that 
PHA-680632 can suppress tumor growth in human tumor 
cell xenografts model and syngenic models in mouse and rat 
[235]. After i.v. administration, a significant tumor growth 
inhibition is observed. A more prolonged exposure to PHA-
680632 has been tested in HCT116 colon carcinoma xeno-
graft, administering the compound i.p. for 12 days. The 
treatment was well tolerated and tumour growth inhibition 
was 75% compared with controls [235]. In vivo xenografts 
(p53
-/-
 HCT116) of a mice study showed enhanced tumour 
growth delay after the PHA-680632-IR combinatorial treat-
ment compared with IR alone. PHA-680632 in association 
with radiation leads to an additive effect in cancer cells, 
especially in the p53-deficient cells, but does not act as a 
radiosensitiser in vitro or in vivo [235]. 
PHA-739358 
 PHA-739358 is a small-molecule 3-aminopyrazole 
derivative developed by Nerviano Medical Sciences, that 
exhibits activity in nanomolar range against all Aurora 
Kinases [228]. In a biochemical assay, it inhibits Aurora A, 
B and C with an IC50s of 13, 79 and 61 nmol/L respectively. 
It also acts on other relevant cancer tyrosine kinases, such as 
wild type and mutated ABL, RET, TRK-A and FGFRs 
[228]. After treatment whit this inhibitor, cells fail to divide, 
resulting in polyploidy without a strong impact on the timing 
of mitosis and finally leading to a reduction in viability. In 
some cell lines, an increased apoptosis was observed. 
Overall, most of the effects of the drug are related to the 
inhibition of Aurora B [233]. During a phase I clinical trial 
grade 3/4 of neutropenia were reported, no tumour responses 
were observed but 8 out of 40 patients has stable disease for 
at least 4 months [219]. PHA-739358 is currently in phase II 
clinical trial and have a favorable preclinical profile. 
REVERSINE 
 Reversine [2-(4-morpholinoanilino)-N
6
-cyclohexyla-
denine] is a substituted purine analogue, that occupies the 
ATP-binding pocket at the interface between small and large 
lobes [229, 236]. It was originally shown to promote the 
dedifferentiation of myotubes derived from the murine 
myoblast cell line C20 [236]. To provide a molecular expla-
nation for the function of reversine, its activity was tested on 
a broad panel of protein kinases and it was found that 
reversine specifically inhibits the function of Aurora kinases, 
both in vitro and in cell-based assay. It has been demon-
strated that reversine inhibits Aurora B kinase, causing 
inhibition of cytokinesis and induction of polyploidy. How-
ever, the IC50 of reversine on Aurora A is 400nmol/L, 
whereas Aurora B and C IC50s were 500 and 400nmol/L 
respectively [229, 236]. After 12 hours treatment with 
reversine, the majority (~80%) of HCT116 human colon car-
cinoma cells had doubled their DNA content (4N). Longer 
reversine treatments resulted in DNA endo-reduplication and 
in the accumulation of poliploid cells. It was demonstrated 
that reversine was less potent on normal cells than VX-680 
[229].  
CYC116  
 CYC116, developed by Cyclacel, inhibits Aurora A, 
Aurora B and Aurora C with IC50s values of 44nM, 19nM 
and 65nM, respectively. In comparison to pan-Aurora kinase 
inhibitor VX-680, treatment of CYC116 showed similar 
molecular alteration to Aurora A and Aurora B in A549 lung 
carcinoma cells. In addition, 0.5-1μM of CYC116 induced 
mitotic arrest and delayed cell cycle entry in HeLa cells. 
Multinucleation of HeLa cells was shown in CYC116 
treatment group in vitro. In NCI-H460 NSCLC xenograft 
mice, orally administrated CYC116 at doses of 75mg/kg and 
100mg/kg reduced tumor growth by 42% and 79% respec-
tively. Further, CYC116 reduces phosphorylation on Ser
10
 of 
histone H3 in tumor. In combination therapies, CYC116 
shows a synergistic effect with several chemotherapeutic 
agents such as cisplatin and gemcitabine when CYC116 is 
given before the other drug. Besides Aurora kinase, this 
compound also inhibits VEGFR2 with an IC50 value of 
69nM. In vivo investigation shows that CYC116 exhibits 
anti-angiogenic properties [219, 237-244]. 
SNS-314 
 A recent paper discusses the discovery and development 
of SNS-314, which is in Phase I clinical trials. SNS-314 
inhibits Aurora A, Aurora B and Aurora C with IC50s values 
of 9nM, 31nM and 3.4nM, respectively. At molecular and 
cellular level, SNS-314 inhibits phosphorylation of histone 
H3 and disrupts mitosis. SNS-314 blocks proliferation in 
various human tumor cell lines such as HT-29, PC3, HeLa 
and A375 with a BrdU IC50 value ranging from 1.8 to 
9.3nM. In human HCT116 colon xenograft mice, adminis-
tration of SNS-314 at doses of 100, 125 and 150mg/kg once 
daily or twice weekly for 5 days with a 9-day treatment-free 
interval significantly reduced tumor volume. In addition, it 
has potent anti-tumor activity in mouse xenograft models, 
such as A375 (melanoma), PC3 (prostate) and CALU6 
(NSCLC). 
 In the clinical study, SNS-314 was given as a 3-h i.v. 
infusion with a treatment schedule once a week for 4 weeks 
continuously. The initial dose of the treatment was 30mg/ 
m2. Serum-drug concentrations have exceeded preclinical 
target thresholds at the 120mg/m2 dose level. Dose-limiting 
toxicity or grade 3 or higher related adverse events have not 
been observed so far. SNS-314 is now undergoing another 
Phase I clinical trial in patients with advanced solid tumors 
[219, 245-250]. 
PF-03814735  
 PF-03814735 is an ATP-competitive, reversible inhibitor 
of Aurora A and Aurora B with IC50s values of 5nM and 
232    Recent Patents on Anti-Cancer Drug Discovery, 2010, Vol. 5, No. 3 Libertini et al. 
0.8nM respectively. In addition, it inhibits autophosphory-
lation of Aurora A at submicromolar concentrations. Pheno-
typically, PF-03814735 inhibits cytokinesis, and induces 
formation of multinucleated cells. In animal models, treat-
ments of PF-03814735 inhibited tumor growth in HCT-116, 
Colo-205 and HL-60 tumor xenograft mice. This compound 
is now undergoing Phase I clinical trial evaluation. Twenty 
patients with colorectal, breast, bladder, ovarian, renal and 
head and neck cancers and melanoma, NSCLC and SCLC 
received PF-03814735 with dosages of 5-100 mg/day for 5 
days. Mild-to-moderate diarrhea, vomiting, anorexia, fatigue 
and nausea were observed in 16 patients. Dose-limiting 
febrile neutropenia was observed in two out of seven patients 
treated at 100mg/day [219, 251-253]. 
ENMD-2076  
 ENMD-2076 [L-(+)-Lactic acid salt of ENMD-981693] 
is an orally active, vinyl-pyrimidine-based compound and 
selectively inhibits Aurora A with an IC50 value of 14nM, 
instead of Aurora B kinase (290nM). It also inhibits 
molecules such as Src, cKit, FAK and VEGFR2 with IC50s 
values of 100, 40, 5 and 80 nM respectively. Molecular 
studies on human HCT-116 and U937 cells show that 
incubation of ENMD-2076 induced cell cycle arrest at G2/M 
phase and subsequent apoptosis. In a preclinical animal 
model, ENMD-2076 increased proportion of phospho-
histone H3 positive 1A9 ovarian cancer cells by 80%. Fifty-
one percent of tumor growth inhibition was observed in 
human MDA-MB-231 breast-cancer-injected SCID mice at a 
dosage of 50mg/kg p.o. q.d. Moreover, 70% of tumor 
regression was observed at a dosage of 200mg/kg p.o. b.i.d.. 
These data show that ENMD-2076 has a unique combination 
of anti-angiogenic, cell cycle and antiproliferative activities 
and support clinical rationale for this compounds utility in 
hematological cancers, including multiple myeloma. A Phase 
I clinical study of ENMD-2076 was initiated in March 2008 
in patients with solid tumors, and there are plans to initiate a 
second Phase I study in patients with hematological 
malignances [219, 254-256]. 
AT9283  
 AT9283, by Astex Therapeutics, is a multitargeted kinase 
inhibitor that inhibits tyrosine and serine/threonine kinases 
such as Aurora A and B, JAK-2 and -3, Tyk2, RSK2 with 
IC50s values less than 10nM in vitro. AT9283 has potent 
anti-proliferative activity against human cell lines expressing 
the wild-type BCR-ABL or mutated-BCR-ABL. AT9283 has 
potential antiproliferative activity in a panel of BAF3 and 
human cell lines expressing the BCR-ABL or its mutant 
forms. Series of Phase I/II clinical studies of this compound 
are in progress to investigate it in patients with advanced 
solid tumors and leukemia. In a Phase I study of AT9283 in 
patients with refractory solid tumors, 72h of intravenous 
infusion every 3 weeks with dose escalation was used. Maxi-
mum tolerated dose was determined at 9mg/m2/day. Results 
from another Phase I clinical study in patients with refractory 
leukemia were disclosed at the 2008 ASCO meeting. 
AT9283 was administered by 72h i.v. continuous infusion in 
patients with refractory AML, ALL, high-risk myelodys-
plastic syndromes (MDS) and imatinib- and dasatinib-refrac-
tory CML [219, 257-261]. 
R763 (AS703569)  
 R763 (AS703569), by Rigel, is an orally available 
inhibitor of Aurora A, Aurora B and several other kinases. 
AS703569 induced dose-dependent and time-dependent 
antiproliferative effects in SCC61 and Miapaca-2 cancer cell 
lines with IC50s of 5μM and 2μM respectively. AS703569 
also inhibited the phosphorylation of a tyrosine kinase 
receptor, FGFR1. In vitro study reveals that combination of 
AS703569 with imatinib displayed synergistic effects, when 
SCC61 cancer cells were pre-exposed to AS703569 before 
imatinib. In 2006, Merck Serono initiated a Phase I study of 
AS703569 in patients with solid tumor. The starting dose 
level was 6mg/m2 p.o. per 21-day cycle divided in two or 
three doses. A total of 15 patients, comprising three cases of 
uterine/cervical cancer and two cases of breast cancer, have 
been included in the study so far. No severe adverse effect 
has been observed in drug-treated patients. Two patients 
were withdrawn from the study because of disease pro-
gression. Rigel has announced an initiation of a Phase I 
combination therapy study of R763 with gemcitabine in 
cancer patients with advanced malignancies [219, 262-264]. 
VX-689/MK-5108  
 In February 2008, Merck initiated a Phase I clinical trial 
of MK-5108 in patients with advanced and refractory solid 
tumors, dosed orally as monotherapy and also in combi-
nation with i.v. docetaxel. However, the chemical structure 
and in vitro data related to this compound are not available 
[219, 265]. 
MP529 
 MP529 shows selective inhibition on Aurora A kinase 
with an IC50 value of 110nM, where as IC50 value of Aurora 
B inhibition is > 10,000nM. MP529 is in late-stage preclini-
cal development, the details of which were revealed at the 
2008 AACR meeting [218]. 
MK615 
 MK615, an extract from the Japanese apricot, contains 
several triterpenoids and has been shown to exert an anti-
neoplastic effect against human cancers. This is not a 
classical Aurora kinase inhibitor (small molecules), being 
able to inhibit Aurora A and B gene expression. However, 
the entire mechanisms of the anti-neoplastic effects of 
MK615 have not been elucidated. MK615 had an anti-
neoplastic effect that was exerted by dual inhibition of 
Aurora A and B kinases. Previous studies have revealed that 
this drug has anti-neoplastic effects against gastric cancer 
[266], breast cancer [267], hepatocellular carcinoma [268], 
and colon cancer [269]. The mechanisms responsible for the 
anti-neoplastic effect of MK615 include induction of 
apoptosis [266, 267] and autophagy [269], and suppression 
of Aurora A kinase [268] in cancer cells. A previous study 
showed that MK615 induced cell cycle arrest at the end of 
G2 phase in hepatocellular carcinoma [268]. MK615 
treatment increased the cell population in G2-M phase, 
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inhibits Aurora A and Aurora B kinases and may induce 
cancer cell death at the G2-arrest checkpoint [270, 271]. 
Although further investigation is needed, MK615 seems to 
have the property anti-Aurora kinase compound [272]. 
Selective Aurora B inhibitors 
 Selective inhibitors of Aurora B have also been 
developed, including AZD1152 [222] (highly potent and 
selective inhibitor of Aurora B), and GSK1070916 (a potent 
and selective inhibitor of Aurora B and Aurora C kinases) 
[273]. The general chemical structures of selective Aurora B 
inhibitors are shown in Fig. (4). 
AZD1152 
 AZD1152 (AstraZeneca) is a novel acetanilide-substitute 
pyrazole-aminoquinazoline prodrug that is converted rapidly 
to the active drug AZD1152 hydroxy-QPA (AZD1152-
HQPA) [213].  
 It is a highly potent and selective inhibitor of Aurora B 
(Ki, 0.36nmol/L), compared with Aurora A (Ki, 1,369 
nmol/L), and has less activity against a panel of 50 other 
kinases including FLT3, JAK2 and Abl [213].  
 In vitro treatment of human tumor cell lines with 
AZD1152-HQPA suppresses the phosphorylation of the 
Aurora B substrate histone H3. In acute myeloid leukemia 
cell lines and primary acute myeloid leukemia cultures, 
AZD1152-HQPA induces growth arrest and the accumu-
lation of polyploid cells in a dose- and time-dependent 
manner (almost identical to the mode of action of ZM1) 
[274]. Leukemia cells exposed to AD1152-HQPA exit mito-
sis and subsequently proceed through S phase in the absence 
of cytokinesis, with an increased population of cells with 
4N/8N DNA content. Treatment with AZD1152 (1-10nM) 
for 24 and 48 hours in these cells induces apoptosis in a 
dose-dependent manner [274]. 
 Administering AZD1152 to animals bearing human 
tumor xenografts resulted in profound antitumor effects in 
colorectal, lung and acute myeloid leukemia human tumor 
xenograft models [213, 274, 275]. AZD1152 was well 
tolerated within the dose range required to elicit a potent and 
durable antitumor effect, with animals showing only tran-
sient loss of body weight. Bone marrow analyses revealed 
reversible myelosuppression in AZD1152-treated animals, 
with full recovery occurring within a week of cessation of 
dosing. Analysis of peripheral blood cells also indicated a 
neutropenia followed by full recovery [213, 274]. 
 It was also demonstrated that AZD1152 enhances the 
effect of radiation on p53-deficient cancer cells, in particular 
it is observed an enhanced cell killing when cells were 
irradiated 24h after exposure to AZD1152 [276, 277]. 
Apoptosis and DNA repair play a minor role in the response 
of tumor cells exposed to ADZ1152. In contrast, mitotic 
death is the major cell death mechanism following AZD1152 
exposure, both in vitro and in vivo [276, 277]. 
 AZD1152 is currently being studied in phase I-II clinical 
trials in solid tumor patients Table 2. In early results, the 
drug is reported to be well tolerated when administered by 
i.v. infusion at doses up to 300mg with significant disease 
stabilization in five of eight reported patients; transient 
neutropenia being the only noteworthy toxicity. No signi-
ficant anemia, thrombocytopenia or neuropathy was obser-
ved. Melanoma, nasopharyngeal carcinoma and adenocystic 
carcinoma patients achieved prolonged stable disease lasting 
more than 25 weeks [275].  
GSK1070916 
 GSK1070916 is a highly potent and selective Aurora 
B/Aurora C kinase inhibitor [273, 278]. This inhibition 
results in antiproliferative activity in multiple cancer cell 
lines and in mouse xenograft models of human tumors. 
Anderson et al. evaluated the selectivity of the drug and in 
this study they have demonstrated that GSK10700916 is an 
ATP competitive inhibitor of the Aurora B/INCENP 
enzyme. GSK1070916 inhibits Aurora A, Aurora B/INCENP 
and Aurora C/INCENP with IC50s values of 1100, 3.5, and 
6.5nM respectively. The selectivity may be partly due to the 
differences in the ATP-binding pockets of Aurora B/Aurora 
C versus Aurora A induced upon different cofactor binding. 
Moreover, GSK1070916 inhibitory activity became more 
potent over time, suggesting that the drug inhibits Aurora 
B/INCENP in a time-dependent fashion. At molecular level, 
GSK1070916 inhibits phosphorylation of histone H3 and 
shows potent antiproliferative activity against various human 
 
 
 
 
 
 
 
 
Fig. (4). Selective Aurora B inhibitors. Chemical structures of (a) AZD1152, (b) GSK1070916. 
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tumor cell lines in vitro [278]. In animal models, adminis-
tration of GSK1070916 at a dose of 25 mg/kg induced 
complete inhibition of histone H3 in human Colo205 colon 
tumor xenograft mice. In addition, intraperitoneal adminis-
tration of GSK1070916 at a dose of 100mg/kg (maximum 
tolerated dose) for 5 consecutive days with two cycles 
induced tumor regression [279]. Furthermore, human-
leukemia-cell-implanted SCID-NOD mice were sensitive to 
GSK1070916 treatment at a dose of 25mg/kg with the same 
schedule of administration [279]. This compound is being 
progressed to Phase I clinical trials in patients with advanced 
solid tumors. This inhibitor may represent an “ultimate 
physiological inhibitor” that exerts a constant inhibition of 
Aurora B until the enzyme is degraded and replaced by new 
protein synthesis [273, 278]. Patents references [218, 280-
286]. 
CURRENT & DEVELOPMENTS 
 Evidences suggest that deregulation of Aurora kinases 
contributes to the development of human neoplasia. The role 
of Aurora A in cancer has been clarified, being the gene 
frequently amplified in human tumours. On the other hand, 
the role of Aurora B in human tumourigenesis remains to be 
fully clarified.  
 The efficacy of Aurora inhibitors for the treatment of 
human neoplasia remains to be defined, and it is still not 
clear if these drugs present a better therapeutic index 
compared to antimitotic drugs, which include taxol and vinka 
alkaloids, all proved successful in the clinic. However, 
antimitotic drugs frequently show the appearance of drug 
resistance, adverse side effects (neurotoxicity) and their 
clinical effects are not predictable. Aurora inhibitors lacks 
neurotoxicity and could contribute to the treatment of human 
neoplasia [287, 288]. 
 A large number of Aurora inhibitors have been obtained; 
most of them yield activity against both Aurora A and 
Aurora B. As expected by their mechanisms of action, clini-
cal trials have shown that, compared to classical antimitotic 
drugs, these inhibitors do not induce irreversible neutropenia, 
but consistent with their activity on proliferating cells- 
induce bone marrow suppression, alopecia, nausea, vomiting 
and diarrhoea. Several Aurora B and dual A/B inhibitors are 
currently under clinical trials, but little information about the 
clinical outcome is available. The dual A/B inhibitor PHA-
739358 has resulted in partial/complete response in chronic 
myeloid leukemia (CML) and stabilization of the disease in 
solid tumours. Other clinical trials are ongoing to evaluate 
the clinical benefit of PHA-739358. Less encouraging data 
have been obtained with VX-680, that has been suspended 
on the base of preliminary safety data.  
 Overexpression of Aurora B and hyper-phosphorylation 
of histone H3 could be used to select patients likely to 
benefit of a treatment with dual or specific Aurora B kinase 
inhibitors, and the reduction of H3 phosphorylation in target 
tissues could help in monitoring the efficacy of these 
treatments. Furthermore, accumulating preclinical data are 
predicting that the association of these inhibitors with 
conventional chemotherapy and radiotherapy display addi-
tive or even synergistic anticancer effect. Emerging data 
suggest that spindle checkpoint inhibitors, in combination 
with DNA damaging agents, may be valid tools for the 
treatment of human neoplasia [279]. The rationale is that, in 
normal cells, these agents would arrest the cells mostly in G1 
in a p53-dependent manner, whereas p53-deficient cells, 
accounting for over half of all tumor-types, have to rely on S 
or G2-M checkpoint -although weaker than in healthy cells- 
to arrest cell cycle and repair the DNA. Therefore, 
combining a G2 checkpoint inhibitor with a DNA damaging 
agent should kill tumor cells, but most importantly spare the 
normal ones. Recent data demonstrates the efficacy of this 
association [177, 235, 277, 289, 290], thus opening new 
avenues towards the cure of certain cancers. 
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AZD1152 negatively affects the growth
of anaplastic thyroid carcinoma cells
and enhances the effects of oncolytic
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*(S Libertini is now at The Beatson Institute for Cancer Research, Switchback Road, Bearsden, Glasgow G61 1BD, UK)AbstractNovel therapeutic approaches are required for the treatment of anaplastic thyroid carcinoma
(ATC), an incurable disease resistant to current available therapies. Aurora B is an important
mitotic kinase involved in chromosome segregation and cytokinesis. It is overexpressed in many
cancers including ATC and represents a potential target for chemotherapy. The effects of
AZD1152, a specific Aurora B kinase inhibitor, have been evaluated against ATC, showing G2/M
accumulation, polyploidy and subsequent cell death by mitotic catastrophe upon drug treatment.
Only three administrations of AZD1152 significantly reduced the growth of ATC tumour
xenogratfs. Oncolytic viruses in association with other forms of treatment have proven highly
promising in preclinical and clinical reports. The oncolytic adenovirus dl922-947 is active against
ATC cells, and we have evaluated the effects of the association between AZD1152 and dl922-947.
In cells treated with virus and drug, we report additive/synergistic killing effects. Interestingly,
the phosphorylation of histone H3 (Ser10), the main Aurora B substrate, is inhibited by dl922-947
in a dose-dependent manner, and completely abolished in association with AZD1152.
The combined treatment significantly inhibited the growth of ATC tumour xenografts with respect
to single treatments. Our data demonstrate that the Aurora B inhibitor AZD1152, alone or in
combination with oncolytic virus dl922-947, could represent a novel therapeutic option for the
treatment of ATC.Endocrine-Related Cancer (2011) 18 129–141Introduction
Anaplastic thyroid carcinoma (ATC) is one of the most
aggressive human malignancies, responsible for up
to 40% of mortality from thyroid cancer. Although
multimodality treatments are successfully applied for
well-differentiated thyroid carcinomas, ATC survival
rates have not been improved for decades: after
diagnosis, patients have a median survival time of
4–6 months (Smallridge et al. 2009). Development
and evaluation of novel therapeutic strategies are,
therefore, desperately required.Endocrine-Related Cancer (2011) 18 129–141
1351–0088/11/018–129 q 2011 Society for Endocrinology Printed in GreatSeveral approaches of gene therapy have been
studied for ATC, such as differentiating therapy to
restore radioiodine uptake, suicide therapy and
oncolytic viruses. The latter are viral mutants able to
replicate selectively in, and destroy tumour cells. The
most common approach to achieve selectivity is the
deletion of viral genes whose product is necessary for
replication in normal cells, but expendable in cancer
cells (Mullen & Tanabe 2002).
dl922-947 is an oncolytic adenovirus, which bears a
deletion of 24 bp in E1A-conserved region 2 (CR2)Britain
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(Heise et al. 2000). This region normally binds to, and
inactivates, host cell Rb, thus causing the release of
E2F, followed by S-phase entry and subsequent viral
DNA replication. Lacking a functional E1A-CR2
region, dl922-947 mutant is unable to trigger S-phase
entry of quiescent normal cells, but can actively
replicate in cells with an aberrant G1–S checkpoint.
This checkpoint is lost in almost all cancer cells, and
several in vitro and in vivo studies demonstrate the
efficacy of dl922-947 in a range of cancer cell lines
(Heise et al. 2000). Its killing activity exceeds that of
adenovirus 5 wild type (Ad5wt) and of the first
generation virus dl1520 (Heise et al. 2000); a phase I
trial of dl922-947 in women with relapsed ovarian
cancer is under way (Baird et al. 2008).
We have shown that dl922-947 is active against
ATC cell lines and tumour xenografts (Libertini et al.
2008). However, data accumulated so far suggest that
the oncolytic activity of viruses, although impressive,
requires assistance in order to reach full efficacy. Using
viruses in association with other forms of treatment has
proven highly promising in preclinical and clinical
reports. The association of viruses with specific drugs,
not only able to directly kill tumour cells but also to
increase viral oncolytic activity, would represent a
powerful therapeutic tool.
The mitotic serine–threonine kinase Aurora B is
a chromosomal passenger protein (Keen & Taylor
2009). Together with INCENP, Borealin and survivin,
it exerts essential functions during mitosis, such as
modifying histones at the chromatin, correcting
misattachments while at the centromere, and regulat-
ing cytokinesis at the central spindle and later
midbody (Keen & Taylor 2009). Aurora B is over-
expressed in several human cancers, and its expression
directly correlates with malignancy (Katayama et al.
1999, Araki et al. 2004, Chieffi et al. 2004, 2006,
Kurai et al. 2005, Smith et al. 2005, Sorrentino
et al. 2005, Lo´pez-Rı´os et al. 2006, Vischioni et al.
2006, Qi et al. 2007, Tanaka et al. 2008). Upon
Aurora B depletion or inhibition, the cells with intact
checkpoint function arrest with 4N DNA content,
while those with compromised p53-dependent
pathway undergo endoreduplication and apoptosis
(Keen & Taylor 2004).
Cells lacking a p53-mediated post-mitotic check-
point are highly responsive to Aurora B inhibition, thus
suggesting a wide therapeutic window between normal
and tumour cells (Keen & Taylor 2004). In human
ATC, alterations of the p53 tumour suppressor gene are
a constant feature (Smallridge et al. 2009), and we
have previously shown that Aurora B is overexpressed
in ATC (Sorrentino et al. 2005). All these data indicate130that the treatment of ATC could benefit from the use
of an Aurora B inhibitor.
It has been reported that the block in G2/M phase
improves viral entry and replication (Seidman et al.
2001); therefore, we have hypothesized that Aurora B
inhibition could enhance the oncolytic effects of
dl922-947 adenovirus. We selected AZD1152 as an
Aurora B inhibitor due to its high selectivity for Aurora
B and its good solubility, which makes it appropriate
for clinical use (Wilkinson et al. 2007). Recent studies
showed that AZD1152 significantly reduces tumour
growth in a panel of solid human cancer xenograft
models (Wilkinson et al. 2007).
In this report, we show that AZD1152 is active
against ATC cells, inducing cell death through
mitotic catastrophe. We also demonstrate that the
drug is able to enhance the anti-neoplastic effects of
dl922-947 oncolytic virus in both in vitro and in vivo
models of ATC. Our data hint towards a mechanism
of how AZD1152 and dl922-947 can synergistically
kill ATC cells.Materials and methods
Cells, adenoviruses and drugs
Human ATC cell lines such as BHT101-5, Cal62, FRO
and 8505C have been authenticated as shown pre-
viously (Schweppe et al. 2008). All ATC cell lines
used have a non-functional p53 gene: in BHT101-5
cells, a 251 Ile/Thr substitution has been reported,
8505C cells present an Arg/Gly in position 248,
Cal62 cells are characterized by A161D mutation
while FRO cells are p53 null (Schweppe et al. 2008).
dl922-947 has a 24-bp deletion in E1A-CR2 (Heise
et al. 2000). AdGFP is a non-replicating E1-deleted
adenovirus encoding green fluorescent protein (GFP;
Libertini et al. 2007). Viral stocks were expanded,
purified, stored and quantified as previously reported
(Libertini et al. 2007).
AZD1152-HQPA was dissolved in DMSO to a final
concentration of 10 mM and stored at K20 8C.
AZD1152 was dissolved in 0.3 M Tris–HCl (pH 9) to
a final concentration of 10 mg/ml, each mouse received
300 ml of suspension i.p., i.e. 3 mg of prodrug,
corresponding to 2.5 mg of active drug.
Viability assay
BHT101-5, Cal62, FRO and 8505C cell lines have
been treated with a different range of drug concen-
trations since their sensitivity to AZD1152 treatment
varies. Treated cells were fixed with 50% TCA and
stained with 0.4% sulforhodamine B in 1% aceticwww.endocrinology-journals.org
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acid as already described (Libertini et al. 2008). The
percentages of surviving cells after treatment were
calculated by assuming that the number of surviving
untreated cells is 100%.FACS analysis
PH3 and cell cycle
Cells treated with AZD1152, virus or both were
harvested by trypsinization, fixed in 70% cold ethanol
and prepared as already described (Esposito et al. 2009)
using antibodies anti-phospho-histone H3 (Ser10)
and anti-histone H3 (Upstate, Biotechnology Inc,
Waltham, MA, USA).
AdGFP infection
FRO cells were treated for 24 h with AZD1152 25 nM,
washed and then infected with AdGFP (0, 25 or
50 pfu/cell). Forty-eight hours post infection, cells
were trypsinized, washed, resuspended in 300 ml of
PBS and analysed for the emission in FITC channel.
Samples were acquired with a CYAN flow
cytometer (DAKO Corporation, San Jose, CA, USA)
and analysed using SUMMIT software.Micronuclei counting
Cells grown on cover slips and treated as described
were fixed 15 0 in 3% paraformaldehyde, permeabilized
with 0.2% Triton X-100 10 0 and then stained 5 0 with
Hoechst 33258 (1 mg/ml, Sigma–Aldrich). The washes
were followed by mounting the cover slips onto glass
slides with glycerol:PBS 1:1.Synchronization
Cells were treated for 12 h with thymidine (2 mM),
released for 10 h in fresh media and retreated
for further 12 h with thymidine. Cells were washed
twice in fresh media, then treated and harvested
as indicated.Antibodies for western blot
Procaspase-3 (sc-56053; 1:100, Santa Cruz Biotech-
nology Inc, Santa Cruz, CA, USA), caspase-3 (ab13585,
1:500, Abcam, Cambridge, MA, USA), phospho-histone
H3 (Ser10) (06570, 1:500, Upstate Biotechnology Inc,
Waltham, MA, USA), histone H3 rabbit polyclonal
IgG (31949; 1:1000, Upstate) and actin (sc-10731, 1:500,
Santa Cruz) are the antibodies used for western blot.www.endocrinology-journals.orgTumourigenicity assay, viral replication and
distribution
Experiments were performed in 6-week-old female
athymic mice (Charles River Laboratories Inter-
national Inc, MA, USA). Mice were maintained at
the Dipartimento di Biologia e Patologia Animal
Facility. Animal experiments were conducted in
accordance with accepted standards of animal care
and in accordance with the Italian regulations for the
welfare of animals used in the studies of experimental
neoplasia. The study was approved by our institutional
committee on animal care.
To evaluate the effects of dl922-947 in combination
with AZD1152, FRO cells (1!107) were injected into
the right flank of 80 athymic mice. After 40 days,
tumour volume was evaluated, and the animals were
divided into four groups (20 animals/group) with
similar average tumour size. Tumour diameters
were measured with callipers, and tumour volumes
(V) were calculated by the formula of rotational
ellipsoid: VZA!B2/2 (A is the axial diameter and
B is the rotational diameter).
Viral replication and distribution were evaluated
as previously described (Libertini et al. 2008).Statistical analysis
The analysis of the cell killing effect in vitro was
made by isobolograms generated to calculate the con-
centration of each agent killing 50% of cells (EC50) using
untreated cells or cells treated with one agent only as
controls, as previously described (Cheong et al. 2008).
Comparisons among different treatment groups in
the experiments in vivo were made by the ANOVA
method and the Bonferroni post hoc test using
commercial software (GraphPad Prism 4, GraphPad
Software Inc, La Jolla, CA, USA). Differences in the
rate of tumour growth in mice were assessed for each
time point of the observation period.Results
AZD1152 treatment induces cell death in
ATC cells
Aurora B kinase is overexpressed in ATC, and blocking
its expression or activity reduces ATC cell growth
(Sorrentino et al. 2005). To confirm Aurora B as a
therapeutic target, we have evaluated the effects of
Aurora B inhibitor AZD1152 on the survival of human
ATC cell lines FRO, BHT101-5, 8505C and Cal62.
All cell lines are highly sensitive to AZD1152, with
an IC50 ranging from 8 to 50 nM for Cal62 and131
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FRO cells respectively (Fig. 1A). Aurora B inhibition
induces endoreduplication thus increasing cell dia-
meter; this could underestimate drug effects when
standard proliferation assays are used. Therefore, the
anti-proliferative effect of AZD1152 was also
determined by cell counting. As shown in Fig. 1B,
the inhibitor significantly reduces cell number after
1 day of treatment, further confirming the high efficacy
of the drug.
AZD1152 blocks Ser10 H3 phosphorylation
and induces mitotic catastrophe
Aurora B phosphorylates histone H3 on serine 10
during mitosis (Prigent & Dimitrov 2003). To confirm
AZD1152 effects on Aurora B activity, we treated FRO
and BHT101-5 cells for 24 h and performed a FACS
analysis by using a specific anti-phospho-Ser10 histone
H3 antibody (Fig. 1C).100
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dependent increase in polyploid cells was observed;
this increase was paralleled by the reduction in Ser10
H3 phosphorylation levels (Fig. 1C). After 24 h of
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Endocrine-Related Cancer (2011) 18 129–141chromosome segregation and cell division, and leads
to the formation of large non-viable cells charac-
terized by micronuclei (Castedo et al. 2004a).
Micronuclei are nuclear envelopes around clusters
of missegregated chromosomes (examples in
Fig. 2C). By immunofluorescence, we have quantified
the number of FRO- and BHT101-5-micronucleated
cells after AZD1152 treatment (Fig. 2D). A clear
dose- and time-dependent increase in the number of
micronucleated cells was observed.AZD1152 and dl922-947 show synergistic effects
on ATC cells
It has been proposed that drugs interfering with mitosis
and cytokinesis could potentiate viral oncolysis
(Seidman et al. 2001). Therefore, we hypothesized
that the association with AZD1152 could positively
affect the activity of the oncolytic adenovirus
dl922-947.www.endocrinology-journals.orgFRO and BHT101-5 cells were treated with
AZD1152 and simultaneously infected with dl922-947;
cell survival was evaluated after 7 days, showing
additive/synergistic effects (Fig. 3A, Table 1). In order
to understand whether AZD1152 sensitizes cells
to viral action, we have treated FRO and BHT101-5
cells with AZD1152 for 24 h and then infected with
dl922-947. The effects were evaluated after 6 days: the
data obtained show that 24 h pre-treatment is sufficient
to significantly increase the killing activity of dl922-
947 (Fig. 3B, Table 2), confirming that the inhibitor
sensitizes cells to viral action. It is also worth noting
that 24 h treatment with AZD1152 alone significantly
affects cell survival.AZD1152 does not affect cellular infectivity
It has been proposed that drugs can enhance viral
oncolytic activity by increasing viral entry in target
cells (Anders et al. 2003). To monitor this step, FRO133
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Figure 3 AZD enhances the oncolytic activity of dl922-947 but does not increase cellular infectivity. (A) FRO and BHT101-5 cells
were treated with five fixed combination ratios of dl922-947 and AZD1152, and cell viability was determined by sulforhodamine B
assay 7 days post infection. Dose–response curve and EC50 values were used to construct isobolograms and calculate combination
indexes (CI) for each ratio. Ratios are expressed as virus (pfu/cell) to drug (nM). A line is drawn connecting the EC50 values of the
virus and drug as a single agent. A ratio producing a CI%0.8 is considered synergistic, a ratio producing CIs between 0.8 and 1.2 is
considered additive and a ratio producing CIR1.2 is considered antagonistic. (B) Cells were treated for 24 h with the drug; then, the
media were replaced with media containing the virus alone. Survival was evaluated after 6 days with isobolograms obtained as
above. (C) FRO cells were treated for 24 h with AZD1152, and then infected with AdGFP. Viral entry was quantified bymonitoring the
percentage of GFP-positive cells (numbers on the bars) and the average expression in FITC channel (numbers on top right) after
24 h. The percentage of GFP-positive cells does not significantly change upon AZD1152 pre-treatment, beingw85% for 25 pfu/cell
andw95% for 50 pfu/cell, regardless of drug pre-treatment. The FITC ratio in infected and uninfected cells upon drug treatment
showed no significant change (75G31-fold increase versus 68G19 for 25 pfu/cell and 466G246-fold increase versus 458G182
for 50 pfu/cell).
S Libertini et al.: dl922-947 and AZD1152cells were pre-treated for 24 h with AZD1152 at a low
concentration (able to induce G2/M block but not death
after 48 h) and then infected with a non-replicating
reporter adenovirus transducing GFP (AdGFP). After
additional 24 h, GFP emission was evaluated by
cytofluorimetric analysis. The percentage of GFP
cells was not modified by AZD1152 pre-treatment,
although a positive shift in FITC channel was observed
(Fig. 3C). This increase is apparent, since AZD1152
treatment enlarges the cells thus enhancing basal
fluorescence. Indeed, analysis of the FITC ratio in
infected and uninfected cells treated or not with134AZD1152 showed no significant difference. Similar
results were obtained with BHT101-5 cells (data
not shown).dl922-947 and AZD1152 induce subG1 phase
population in treated cells
Next, cell cycle profiles in infected cells, treated or not
with AZD1152, were evaluated. To better discriminate
differences in cell cycle phases, timing and cell death, a
double thymidine block was performed to synchronize
cells in G1. As shown in Fig. 4, in untreated cells, 10 hwww.endocrinology-journals.org
AUTHOR COPY ONLY
Table 1 Simultaneous treatment with AZD1152 and dl922-947
Cell line
Ratio
((pfu/cell)/(nM))
EC50
dl922-947
(pfu/cell)
EC50
AZD1152
(nM) CI
BHT101-5 AZD1152 alone 0 13
dl922-947 alone 10 0
1:50 0.2 10 0.79
1:16 0.5 8 0.67
1:6 1 6 0.56
1:1 5 4 0.8
4:1 8 2 0.95
FRO AZD1152 alone 0 50
dl922-947 alone 1 0
1:400 0.1 40 0.9
1:120 0.25 30 0.85
1:40 0.5 20 0.9
1:14 0.7 10 0.9
1:6 0.8 5 0.9
Table 2 AZD1152 pre-treatment on dl922-947-infected cells
Cell line
Ratio
((pfu/cell)/(nM))
EC50
dl922-947
(pfu/cell)
EC50
AZD1152
(nM) CI
BHT101-5 AZD1152 alone 0 24
dl922-947 alone 10 0
1:500 0.04 20 0.84
1:167 0.06 10 0.42
1:114 0.07 8 0.34
1:62 0.08 5 0.21
1:20 0.2 4 0.19
FRO AZD1152 alone 0 100
dl922-947 alone 1 0
1:5000 0.01 50 0.51
1:667 0.06 40 0.46
1:300 0.1 30 0.4
1:50 0.4 20 0.6
1:12 0.8 10 0.9
Endocrine-Related Cancer (2011) 18 129–141after thymidine release, about 30% of the population
re-entered G1 phase; a similar profile was observed
in infected cells. Conversely, after 10 h, AZD1152
induced a G2/M accumulation that was not modified
by the association with dl922-947. Starting from 20 h,
a significant increase in subG1 phase was observed in
both AZD1152- and dl922-947-treated cells. Interest-
ingly, the combination between drug and virus
increased the percentage of cells in subG1 fraction
compared with single treatments. It is also worth
noting that, in the combined treatment, the increase in
subG1 fraction at later time points is associated with a
decrease in polyploidy fractions, suggesting that
dying cells (subG1 fraction) are the ones that escaped
G2/M block.
Caspase-3 activation has been observed in some
models of mitotic catastrophe (Castedo et al. 2004a,b),
and dl922-947 induces subG1 accumulation and
caspase-3 cleavage in ovarian cancer cells (Baird
et al. 2008). Therefore, we analysed caspase-3
activation in treated ATC cells. As shown in Fig. 5A,
while dl922-947 induces caspase-3 cleavage,
AZD1152 does not. Interestingly, in the combined
treatment, an earlier decrease of procaspase-3 with
respect to virus treatment alone was observed. This
observation suggests that the inhibitor could enhance
viral-induced cell death by accelerating the activation
of caspase-3 pathway.
dl922-947 reduces H3 phosphorylation
FRO cells infected with dl922-947 show G2/M
accumulation and tetraploidy (Fig. 4), suggestive of a
mitotic block. During a normal mitosis, histone H3 is
phosphorylated on Ser 10 (28–29); the viral effects onwww.endocrinology-journals.orgcell cycle prompted us to analyse whether dl922-947
acted on this substrate.
We treated FRO cells for 24 h with different
amounts of virus and drug, alone or in combination.
Cells were stained with propidium iodide and with
anti-phospho-Ser10 H3 histone antibody to monitor
the percentage of PH3-positive cells during the cell
cycle (Fig. 5B). dl922-947 alone is able to decrease
the percentage of PH3-positive cells and, together
with AZD1152, Ser10 H3 phosphorylation is almost
completely abolished: FACS data were confirmed by
western blot analysis of PH3 levels (Fig. 5C).AZD1152 increases dl922-947 oncolytic
activity in vivo
To further validate the potential therapeutic use of
AZD1152 in association with dl922-947, we analysed
the effects of the combined treatment on xenograft
tumours. To study the effect of the association in the
worst possible scenario, FRO cells were chosen, being
the least sensitive to AZD1152 effect (Fig. 1) and
viral infection (Libertini et al. 2008). A low viral dose
(1!106 pfu) was used to better evaluate the effects
of the combined treatment; virus was administered by
i.t. injection to avoid first pass effect.
Animals were divided into four groups: untreated,
treated with AZD1152, dl922-947 or both. As shown
in Fig. 6A, AZD1152 and dl922-947 in combination
have a stronger anti-tumour activity than when used
alone. As already described, no toxicities were
observed in virus-treated animals (Libertini et al.
2008). Drug-treated animals showed slight weight loss
and dehydration on the third day of treatment, but135
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Figure 4 AZD1152 and dl922-947 induce tetraploidy and cell death. FRO cells were synchronized in G1 phase and treated with
AZD1152 10 nM, dl922-947 (25 pfu/cell) or both. FACS analysis was performed to analyse the cell cycle.
S Libertini et al.: dl922-947 and AZD1152recovered after 2–3 days. In the combined treatment
group, animals took longer to recover (4–5 days), but
no other symptoms were observed.
Viral replication analysis in animals pre-treated
with AZD1152 showed an increase of genome copies
(Fig. 6B). However, this effect was not observed
in vitro (data not shown). It has been hypothesized that
the pre-treatment with anti-neoplastic drugs could
improve intratumoural viral diffusion by reducing
the number of neoplastic cells (Va¨ha¨-Koskela et al.
2007). To address this point, FRO xenografts animals,
pre-treated or not with AZD1152, were injected
intratumourally with AdGFP. GFP expression was
evaluated by fluorescence microscopy analysis
(Fig. 6C). In control tumours, a faint fluorescence
signal was observed, whereas in AZD1152-treated
tumours, a more intense fluorescence signal wasProcaspase-3
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Figure 5 dl922-947 induces caspase-3 activation and decreases
treated with different combinations of dl922-947 and AZD1152. Att
analysis was performed to quantify procaspase- and activated caspa
FRO cells were treated for 24 h with different amounts of AZD1152
evaluated by FACS (B) and western blot analysis (C).
136detected. It is worth noting that both viral replication
and distribution were increased three times upon drug
treatment (Fig. 6B and C).Discussion
ATC is one of the most lethal neoplasia and leads to
death in a short time. Active therapies are not available,
making the development of novel therapeutic strategies
imperative (Smallridge et al. 2009).
AZD1152 is a reversible ATP-competitive Aurora
inhibitor, which is 1000-fold more selective for Aurora
kinase B than for Aurora kinase A (Wilkinson et al.
2007). The effects of AZD1152 have been already
assessed in in vivo models of human leukaemia
(Wilkinson et al. 2007, Yang et al. 2007, Walsby et al.
2008, Oke et al. 2009), breast cancer (Gully et al. 2010),B
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Figure 6 AZD1152 delays tumour growth and facilitates
dl922-947 replication and distribution. (A) Tumour bearing
mice were randomized into four groups. Two groups received
AZD1152 (100 mg/kg per day) i.p. from T1 to T3 and from T15 to
T17. dl922-947 (1!106 pfu, in a volume of 300 ml) was injected
at T4, T8, T11 and T15 into one AZD1152-treated group and
one untreated group. The control group was injected with saline
solution. Tumour volume is expressed as a percentage of the
volume observed at day 0 in the control group. The difference
between treated and untreated groups becomes statistically
significant (P!0.05) from day 17 for virus versus control and
drug versus control, and from day 8 for combined treatment
versus control. At day 21, a significant difference (P!0.05) was
observed between the combined treatment group and single
treatment groups. From day 23 till the end of the treatment, the
difference became highly significant (P!0.01). (B) FRO cells
(1!107 cells) were injected intratumourally within ten athymic
mice. Forty days later, when tumours were detectable, animals
were divided into two groups, which received respectively
AZD1152 (2.5 mg/mouse) or saline solution i.p. After 24 h,
dl922-947 (1!106 pfu, in a volume of 300 ml) was injected
intratumourally in both groups. Two days later, animals were
killed. DNA was extracted from 100 mg of tumour tissue, and
the number of viral copies was evaluated by real-time PCR. The
data are the mean of three different experiments. (C) Ten FRO-
induced xenograft tumours were injected i.p with AZD1152
(100 mg/kg per day) or saline solution for 3 consecutive days
and, after 2 days, AdGFP (1!107 pfu, in a volume of 300 ml)
was injected intratumourally in both groups. Twodays later, animals
were killed, tumours were excised and GFP distribution was
evaluatedbyconfocalmicroscopy.Thequantificationof thedigitized
signal showed a threefold increase upon AZD1152 treatment.
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www.endocrinology-journals.orghepatocellular carcinoma (Aihara et al. 2010), and
colon and lung cancers (Wilkinson et al. 2007).
AZD1152 and other Aurora inhibitors are currently in
early clinical evaluation, showing reversible neutropenia
as a major side effect (Keen & Taylor 2009).
In the present study, we have demonstrated that
AZD1152 is active against ATC cells and that the
effects are observed within 24 h. These data are
consistent with the high levels of Aurora B expression
(Sorrentino et al. 2005), the lack of a functional
p53 pathway (Schweppe et al. 2008) and the short
doubling time (10 h) of ATC cells. In the present
study, we have also shown that just three doses of
AZD1152 significantly delay the growth of ATC
tumour xenografts.
Another Aurora inhibitor, VX-680, has been
previously evaluated on ATC cell lines showing
inhibition of cell proliferation and cell death; however,
the drug was not evaluated in vivo (Arlot-Bonnemains
et al. 2008). Cells treated with VX-680 showed an
increase in DNA content (O4N), reduction of Ser10
H3 phosphorylation, subG1 accumulation and acti-
vation of caspase-3 (Arlot-Bonnemains et al. 2008).
The authors concluded that VX-680 activated the
apoptotic cascade in ATC cells, and suggested that the
effects reported were due to the inhibition of Aurora A
rather than Aurora B. VX-680 inhibits Aurora kinases
with comparable inhibition constants, ranging from
0.6 nM for Aurora A to 18 nM for Aurora B; hence, it
is plausible that the effects exerted by VX-680 on ATC
cells are due to the inhibition of both Aurora kinases.
In addition, it has been previously reported in other
cell models that effects seen with VX-680 closely
resemble those described for Aurora B inhibition
(Keen & Taylor 2004) and mirror the effects described
here with AZD1152 on ATC cells. Moreover, the IC50
of VX-680 on ATC cells ranged from 25 to 150 nM:
these concentrations are also sufficient to inhibit the
kinase FLT3 (Harrington et al. 2004, Arlot-Bonnemains
et al. 2008). On the other hand, the IC50 of AZD1152
in this study ranges from 5 to 30 nM, indicating that
AZD1152 could achieve a therapeutic effect at lower
and less toxic concentrations. Therefore, our results
clearly indicate using both in vitro and in vivo
models that selective inhibition of Aurora B could
represent a therapeutic option for the treatment of ATC.
Oncolytic viruses are emerging as new therapeutic
tools for the treatment of cancer, and we previously
demonstrated that the mutants dl1520 and dl922-947
are active against ATC in vitro and in vivo (Libertini
et al. 2007, 2008). It has been reported that drugs
able to block cells in G2/M or inhibit cytokinesis
could enhance the effects of oncolytic viruses137
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(Seidman et al. 2001). Since AZD1152 has a clear
effect on cell division, we wondered whether it could
positively affect dl922-947 activity. The data presented
in this manuscript demonstrate the efficacy of this
combination both in vitro and in vivo.
To understand how AZD1152 enhances oncolytic
activity, we first monitored viral entry upon drug
treatment. Our data show that AZD1152 does not affect
viral entry. The synchronization in G2/M phase leads to
modest, but significant, translocation of CAR receptor
to the cell surface of A549 lung carcinoma cells
(Seidman et al. 2001). Although AZD1152-treated
cells accumulate in G2/M phase, membrane levels of
CAR and its co-receptors integrins avb3, avb5 and avb1
do not increase after AZD1152 treatment (data not
shown). By using AdGFP, we did not observe any
difference in viral entry during each cell cycle phase
(data not shown). Our observation is not in agreement
with Seidman et al. (2001); this discrepancy could be
due to the different cellular system used or to a very
slight increase in receptor levels hidden by the increase
in cellular size.
Secondly, we analysed cell death mechanisms
induced by virus and drug, alone or in combination.
AZD1152 induces a G2/M block and tetraploidy in
ATC cells. This aberrant mitotic phenotype, the
presence of micronuclei and the appearance of subG1
population demonstrate that AZD1152-treated cells
die through mitotic catastrophe. According to the
literature, mitotic catastrophe could share biochemical
hallmarks with apoptosis, such as mitochondrial
membrane permeabilization (MMP) and caspase
cleavage (Castedo et al. 2004a,b). In our study, despite
the clear induction of mitotic catastrophe, AZD1152
did not induce caspase-3 activation (Fig. 5) and
MMP (data not shown). Like AZD1152-treated cells,
ATC-infected cells show enlargement and polyploidy.
However, it is possible to exclude death by mitotic
catastrophe since, upon infection, cells detach, a
feature not observed in mitotic catastrophe. Moreover,
in the few adhering cells, we have not observed the
presence of micronuclei (data not shown). We have
also excluded autophagic cell death, since neither
beclin 1 activation nor LC3I–II conversion were
induced, and accumulation of autophagic vesicular
organelles was not observed by FACS analysis in
acridine orange-stained cells (data not shown). Our
data extend to ATC cells the observation of Baird
et al. (2008) that infection with mutant oncolytic
adenovirus leads to programmed cell death lacking
the features of classical apoptosis, but showing some
apoptotic markers, such as subG1 accumulation and
caspase-3 activation. Interestingly, the association with138AZD1152 accelerates the appearance of cleaved
caspase-3 and increases the percentage of cells in
subG1 phase. Our results indicate that AZD1152
enhances the cytotoxic effects of oncolytic viruses,
although the cell death mechanisms are not yet defined.
During mitosis, Aurora B is involved in phosphoryl-
ation of histone H3 on Ser10 (Ditchfield et al. 2003,
Hauf et al. 2003). Accordingly, AZD1152 strongly
reduces H3 phosphorylation. It has been reported that
the oncolytic herpes virus G47D decreases phospho-
Ser10 H3 levels (Passer et al. 2009), and we observed
that the oncolytic adenovirus dl922-947 (Fig. 5B) and
Ad5wt (personal observation) have a similar effect.
These data suggest that modulation of PH3 levels is a
common feature of viral infections; it is conceivable
that viruses prematurely end mitosis in order to switch
cell machinery to viral replication.
The first oncolytic adenovirus described, dl1520
(Heise et al. 1997), has shown improved effects in
clinical trials in combinations with chemotherapy
(Kumar et al. 2008). In 2005, China approved the
world’s first oncolytic virus therapy for cancer
treatment, with modified adenovirus H101, similar to
dl1520 (Yu & Fang 2007). In a phase III trial, a 79%
response rate for H101 plus chemotherapy, compared
with 40% for chemotherapy alone, was observed (Yu
& Fang 2007). Other oncolytic viruses have entered
into clinical trials: their efficacy and safety, and
synergistic effects in association with other drugs
have been demonstrated, confirming virotherapy as
a promising direction for the treatment of cancer
(Liu et al. 2007). Oncolytic viruses target neoplastic
cells using a mechanism different from that of anti-
neoplastic drug; therefore, the combination treatment
could contribute to avoid the development of resistant
cancer cells, thus increasing the cure rate.
Data presented here demonstrate that the selective
inhibitor of Aurora B kinase AZD1152 is highly
effective against ATC cell lines and tumour xenografts,
and could represent a novel therapeutic option for the
treatment of this dismal disease. We have also shown
that AZD1152 enhances the effects of dl922-947
against ATC; similar combined approaches could be
used for the treatment of ATC and other aggressive and
incurable human cancers.Declaration of interest
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Abstract 
Oncolytic viruses represent a novel therapeutic approach for aggressive tumours, such as 
glioblastoma multiforme, which are resistant to available treatments. Autophagy has been observed 
in cells infected with oncolytic viruses, however its role on cell death/survival is unclear. To 
elucidate the potential therapeutic use autophagy modulators in association with viral therapy, we 
analyzed autophagy induction in human glioma cell lines U373MG and U87MG infected with the 
oncolytic adenovirus dl922-947. dl922-947 infection triggered autophagy, as shown by 
development of acidic vesicular organelles, LC3-ILC3-II conversion, reduction of p62 levels. 
Upon infection, Akt/mTOR/p70s6k pathway, a negative regulator of autophagy, was activated, 
while ERK1/2 pathway, which positively regulates autophagy, was inhibited. Accordingly, MEK 
inhibition by PD98059 sensitized glioma cells to dl922-947 effects, whereas autophagy induction 
by rapamycin protected cells from dl922-947-induced death. Treatment with two inhibitors of 
autophagy, chloroquine and 3-methyladenine, increased the cytotoxic effects of dl922- 947 in vitro. 
In vivo, the growth of U87MG induced xenografts was further reduced by adding chloroquine to 
dl922-947 treatment. In conclusion, autophagy acts as survival response in glioma cells infected 
with dl922-947, thus suggesting autophagy inhibitors as adjuvant/neoadjuvant drugs in oncolytic 
viruses based treatments. 
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Introduction 
Malignant glioma of astrocytic origin or glioblastoma multiforme (GBM) is one of the most 
aggressive human tumours (Furnari et al., 2007; Brandes et al., 2008) with a median survival time 
of about 12-15 months. The standard treatment protocol for newly diagnosed GBM includes 
surgical resection, radiotherapy and chemotherapy (Furnari et al., 2007; Brandes et al., 2008). 
However, this therapeutic approach has achieved only a moderate increase in survival (Ahmadi et 
al., 2009), highlighting the need for the development of novel and more effective treatments. 
Conditionally replicating oncolytic viruses (OVs) are a novel promising platform for the treatment 
of cancer. Several studies have demonstrated the feasibility and safety of this therapeutic strategy in 
glioblastoma patients (Haseley et al., 2009). dl922-947 is a replication-selective oncolytic 
adenoviral mutant harbouring a 24-bp deletion in the E1A-Conserved Region 2 (CR2), that is 
necessary for binding and inactivation of pRb (Heise et al., 2000), which regulates the G1 to S 
phase transition. Thus, dl922-947 virus is unable to induce G1 to S phase transition in normal cells, 
but can replicate with high efficiency in cells with an abnormal G1-S checkpoint. Previous studies 
have confirmed the efficacy of E1A CR2-deleted adenoviruses for glioma cells such as Delta24 
(Fueyo et al., 2000; Jiang et al., 2007) and we have demonstrated that dl922-947 exerts 
antineoplastic activity against the glioma cell lines U373MG and U343MG (Botta et al., 2010). 
Recently, a phase I clinical trial for the use of an E1ACR2-deleted mutant (Ad5-∆24RGD) in 
recurrent malignant gliomas has been completed (http://clinicaltrialsfeeds.org/clinical-
trials/show/NCT00805376). 
Although efficacy and safety of OVs have been clearly demonstrated in preclinical and clinical 
studies, most of the molecular and/or biochemical pathways activated in cancer cells, including the 
cell death mechanisms, are not fully understood. A better understanding of such mechanisms would 
be advantageous for future selection of novel drugs or treatments to further enhance the efficacy of 
oncolytic viruses. In different studies, it has been shown that OVs activate the autophagic 
machinery in some cancer cells (Ito et al., 2006; Jiang et al., 2007; Baird et al., 2008; Tyler et al., 
Page 4 of 34
Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801
Human Gene Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
4 
 
2009). Autophagy is an evolutionarily conserved process whereby cytoplasm and cellular organelles 
are degraded in lysosomes for amino acid and energy recycling (Mizushima, 2007). The role of 
autophagy as an alternate energy source, and thus as a temporary survival mechanism under 
stressful conditions, is well recognized. However, it has also been reported that autophagy plays an 
active role in cell death (Baehrecke, 2005; Loos and Engelbrecht, 2009). 
Here, we showed that infection with the oncolytic virus dl922-947 induces formation of acidic 
vescicular organelles and LC3I-II conversion, indicative of an autophagic response.  
Regulation of autophagy requires multiple signaling pathways (Meijer and Codogno, 2004), 
therefore we decided to further study this process. Akt/mTOR/p70s6k is the main pathway involved 
in the negative regulation of autophagy (Blommaart et al., 1995; Yang et al., 2005). Class I 
phosphatidylinositol 3-phosphate kinase (PI3K) is activated by ligand binding to growth factor 
receptors. PI3K activates the downstream target AKT, leading to activation of mammalian target of 
rapamycin (mTOR) (Dìaz-Troya et al., 2008). TOR is a serine/threonine kinase that exerts an 
inhibitory effect on autophagy, which is achieved by either controlling translation and transcription 
or either directly or indirectly affecting the Atg (autophagy related genes) proteins (Dìaz-Troya et 
al., 2008). p70S6k is considered a candidate of the substrates of mTOR and of the control of 
autophagy downstream of mTOR (Blommaart et al., 1995). In the presence of amino acids, mTOR 
promotes phosphorylation of S6 through activation of p70S6K, thus facilitating the translation 
initiation of mRNAs (Dìaz-Troya et al., 2008). On the other side, the ERK1/2 pathway has been 
described as a positive regulator pathway of autophagy (Pattingre et al., 2003). 
Surprisingly, we found that, even thought dl922-947 infection induces autophagy, it also activates 
the main negative regulator of autophagy–the Akt/mTOR/p70S6K pathway- and inhibits the 
positive regulator–the ERK1/2 pathway. In line with this, viral cytotoxicity is decreased by 
rapamycin (an mTOR inhibitor) and increased by ERK1/2 inhibitor PD98059, as well as by specific 
inhibitors of autophagy (3-Methyladenine and Chloroquine) or genetic tools such as Atg5 shRNA. 
Although these data seem to contrast with previous results suggesting autophagy as a cell death 
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mechanism induced by oncolytic viruses in glioma cells (Ito et al., 2006), our results led us to 
speculate that autophagy might play a survival/defensive role in glioma cells infected with dl922-
947. Consistently, we demonstrated that chloroquine treatment of athymic mice bearing glioma 
tumour xenografts enhances the effects of dl922-947 in reducing tumor growth. 
 
Material and methods 
Cell lines and reagents 
Human glioma cell lines U373MG and U87MG were purchased from American Type Culture 
Collection and grown as described (Botta et al., 2010).  
Acridine orange and 3-Methyladenine (3-MA), an inhibitor of class-III-phosphatidylinositol-3 
kinase (PI3KIII), which is known to inhibit autophagic sequestration (Kondo et al., 2005), were 
purchased from Sigma-Aldrich (St. Louis, Missouri). 
Chloroquine (CQ), which prevents the fusion of autophagosomes and lysosomes (Kondo et al., 
2005), was purchased from Fluka, Biochemika (Buchs, Switzerland). PD98059, a mitogen-activated 
protein kinase/extracellular signal-regulated kinase kinase 1 (MEK 1) inhibitor, and rapamycin, a 
natural product which binds directly to mTOR and suppresses mTOR-mediated phosphorylation of 
its downstream target p70S6K, were purchased from Sigma-Aldrich (St. Louis, Missouri). 
 
Preparation of adenoviruses, infection and viability assay 
dl922-947 is a second generation adenoviral mutant that has a 24-bp deletion in E1A Conserved 
Region 2 (CR2). AdGFP is a non replicating E1A-deleted adenovirus encoding green fluorescent 
protein. dl312 is a non replicating adenovirus (∆E1A, ∆E3B) (Cheong et al., 2008). Viral stocks 
were expanded, purified and stored as previously reported (Botta et al., 2010). Virus titre was 
determined by plaque-forming units (pfu) on the HEK-293 cells. 
For the evaluation of the cytoxic effects of the dl922-947 virus, 1 x103 cells were seeded in 96-well 
plates, and 24 hours later cells infected with at different Moltiplicity Of Infection (MOIs), in 
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presence or not of 1.0 mM 3-MA or 10µM CQ. After seven days, cells were fixed with 10% TCA 
and stained with 0.4 % sulforhodamine B in 1% acetic acid (Libertini et al., 2010). The bound dye 
was solubilised in 200 µl of 10 mM unbuffered Tris solution and the optical density was determined 
at 490 nm in a microplate reader (Biorad; Hercules, California). The percent of cell death rates of 
treated cells were calculated. Dose response curves were generated to calculate the concentration at 
which each agent killed 50% of cells (LD50), using untreated cells or cells treated with single agents 
as a control.  
 
Quantification of Acidic Vesicular Organelles With Acridine Orange 
Autophagy is characterized by the development of acidic vesicular organelles. The cytoplasm and 
nucleoli of acridine orange–stained cells fluoresce bright green and dim red, respectively, whereas 
acidic compartments fluoresce bright red (Paglin et al., 2001). Therefore, autophagy was assessed 
in U373MG and U87MG cells by the quantification of acidic vesicular organelles with supravital 
cell staining using acridine orange. Treated cells were detached with 0.05% trypsin–EDTA and 
stained with 1.0 µ g/mL acridine orange for 15 minutes at 37°C. Stained cells were then analyzed 
on a FACS cytometer (Dako Cytomation, Carpinteria, California) and Summit V4.3 software 
(Dako).  
 
Generation of stable clones 
The green fluorescent protein (GFP)-tagged LC3 expressing cells were used to demonstrate 
induction of autophagy (Kabeya et al., 2000). The LC3 expression vector (pCAG-LC3) was kindly 
provided by Drs. N. Mizushima and T.Yoshimori (Osaka University, Suita, Japan). To obtain 
pGFP-LC3, LC3 cDNA was inserted into the BglII and EcoRI sites of pEGFP-C1, a GFP fusion 
protein expression vector (Clontech laboratories; Mountain View, California) (Kabeya et al., 2000). 
Stable expression of GFP-LC3 cDNA in U373MG cells (U373GFP-LC3) was accomplished by 
using the Lipofectamine (Invitrogen; Carlsbad, California) method according to the manufacturer’s 
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instructions. Briefly, cells were cultured in 60 mm dishes (Corning Incorporated, Corning, NY) and 
incubated for 24 h in serum-free DMEM supplemented with 5 µg of cDNA and 15 µl of 
Lipofectamine reagent. An equal volume of DMEM supplemented with 20% fetal calf serum was 
then added for 5 h followed by replacement with DMEM supplemented with 10% serum for 24 h 
before the assays. At 48 h after the medium change, cells were selected in medium containing 400 
mg/ml of G418 (GIBCO;  Carlsbad, California) and G-418 resistant clones were established. 
Expression of GFP-LC3 in the selected clones was evaluated by western blot analysis using anti 
GFP antibody.  
To stably inhibit the expression of ATG5 gene, APG5 shRNA (sc-41445-sh) and control shRNA 
(sc-108060) plasmids were purchased from Santa Cruz biotech (Santa Cruz, California) and 
transfected/selected in U373MG and U87MG cell lines as described above.  
 
Analysis of LC3 localization by immunofluorescence staining 
U373MG cells stably expressing GFP-LC3 plasmid were seeded in 12-wells dishes. After 
treatment, cells were fixed with 3% paraformaldehyde and then examined. Images were acquired 
with a LSM510 inverted confocal microscope (Zeiss, Oberkochen, Germany) using a x40 oil 
objective and processed using LSM software (Zeiss, Oberkochen, Germany). 
 
Western blot analysis 
For protein extraction, cells were homogenised into lysis buffer (50 mM HEPES, 150 mM NaCl, 1 
mM EDTA, 1 mM EGTA, 10% glycerol, 1%Triton-X-100, 1 mM phenylmethylsulfonyl fluoride, 1 
µg/ml aprotinin, 0.5 mM sodium orthovanadate, 20 mM sodium pyrophosphate).  
Tumour tissue samples were homogenised in a Polytron (Brinkman Instruments, Westbury, New 
York) in 20 ml T-PER reagent (Pierce, Rockford, Illinois) per gram of tissue according to 
manufacturer’s instructions. After centrifugation at 5000×g for 5 min, supernatant fraction was 
collected.  
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Total homogenates were separated by SDS-PAGE under reducing conditions. Membranes were 
incubated overnight with the following primary antibodies: LC3-I/II (ab51520, 1:3000) and 
caspase-3 (ab13585, 1:500) from Abcam (Cambridge, United Kingdom); p62 (#5114, 1:1000) , p-
ERK1/2 (#9101S, 1:1000), p-Akt (#9271, 1:1000) and p-p70s6k (#9205S, 1:500), from Cell 
Signalling (Danvers, Massachusetts), ATG5 (sc-8666, 1:500), ERK1/2 (sc-93-G, 1:1000) and β-
actin (sc-10731, 1:2000) from Santa Cruz biotech (Santa Cruz, California); AKT (#28745, 1:1000) 
from Upstate Biotechnology (Billerica, Massachussets).  
 
In vivo antitumor activity 
Experiments were performed in six-week-old female CD-1 athymic mice (Charles-River, 
Wilmington, Massachussets). U87MG cells (5x106) were injected into the right flank of 80 athymic 
mice. After 20 days, when tumours were clearly detectable, tumours volumes were evaluated and 
the animals were randomised into four groups (T=0) with similar average tumour size: untreated, 
treated with CQ, dl922-947, or both. CQ (45 mg/Kg) was administered i.p. every third day, virus 
was administered three times per week by intratumoural injection to avoid first pass effect. A low 
viral dose (1x107 pfu) was used to better evaluate the effects of the combined treatment. The control 
group was injected with saline solution. Tumours diameters were measured with calipers and 
tumours volumes (V) were calculated by the formula of rotational ellipsoid: V=AxB2/2 (A=axial 
diameter, B=rotational diameter). 
Experiment was stopped when tumors reached 1 cm3 in volume and/or symptomatic tumor 
ulceration occurred.  
Mice were maintained at the Dipartimento di Biologia e Patologia Animal Facility. Animal 
experiments were conducted in accordance with accepted standards of animal care and in 
accordance with the Italian regulations for the welfare of animals used in studies of experimental 
neoplasia. The study was approved by our institutional committee on animal care. 
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Statistical analysis 
The analysis of the cell killing effect in vitro was made by calculating the concentration at which 
each agent killed 50% of cells (LD50), using untreated cells or cells treated with one agent only as 
controls. Comparisons among different treatment groups in the experiments in vivo were made by 
the ANOVA method and the Bonferroni post hoc test using commercial software (GraphPad Prism 
4). Differences in the rate of tumour growth in mice were assessed for each time point of the 
observation period. 
 
Results 
Induction of autophagy in malignant glioma cells by dl922-947 
First, we evaluated the cytotoxic effects of dl922-947 in U87MG and U373MG glioma cells, 
confirming its efficacy. U373MG cell line displayed higher sensitivity to dl922/947 with an EC50 of 
0.003 pfu/cell, compared to U87MG EC50 at 0.019 pfu/cell (Fig. 1A). 
Next, we evaluated the activation of autophagy in glioma cells infected with dl922-947. To this end, 
we analysed the formation of acidic vescicular organelles (AVOs), a peculiar feature of autophagy, 
after infection with dl922-947. Quantification of AVOs in U373MG and U87MG cells was 
performed with acridine orange supravital cell staining. U373MG and U87MG cells were infected 
at increasing MOIs of dl922-947 and acridine orange vital staining performed 72 hpi (hours post 
infection). FACS analysis showed an increase in bright red fluorescence in infected cells, in a MOI-
dependent manner, up to 18% (U373MG) or up to 14% (U87MG). Untreated cells exhibited mainly 
green fluorescence (Fig. 1B). Cells infected with a non replicating control adenovirus, dl312 
exhibited a similar pattern (not shown). This indicates an accumulation of AVOs in glioma cells 
infected with dl922-947.  
In amino acid starvation-induced autophagy, the microtubule-associated protein 1 light chain 3, 
LC3-I, undergoes a series of ubiquitination-like reactions, and is modified to LC3-II. LC3-I is 
located in the cytoplasm, conversely LC3-II is a tightly membrane bound protein and is attached to 
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pre-autophagosomal (PAS) and autophagosomal structures. LC3-II amount reflects the abundance 
of autophagosomes and variations in the ratio of LC3-II to LC3-I are indicative of autophagy 
induction (Kabeya et al., 2000). LC3-I to LC3-II conversion was analyzed in U373MG and U87MG 
cells infected with dl922-947 at 72 hpi by western blotting. An increase of LC3-II levels, paralleled 
by a strong reduction of LC3-I levels, was observed in U373MG and U87MG infected cells, in a 
MOI-dependent manner (Fig. 1C).  
During the autophagic process, LC3-II is recruited to autophagosome membranes, therefore we 
decided to monitor LC3 localization during dl922-947 infection. U373MG clones expressing LC3 
fused to green fluorescent protein were generated (U373 GFP-LC3) by stable transfection and GFP-
LC3 tracked by immunofluorescence.  
In untreated U373 GFP-LC3 cells or in cells infected with the non replicating adenoviral mutant 
dl312, a diffuse and mostly cytosolic distribution of fluorescence was observed (Fig. 1E). A less 
diffuse and more punctate pattern was observed after infection with 0.1 pfu of dl922-947 72 hpi, 
indicating that LC3-II is recruited to the autophagosomal membranes. As a positive control, U373 
GFP-LC3 cells were treated with the autophagy inducer rapamycin, showing the typical LC3-II 
localization pattern. 
The accumulation of LC3-II could be due to the autophagy flux or to an interference with 
autophagosomal/lysosomal function. To discriminate between the two options, we have evaluated 
the levels of the specific autophagy substrate p62/SQSTM1. During autophagy, p62 levels are 
reduced whereas, in the absence of autophagy, p62 levels are unmodified (Komatsu and Ichimura, 
2010). As shown in Fig 1C, a clear decrease of p62 levels was observed, demonstrating that dl922-
947 enhances the autophagic flux.  
To confirm that autophagy is due to the infection with a replicating virus, glioma cells were also 
infected with a non replicating adenovirus expressing green fluorescence protein (AdGFP). AdGFP 
infection did not induce changes in LC3-II/LC3-I ratio nor in p62 levels (Fig. 1D). 
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Taken together, these data demonstrate that glioma cells infected with the dl922-947 virus activate 
autophagic processes. 
 
dl922-947 infection modulates autophagic signalling pathways and its effects are modified by 
specific pharmacological inhibitors 
We evaluated the effects of dl922-947 infection on Akt/mTOR/p70s6k and ERK1/2 pathways, 
respectively negative and positive regulatory pathways of autophagy. 
U373MG and U87MG cells were infected with dl922-947 in a dose-response experiment. 
Phosphorylation of p70s6k and AKT increased in a dose-dependent manner (Fig. 2A) in both cell 
lines, indicating activation of the negative regulatory pathway. Conversely, ERK1/2 
phosphorylation was reduced upon infection with dl922-947 in a dose-dependent manner (Fig. 2A), 
indicating an inhibition of the positive regulatory pathway. AdGFP infection did not induce any of 
these effects (Fig. 2B). These data suggest that, along with autophagy activation occurring in 
infected cells, dl922-947 also induces compensatory mechanisms. 
To clarify the effects of ERK1/2 pathway on autophagy upon infection, glioma cells were infected 
with dl922-947 in the presence of MEK 1 inhibitor PD98059.  An inhibitory dose of 25 µM was 
used for all the experiments. The combined treatment led to further reduction of ERK 1/2 
phosphorylation (Fig. 3A) along with a reduction on LC3 conversion; conversely, in uninfected 
cells, the drug did not modify LC3I/LC3II ratio (Fig. 3A). Accordingly, PD98059 enhanced dl922-
947 induced cytotoxicity. A significant reduction of LD50 values was obtained in both cell lines: 
from 0.14 to 0.02 in U373MG cells, and from 0.33 to 0. 1 in U87MG cells (Fig. 3B).  
To investigate the role of Akt/mTOR/p70s6k pathway in dl922-947 infection, glioma cells were 
treated with the mTOR inhibitor rapamycin, a well known autophagy inducer (Meijer and Codogno, 
2004), and then infected with dl922-947. Treatment with rapamycin led to a reversion of p70S6K 
phosphorylation induced by the virus, paralleled by an increase of LC3-II/LC3 I ratio (Fig. 4A). In 
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both cell lines, rapamycin treatment led to a significant reduction of viral cytotoxicity, with more 
than hundred fold increase in LD50 (Fig. 4B).  
These data strongly indicate that autophagy plays a survival role in glioma cells infected with 
dl922-947 and that the attenuation of autophagic response could increase viral cytotoxicity. 
 
Inhibition of autophagy increases dl922-947 cytotoxicity in glioma cells  
Next, we evaluated the effect of pharmacological inhibition of autophagy on dl922-947 infection. 
To this aim, we used two well known inhibitors of autophagy: 3-methyladenine (3-MA) and 
hydroxychloroquine (CQ), acting at early and late stages of autophagy, respectively. CQ blocks the 
formation of autolysosomes where LC3-II degradation occurs, thus inducing LC3II accumulation 
(Amaravadi et al., 2007), whereas 3-MA, an inhibitor of class-III-phosphatidylinositol-3 kinase 
(PI3KIII), blocks early autophagocytic signaling, preventing LC3I-LCII conversion (Kondo et al., 
2005).  
Accordingly, dl922-947-mediated LC3-II induction and AVOs formation were further increased by 
CQ, while treatment with 3-MA partially reverted the LC3-II increase and AVOs formation (Fig. 
5A ). 
The treatment with a single dose of CQ (10 µM) or 3-MA (1 mM) increased dl922-947 induced 
cytotoxicity, with a reduction of LD50 values ranging from two to thirty fold (Fig. 5B). At the 
concentrations used, CQ or 3-MA treatment alone did not induce any toxic effect (not shown). 
Since CQ and 3-MA have a wide range of effects, not only specifically linked to autophagy, we 
have evaluated the effects of autophagy inhibition by generating stable glioma cells clones 
expressing  Atg5 shRNA. We have chosen Atg5 being this gene involved in both canonical and not 
canonical autophagy (Scarlatti et al., 2008). Although we did not obtain a complete gene silencing, 
in all transfected clones a strong increase of viral induced cell death was observed (Fig. 5C). 
Our data confirm that inhibition of autophagy sensitises glioma cells to the oncolytic effect of 
dl922-947. 
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Chloroquine increases dl922-947 oncolytic activity in vivo 
To validate the potential therapeutic use of anti-autophagic drugs in association with dl922-947, we 
analyzed the effects of the virus combined with CQ in U87MG xenograft tumours. Athymic mice 
were injected with U87MG cells and after 20 days animals were randomised in four groups (T=0).  
In mice receiving the single treatments (dl922-947 or CQ), a non significant reduction of tumor 
growth was observed, whereas CQ and dl922-947 combination treatment resulted in a highly 
significant tumor growth inhibition (Fig. 6A). Starting from T=11, a significant difference 
(*p<0.05) was observed between the group receiving the combined treatment, the untreated and the 
groups receiving single treatments. At T=23, the difference became highly significant (**p<0.01).  
No toxicities were observed in virus-treated animals, or in CQ-treated animals. 
As shown in Fig. 6B, CQ and dl922-947 were both able to increase LC3-II/LC3 I ratio, this effect 
was further increased in the combined treatment.  
The existence of a double switch between apoptosis and autophagy has been suggested (Platini et 
al., 2010), and recent studies have demonstrated that the inhibition of autophagy increased apoptotic 
cell death in cancer cells (Kanzawa et al., 2004; Boya et al., 2005; Dalby et al., 2010). Therefore, 
we analysed caspase-3 activation in treated tumours.  
Cleaved caspase 3 levels were undetectable in control tumours and barely detectable in dl922-947 
infected tumours. At variance, in CQ-treated tumours, dl922-947 led to more intense caspase 3 
activation, compared to the tumours undergoing the CQ single treatment (Fig. 6B), thus indicating 
that chloroquine is effective in increasing the antitumour activity of dl922-947 and in inducing 
apoptosis in experimental glioma in vivo.  
 
Discussion 
Glioblastoma multiforme (GBM) is one of the deadliest human cancer (Furnari et al., 2007). The 
therapy for GBM, which includes surgical resection, radiotherapy, and chemotherapy, has shown a 
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limited success. Consequently, there is an urgent need for the development of novel therapeutic 
approaches to improve patient survival. A number of promising oncolytic viruses have 
demonstrated anti-glioma activity in both preclinical and clinical settings (Brandes et al., 2008).  
In the present study, we have analysed the effects of E1A mutated adenovirus dl922-947 against 
glioma cells, confirming its efficacy and showing that glioma cells undergo autophagy in response 
to dl922-947 infection, as confirmed by the dose-dependent development of acidic vescicular 
organelles, the increase of LC3-II levels and the reduction of p62 levels. These effects were not 
observed upon infection with control non replicating adenoviruses (AdGFP or dl312), indicating 
that the activation of autophagy is dependent on viral replication. 
In contrast with the induction of autophagy observed in infected cells, we show that dl922-947 
infection activates the Akt/mTOR/p70s6k pathway, which is considered the main negative 
regulatory mechanism for autophagy (Blommaart et al., 1995; Yang et al., 2005), and 
simultaneously inhibits ERK1/2 pathway, which is known to promote it (Pattingre et al., 2003). 
Non replicating control adenovirus AdGFP did not induce these effects. This apparent discrepancy 
could be possible due to compensatory mechanisms selectively operated by glioma cells to escape 
dl922-947 killing. 
To address the role of these modulatory pathways in dl922-947-infected cells, we have used 
pharmacological inhibitors. The MEK1 inhibitor PD98059 induced a block of autophagy, as shown 
by a reduction of LC3 conversion. Interestingly, this block was paralleled by an increase of dl922-
947 cytotoxicity. Conversely, the induction of autophagy by rapamycin in infected cells sharply 
increased cell survival. All together, our data suggest that autophagy plays a defensive/survival role 
during the infection with dl922-947, the autophagic machinery probably being involved in the 
destruction of viral structures. On the other hand, the effects exerted by dl922-947 infection on 
intracellular signal could likely represent an attempt of the virus to overcome the cellular 
autophagic response by modulating important autophagic signalling pathways. 
Page 15 of 34
Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801
Human Gene Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
15 
 
It is known that viral infections have complex interconnections with the autophagic process. It has 
been suggested that autophagosomes could serve as sites of viral replication during some viral 
infections and therefore autophagy can support viral replication and assembly (Lin et al., 2010). 
Moreover, it has been observed that Hepatitis C virus (Dreux et al., 2009; Tanida et al., 2009), polio 
virus (Suhy et al., 2000) and Dengue Virus serotypes 2 and 3 (Panyasrivanit et al., 2009) subvert or 
induce autophagy to create membrane alterations advantageous for their replication. On the other 
hand, it has been suggested that autophagy may confine viral replication within vesicles as a 
defense mechanism, since it is well documented that autophagy acts as a host defense against 
intracellular pathogens (xenophagy) (Lin et al., 2010). An antiviral effect of autophagy has been 
confirmed during neurotropic Sindibis virus infection and in HSV 1 encephalitis (Lin et al., 2010).  
Oncolytic viruses can modulate autophagy in target cells, including glioma cells. Delta-24-RGD 
oncolytic adenovirus has been shown to induce autophagic cell death in brain tumour stem cells 
(Jiang et al., 2007; Jiang et al., 2011). Auto-phagosomal-mediated cell death was also observed in 
glioma cells infected with an oncolytic adenovirus driven by the survivin promoter (Ulasov et al., 
2009). Furthermore, hTERT-Ad, an oncolytic adenovirus regulated by the human telomerase 
reverse transcriptase promoter, induced autophagic cell death in human malignant glioma through 
inactivation of the AKT/TOR pathway (Ito et al., 2006) and the inhibition of autophagy reduced 
viral cytotoxicity (Yokoyama et al., 2008). These results have led to the speculation that autophagy 
is the main pathway of cell death in cells infected with replicating adenoviral vectors (Ito et al., 
2006). In line with this hypothesis, recent in vitro studies showed that autophagy inhibition can 
decrease the oncolytic activity of Delta-24-RGD on glioma cell lines (Jiang et al., 2011) and of the 
E1B deleted adenovirus Adhz60 on lung carcinoma cell lines (Rodriguez-Rocha et al., 2011). 
Here, we show in vitro and in vivo that inhibition of autophagic pathways increases the activity of 
the E1A deleted oncolytic virus of dl922-947, indicating that autophagy acts as cell survival 
response. Our observation is consistent with Baird and colleagues (Baird et al., 2008), that have 
already shown that 3MA and chloroquine enhanced the effects of dl922-947 in ovarian carcinoma 
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cells, but in contrast with the above mentioned studies from Jiang et al (Jiang et al., 2011)  and 
Rodriguez-Rocha et al (Rodriguez-Rocha et al., 2011). The discrepancies could be due to the 
different oncolytic adenoviruses analysed. It is also conceivable that different viruses elicit different 
cellular responses depending on cancer cell type. In this regard, in anaplastic thyroid carcinoma 
cells, we did not observe autophagy following dl922-947 infection (Libertini et al., 2010), 
suggesting that the activation of the autophagic process and the subsequent cellular fate are most 
likely virus-and cell type-dependent. Further studies are required to better understand how 
adenoviruses interact with host cells.    
Autophagy inhibition is receiving attention as a novel strategy for cancer treatment. New autophagy 
inhibitors have been reported as potent anticancer drugs and/or to sensitize cancer cells to the 
activity of anticancer agents (Amaravadi et al., 2007; Carew et al., 2007; Rubinsztein et al., 2007; 
Shingu et al., 2009). Chloroquine itself is emerging as a potential anticancer agent against various 
cancers, including gliomas (Degtyarev et al., 2008; Solomon and Lee, 2009). Here, we show that 
chloroquine strongly enhances the oncolytic effects of dl922-947 both in vitro and in vivo, 
encouraging the use of anti-autophagic drugs for the development of therapies based on the use of 
dl922-947 virus for the treatment of gliomas. 
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Fig. 1 dl922-947 induces cell death and autophagy in malignant glioma cells  
(A) U373MG and U87MG cells were infected at the indicated MOIs and cell survival was analyzed seven days 
post-infection. The percent survival rates of cells exposed to the virus were calculated by assuming the 
survival rate of untreated cells to be 100%.  
(B) U373MG and U87MG cells were infected with dl922-947 for 72 h, stained with acridine orange for 15 min 
and then subjected to flow cytometric analysis.  
Red-positive cells in upper quadrants were considered as AVOs and calculated percentages shown.  
(C-D) Cells were infected with dl922-947 (C, D) or with AdGFP (D) and LC3I-II expression analysed after 72 
hours. β-actin was used as a loading control.  
(E) Stable clones of U373MG cells expressing a fusion protein GFP-LC3 (U373 LC3-GFP) were infected with 
dl922-947 or dl312 (0.1 pfu/cell), or treated with rapamycin (500 nM) for 72 h and analysed by confocal 
microscope.  
Experiments shown are representative of three independent experiments.  
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Fig. 2 Autophagy signalling pathways are modulated in response to dl922-947 infection in glioma cells  
(A) U373MG and U87MG cells were infected with dl922-947 at indicated MOIs for 72 h.  
(B) Cells were infected with dl922-947 or AdGFP at indicated MOIs for 72 h. Expression of total and 
phosphorylated (p-) P70S6K, AKT and ERK1/2 were analysed by western blot.  
Results shown are representative of three independent experiments.  
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Fig. 3 Inhibition of ERK1/2 pathway inhibits autophagy and enhances dl922-947-induced citotoxicity  
(A) U373MG and U87MG cells were treated with PD98059 (25 µM) for 2 h and then infected with dl922-947 
at indicated MOIs. Expression of total and phosphorylated (p)-ERK1/2, and LC3I-II were analysed by 
western blot after 72 hours.  
(B) Cells were treated with PD98059 (25 µM) and after 2 hours infected with dl922-947 at indicated MOIs. 
Cell survival was evaluated after 7 days. PD98059 treatment alone induced 15% and 20% of cytotoxicity in 
U373MG cells in U87MG cells, respectively.  
Results shown are representative of three independent experiments.  
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Fig. 4 Inhibition of mammalian target of rapamycin (mTOR) pathway induces autophagy and decreases 
dl922-947-induced citotoxicity  
(A) U373MG and U87MG cells were treated with rapamycin (500 nM) for 2 h and infected with dl922-947 at 
indicated MOIs. Expression of total and phosphorylated (p-) P70S6k, and LC3I-II were analysed by western 
blot after 72 hours.  
(B) Cells were treated with rapamycin (500 nM) and infected with dl922-947 after 2 hours at indicated 
MOIs. Cell survival was evaluated after 7 days. A significant increase of LD50 values was obtained in both 
cell lines in the presence of rapamycin: from 0.09 to 9.18 in U373MG cells, and from 0.01 to 31.9 in U87MG 
cells.  
Results shown are representative of three independent experiments.  
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Fig. 5 Pharmacological autophagy inhibitors enhance dl922-947-induced cytotoxicity  
(A) U373MG (left) and U87MG cells (right) were treated with CQ (10 µM) or 3-MA (1mM) for 2 hours, 
infected with different MOIs of dl922-947 for 72 hours and LC3I-II levels or AVOs formation analysed after 
72 hours respectively by western blot (upper panel) and FACS analysis (lower).  
(B) Cells were treated with CQ or 3-MA for 2 hours and then infected at different MOIs of dl922-947. Cell 
survival was evaluated after 7 days.  
(C) U373MG and U87MG clones stably expressing a scrambled (ShCTR) or a specific shRNA for ATG5 
(shATG5) were infected with different MOI of dl922-947 and cell survival evaluated 7 days.  
Results shown are representative of three independent experiments.  
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Fig. 6 Chloroquine enhances the activity of dl922-947 and delays the growth of glioma tumour xenografts  
(A) Animals bearing U87MG tumour xenografts were randomised into four groups. Two groups received CQ 
(45mg/kg/die) i.p. every third day. dl922-947 (1x 106x106pfu, in a volume of 200 µl) was injected three 
times per week into one CQ-treated group and one untreated group. Tumour volume is expressed as a 
percentage of the volume observed at day 0 in the control group. The difference between the untreated 
group or the group receiving the combined treatment become statistically significant (*p<0.05) from day 
11. From day 17, until the end of the treatment, the difference became highly significant (**p<0.01).  
A statistically significant difference was also observed between the group receiving the combined treatment 
and single treatment groups (*p<0.05) from day 11 and from day 17 (**p<0.01).  
No statistically significant difference was observed between the groups receiving the single treatments and 
the untreated control group.  
(B) Animals bearing U87MG xenograft were treated or not with CQ (45mg/Kg) and intratumourally injected 
with dl922-947 (1x107 pfu) after 24 hours. Tumour tissue samples were homogenized after 48 hours and 
LC3I-II or caspase-3 levels analysed by western blot. β-actin was used as loading control.  
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Figure legends 
 
Fig. 1 dl922-947 induces cell death and autophagy in malignant glioma cells  
(A) U373MG and U87MG cells were infected at the indicated MOIs and cell survival was analyzed 
seven days post-infection. The percent survival rates of cells exposed to the virus were calculated 
by assuming the survival rate of untreated cells to be 100%.  
(B) U373MG and U87MG cells were infected with dl922-947 for 72 h, stained with acridine orange 
for 15 min and then subjected to flow cytometric analysis. 
Red-positive cells in upper quadrants were considered as AVOs and calculated percentages shown.  
(C-D) Cells were infected with dl922-947 (C, D) or with AdGFP (D) and LC3I-II expression 
analysed after 72 hours. β-actin was used as a loading control.  
(E) Stable clones of U373MG cells expressing a fusion protein GFP-LC3 (U373 LC3-GFP) were 
infected with dl922-947 or dl312 (0.1 pfu/cell), or treated with rapamycin (500 nM) for 72 h and 
analysed by confocal microscope. 
Experiments shown are representative of three independent experiments. 
 
Fig. 2 Autophagy signalling pathways are modulated in response to dl922-947 infection in glioma 
cells 
(A) U373MG and U87MG cells were infected with dl922-947 at indicated MOIs for 72 h.  
(B) Cells were infected with dl922-947 or AdGFP at indicated MOIs for 72 h. Expression of total 
and phosphorylated (p-) P70S6K, AKT and ERK1/2 were analysed by western blot.  
 Results shown are representative of three independent experiments.  
 
Fig. 3 Inhibition of ERK1/2 pathway inhibits autophagy and enhances dl922-947-induced 
citotoxicity  
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(A) U373MG and U87MG cells were treated with PD98059 (25 µM) for 2 h and then infected with 
dl922-947 at indicated MOIs. Expression of total and phosphorylated (p)-ERK1/2, and LC3I-II 
were analysed by western blot after 72 hours.  
(B) Cells were treated with PD98059 (25 µM) and after 2 hours infected with dl922-947 at 
indicated MOIs. Cell survival was evaluated after 7 days. PD98059 treatment alone induced 15% 
and 20% of cytotoxicity in U373MG cells in U87MG cells, respectively.  
Results shown are representative of three independent experiments. 
 
Fig. 4 Inhibition of mammalian target of rapamycin (mTOR) pathway induces autophagy and 
decreases dl922-947-induced citotoxicity  
(A) U373MG and U87MG cells were treated with rapamycin (500 nM) for 2 h and infected with 
dl922-947 at indicated MOIs. Expression of total and phosphorylated (p-) P70S6k, and LC3I-II 
were analysed by western blot after 72 hours. 
(B) Cells were treated with rapamycin (500 nM) and infected with dl922-947 after 2 hours at 
indicated MOIs. Cell survival was evaluated after 7 days. A significant increase of LD50 values was 
obtained in both cell lines in the presence of rapamycin: from 0.09 to 9.18 in U373MG cells, and 
from 0.01 to 31.9 in U87MG cells. 
Results shown are representative of three independent experiments.  
 
Fig. 5 Pharmacological autophagy inhibitors enhance dl922-947-induced cytotoxicity 
(A) U373MG (left) and U87MG cells (right) were treated with CQ (10 µM) or 3-MA (1mM) for 2 
hours, infected with different MOIs of dl922-947 for 72 hours and LC3I-II levels or AVOs 
formation analysed after 72 hours respectively by western blot (upper panel) and FACS analysis 
(lower).  
(B) Cells were treated with CQ or 3-MA for 2 hours and then infected at different MOIs of dl922-
947. Cell survival was evaluated after 7 days. 
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 (C) U373MG and U87MG clones stably expressing a scrambled (ShCTR) or a specific shRNA for 
ATG5 (shATG5) were infected with different MOI of dl922-947 and cell survival evaluated 7 days. 
Results shown are representative of three independent experiments.  
 
Fig. 6 Chloroquine enhances the activity of dl922-947 and delays the growth of glioma tumour 
xenografts 
(A) Animals bearing U87MG tumour xenografts were randomised into four groups. Two groups 
received CQ (45mg/kg/die) i.p. every third day. dl922-947 (1x 106x106pfu, in a volume of 200 µl) 
was injected three times per week into one CQ-treated group and one untreated group. Tumour 
volume is expressed as a percentage of the volume observed at day 0 in the control group. The 
difference between the untreated group or the group receiving the combined treatment become 
statistically significant (*p<0.05) from day 11. From day 17, until the end of the treatment, the 
difference became highly significant (**p<0.01).  
A statistically significant difference was also observed between the group receiving the combined 
treatment and single treatment groups (*p<0.05) from day 11 and from day 17 (**p<0.01). 
No statistically significant difference was observed between the groups receiving the single 
treatments and the untreated control group.  
(B) Animals bearing U87MG xenograft were treated or not with CQ (45mg/Kg) and 
intratumourally injected with dl922-947 (1x107 pfu) after 24 hours. Tumour tissue samples were 
homogenized after 48 hours and LC3I-II or caspase-3 levels analysed by western blot. β-actin was 
used as loading control. 
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